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Abstract 
Background: Type 2 diabetes is characterised by chronic hyperglycaemia, insulin 
resistance and associated mitochondrial dysfunction. (Poly)phenols have been shown to 
attenuate cellular oxidative stress and restore glucose homeostasis, but the specific 
mechanisms and compounds responsible remain unknown. 
Methods: HepG2 cells were used as an in vitro hepatic model, on which the effects of 
quercetin on high glucose-induced oxidative stress and mitochondrial dysfunction were 
investigated. Mitochondria were assessed for complex I activity, cellular redox status, 
mitochondrial respiration and PGC-1α expression. LHCN-M2 human skeletal myocytes 
were differentiated in various glucose and insulin concentrations and characterised for 
their use as a model to explore the effects of relevant (poly)phenol metabolites on glucose 
uptake and metabolism. Metabolic phenotype and the effects of metabolites derived from 
ferulic acid, flavonols, resveratrol and berry (poly)phenols were evaluated by Western 
capillary protein assays, uptake of 2-[1-14C(U)]-deoxy-D-glucose and D-[14C(U)]-
glucose; respirometry and the ROS assay were also used for initial metabolic 
characterisation. 
Results: Mitochondrial function was restored by quercetin in HepG2 cells exposed to 
high glucose, by reversing the increased cellular NADH, enhancing mitochondrial 
respiration and preventing proton leak, and upregulating PGC-1α, all of which led to 
restored complex I activity after 24 h. The LHCN-M2 model was established and cells 
differentiated in a normal or high glucose/insulin environment. Glucose transport was 
restored, and metabolism increased, in high glucose/insulin myotubes by various 
metabolites. Isovanillic acid 3-O-sulfate in particular elicited this effect by upregulating 
GLUT1, GLUT4 and PI3K protein expression, and acutely activating the insulin 
signalling pathway. 
Conclusions: Quercetin protects against hepatic mitochondrial dysfunction through 
pleiotropic effects involving improved redox status and enhanced mitochondrial 
respiration and function. (Poly)phenol metabolites, including the gut microbiome 
catabolite isovanillic acid 3-O-sulfate, restore glucose uptake and metabolism in human 
skeletal muscle exposed to high glucose and insulin, via insulin-dependent pathways. 
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Chapter 1  
Introduction and Literature Review. 
1.1 Introduction 
The incidence of diabetes is on the rise worldwide. It is estimated that 422 million adults 
are currently living with the disease, a number which has almost quadrupled in the last 
35 years and is representative of 8.5% of the global population. This chronic metabolic 
disease is best known by elevated blood glucose levels and 3.7 million deaths were 
attributable to hyperglycaemia-related pathologies, 1.5 million of these directly caused 
by diabetes, in 2012 (WHO 2016). Type 2 accounts for around 90% of all diabetes cases 
and, worryingly, a further ~193 million people are undiagnosed, with increasing 
occurrences in children, too (Chatterjee, Khunti et al. 2017). The disease is no longer 
considered exclusive to the ‘Western’ world, with a substantial increase in the Asian 
population, for example (Lam and LeRoith 2012). Considerable physical, psychological 
and socioeconomic pressures are placed on patients and an overwhelming burden hangs 
over health care systems and economies, with an estimated cost of more than $825 billion 
US dollars per year, accounting for treatment as well as absenteeism, early retirement 
and social benefits for associated disabilities (Seuring, Archangelidi et al. 2015). 
Management of blood glucose and lipid concentrations and blood pressure are required 
to minimise disease progression and complications such as cardiovascular disease 
(CVD). To lower prevalence and the associated huge costs, a better understanding of the 
genetic and metabolic risk factors, as well as early diagnosis, better therapies and disease 
management tailored to each patient, are still needed (Chatterjee, Khunti et al. 2017). For 
example, only in recent years has it been acknowledged that there is a need to treat the 
underlying metabolic disorder of individuals with CVD (Mellbin, Anselmino et al. 2010). 
Prevention is better than cure and therefore early changes in lifestyle and increasing 
education are key. Being overweight/obese is the biggest risk factor (though this can vary 
between populations; South-East Asians are at higher risk for example) (WHO 2016) and 
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therefore improvements in diet and increased physical activity can be effective in 
prevention and treatment. Excessive overall calorie intake, and notably free sugars, fats, 
and a lack of dietary fibre are correlated with increased risk of type 2 diabetes (WHO 
2016). Epidemiological evidence suggests that increased consumption of foods rich in 
(poly)phenols, substances synthesized and stored in plants for their protection, is 
inversely correlated with incidence (Ley, Hamdy et al. 2014, Amiot, Riva et al. 2016, 
Kim, Keogh et al. 2016) and as such there is a focus on looking for novel means of using 
(poly)phenols to control carbohydrate and lipid metabolism to manage, or even prevent, 
diabetes. 
A diet rich in plant-based foods and (poly)phenols over the course of a lifetime may 
lower the incidence of metabolic disorders (Kim, Keogh et al. 2016) and prescription of 
such a diet or applications with specific (poly)phenols may be used to provide new 
nutraceutical therapies for patients already diagnosed with disorders such as diabetes and 
CVD (Bozzetto, Annuzzi et al. 2015, Amiot, Riva et al. 2016). This literature review will 
draw on the current understanding of metabolic disease aetiology and the effects that 
dietary (poly)phenols can have on contributing risk factors, and identify gaps and 
shortcomings in the research. Focus will be placed on two central aspects of metabolic 
disease pathophysiology with potential to be influenced by (poly)phenols, and these will 
form the basis of the in vitro investigations in this project. These aspects are glucose 
metabolism and oxidative stress in the liver, and glucose uptake in the skeletal muscle. 
1.2 Type 2 diabetes: a metabolic disease 
Diabetes mellitus is a metabolic disease characterised by chronic hyperglycaemia 
(Krentz and Hompesch 2016). Symptoms include increased urination, thirst and hunger 
and, if left undiagnosed, untreated or poorly managed, long-term complications include 
CVD, stroke, kidney failure, gout and retinopathy. Hyperglycaemia and the 
encompassing syndrome arises either from the pancreas failing to produce sufficient 
insulin to maintain glucose homeostasis, referred to as type 1, or from the cells of the 
peripheral tissues involved in glucose homeostasis becoming insulin resistant, which in 
turn can also lead to pancreatic failure; this is type 2 and in this case early symptoms tend 
to develop slower and can be subtle or event absent. Gestational diabetes is another type, 
in which women develop hyperglycaemia during pregnancy, and it is typically resolved 
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after birth but comes with its own complications and increases the risk of eventually 
developing type 2 (WHO 2016, Chatterjee, Khunti et al. 2017). 
Prevention and treatment involve a controlled diet and regular physical exercise and, for 
those with the disease, maintaining strict control of blood glucose homeostasis. Type 1 
management requires insulin injections combined with diet control, while type 2 is 
managed by improvements in diet and lifestyle with drugs, with or without insulin 
injections. The direct causes of type 1 are still unknown (WHO 2016), though it is 
characterised by loss of β-cell function in the pancreatic islets of Langerhans and thus 
the compromised insulin secretion. As well as genetic and environmental factors, it is 
thought that an auto-immune attack can initiate the β-cell dysfunction (Rother 2007). 
Type 2 is caused initially by insulin resistance, resulting from preventable risk factors 
including obesity, poor diet and a sedentary lifestyle, in addition to other factors such as 
age, ethnicity and genetic predisposition (WHO 2016, Chatterjee, Khunti et al. 2017). 
Epidemiology suggests the dominant dietary factors include the types of fats consumed 
and/or excessive carbohydrates (Riserus, Willett et al. 2009, Malik, Popkin et al. 2010, 
Hu, Pan et al. 2012). 
Carbohydrate digestion is governed by α-glycosidases throughout the gastrointestinal 
tract, producing monosaccharides which are then absorbed predominantly via sodium-
dependent glucose transporter SGLT1 and glucose transporter GLUT2 (or GLUT5 for 
fructose) from the lumen of the small intestine into the blood in the hepatic portal vein 
(Williamson 2013). Glucose is taken up into the liver (primarily via GLUT2) and other 
peripheral tissues, such as skeletal muscle (via GLUT4), where any excess is stored as 
glycogen to minimise the post-prandial fluctuation in glycaemia (Cura and Carruthers 
2012, Mueckler and Thorens 2013). In the fasting state, the liver plays a crucial role in 
producing glucose from glycogenolysis and gluconeogenesis to prevent a drop in 
glycaemia, controlled by glucagon; while in the post-prandial state, in response to 
increased glycaemia and insulinaemia, the liver shifts from net glucose output to net 
glucose uptake (Moore, Coate et al. 2012, Titchenell, Chu et al. 2015). Insulin lowers 
glucose synthesis and efflux in the liver and stimulates the translocation of GLUT4 to 
the plasma membrane for glucose uptake in muscle and adipose tissue. Insulin also 
increases glycolysis, promotes glycogenesis and lipogenesis, besides controlling a 
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variety of other cellular functions outside of glucose and lipid metabolism (Saltiel and 
Kahn 2001, Desvergne, Michalik et al. 2006, Huang and Czech 2007). 
In a very simplified view, it can be said that persistent or excessive hyperglycaemia 
causes insulin resistance and this in turn exacerbates hyperglycaemia. However, it is 
debated in the literature whether a common cause in the aetiology of diabetes exists. 
Hyperglycaemia and hyperlipidaemia, resulting from chronic, excessive calorie intake, 
have a number of cellular consequences that start with a dysregulation in glucose and 
lipid fluxes and metabolism. Overactive lipogenesis results in lipid accumulation in the 
liver and adipose tissue, as well as in circulation, and obesity ensues (Taylor 2013, 
Zaccardi, Webb et al. 2016). Excessive levels of the lipid intermediates, diacylglycerol 
(DAG) and ceramide, can disrupt insulin signalling (Samuel, Petersen et al. 2010, Bruce, 
Risis et al. 2012) and surplus lipid storage (and glycogen too, as recently demonstrated 
(Ceperuelo-Mallafré, Ejarque et al. 2016)) in adipose tissue triggers the release of 
adipokines, inducing a pro-inflammatory state resulting in increased fatty acid release 
from adipocytes and leading to insulin resistance in myocytes and hepatocytes (Rabe, 
Lehrke et al. 2008, Harwood 2012, Kwon and Pessin 2013). Excessive consumption of 
fructose, while contributing less to hyperglycaemia and the associated adverse effects, 
has been linked with hepatic lipid accumulation and hyperlipidaemia (Bantle 2009). 
Insulin resistance leads to lowered glucose uptake and uncontrolled hepatic glucose 
metabolism and efflux, resulting in chronic hyperglycaemia, as well as dyslipidaemia. 
This in turn increases systemic oxidative stress, inflammation, and cardiovascular 
problems such as endothelial lipid disposition (Lumeng and Saltiel 2011, 
Tangvarasittichai 2015). The role of oxidative stress, as a result of high glucose 
specifically, in the onset of diabetes, will be the focus of the next section and further 
studies. 
1.2.1 Oxidative stress in diabetes pathophysiology 
High levels of glucose in the blood leads to intracellular oxidative stress and insulin 
resistance in tissues involved in glucose metabolism (Murphy 2009, Yan 2014, Gero, 
Torregrossa et al. 2016). A principal source of oxidative stress in the cell is the 
mitochondrion (Brand 2010). The catabolism of glucose by glycolysis, of free fatty acids 
(FFAs) by β-oxidation and of amino acids, generates NADH (nicotinamide adenine 
dinucleotide) via acetyl coenzyme A (acetyl-CoA)) and the tricarboxylic acid (TCA) 
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cycle. NADH is oxidised by complex I of the ETS (electron transfer system) to NAD+, 
transferring electrons to downstream complexes and oxygen, and protons to the IMS 
(intermembrane space), generating the proton gradient for ATP (adenosine triphosphate) 
synthesis in order to meet cellular energy requirements, thus fulfilling the primary 
function of mitochondria. An inherent level of superoxide, the precursor to other ROS 
(reactive oxygen species), is produced by complex I but basal levels of ROS are required 
for cell signalling and are tightly controlled by the cell’s antioxidant defence systems 
(Brandt 2006, Murphy 2009, Liemburg-Apers, Willems et al. 2015, Hirst and Roessler 
2016). Overproduction of NADH from excessive glucose and lipid influx, particularly in 
hepatocytes and pancreatic β-cells where glucokinase of the glycolysis pathway is not 
inhibited by glucose-6-phosphate, results in a reductive stress. This puts pressure on 
complex I with the overflux of NADH increasing the inner mitochondrial membrane 
(IMM) potential, which stalls complex III and increases coenzyme Q10 (CoQ) half-life 
and electron leakage and superoxide production beyond basal. The accumulation of 
NADH, and the imbalanced NAD+/NADH and redox status, creates a condition known 
as pseudohypoxia whereby oxygen cannot be effectively consumed by NAD+, leaving 
more oxygen available for partial reduction by the leaked electrons. Oxidative stress 
ensues (Munoz and Costa 2013, Yan 2014). 
The situation is worsened by the inhibition of GAPDH (glyceraldehyde 3-phosphate 
dehydrogenase) by both ROS and NADH. This prevents carbon flux from glycolysis to 
pyruvate and the TCA cycle and induces alternative metabolic pathways branching from 
glycolysis to mediate the accumulation of glyceraldehyde 3-phosphate (G3P) (Yan 2014, 
Luo, Wu et al. 2016), all of which exacerbate oxidative stress (Fig. 1.1) and have 
implications in the onset of diabetes and associated complications. 
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Figure 1.1: Excess intracellular glucose activates alternative metabolic pathways 
branching off glycolysis, which contribute to increased NADH and ROS. 
Increased NADH and ROS result in reductive and oxidative stresses respectively. 
Boxes indicate significant branching pathways; dashed lines indicate additional 
steps not shown. Adapted and added to from (Yan 2014). 
In the polyol pathway glucose is converted to fructose via sorbitol and, in doing so, 
NADH is produced from nicotinamide adenine dinucleotide phosphate (NADPH), 
further contributing to the reductive stress. In addition, with less NADPH, cellular 
glutathione (GSH) decreases and compromises the antioxidant defence system (Tang, 
Martin et al. 2012, Yan 2014, Luo, Wu et al. 2016). The hexosamine pathway converts 
fructose 6-phosphate to uridine diphosphate (UDP)-N-acetylglucosamine via 
glucosamine 6-phosphate and this inhibits insulin receptor substrate (IRS)-1 (see 1.2.2), 
generates ROS (Issad, Masson et al. 2010) and instigates post-translational modifications 
in the pathogenesis of diabetic complications such as retinopathy (Gurel, Sieg et al. 
2013). The accumulation of G3P increases DAG synthesis and this activates protein 
kinase C (PKC). The PKC activation pathway is also involved in diabetic complications; 
PKC-mediated expression and secretion of vascular endothelial growth factor (VEGF) 
in the mesangial cells of the kidney can lead to proteinuria and glomerular dysfunction 
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in diabetic nephropathy (Xia, Wang et al. 2007) and chronic PKC activation is involved 
in CVD comorbidities (Geraldes and King 2010). Furthermore, PKC activates NADPH 
oxidase (NOX), which generates superoxide from oxygen and can induce insulin 
resistance and endothelial dysfunction by inhibiting Akt phosphorylation and thus 
reducing Akt-dependent insulin signalling and nitric oxide synthase (NOS) activation 
(Naruse, Rask-Madsen et al. 2006). Another product of G3P is methylglyoxal and this 
forms advanced glycation end products (AGEs) via the glycation of proteins. One such 
AGE is glycated haemoglobin (HbA1c), used as a biomarker for diabetes. AGEs have 
implications in diabetic cardiac pathology (Mellor, Brimble et al. 2015) and Alzheimer’s 
disease (Lovestone and Smith 2014), as well as inhibiting insulin signalling (Riboulet-
Chavey, Pierron et al. 2006). The glycation pathway liberates ROS and leads to chronic 
inflammation via activation of AGE receptors and nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB). AGEs can also arise from the autoxidation of G3P, 
generating α-ketoaldehydes such as methylglyoxal (Wolff and Dean 1987, Brownlee 
2001). 
Enzymatic sources of ROS include oxidases, cyclooxygenase and nitric acid synthase 
(NOS) (Johansen, Harris et al. 2005). In a study comparing blood vessels from diabetic 
patients with coronary artery disease and nondiabetics it was evident that superoxide 
generation was enhanced in the former and this was predominantly mediated by 
increased activity and levels of NOX, and dysfunctional endothelial NOS (eNOS). The 
superoxide generation was diminished by a PKC inhibitor (Guzik, Mussa et al. 2002). 
The NOX family of enzymes are important in redox signalling and under controlled 
conditions generate ROS from NADPH at the plasma membrane in neutrophils to attack 
pathogens, but in a high glucose environment are over-activated by PKC and involved in 
the major diabetic complications (Gorin and Block 2013). However, the role of NOX 
signalling could be more complex as it was recently demonstrated in obese diabetic mice 
and hepatocytes in vitro that knockdown/inhibition of NOX4, and hence its dysfunction 
in vivo, alone can disrupt insulin signalling (Wu and Williams 2012). Regulation of NOS 
is another critical point. It requires cofactors and the substrate L-arginine to produce 
nitric oxide; if one of these is not present the oxidation of L-arginine and reduction of 
oxygen function of NOS is uncoupled and it can produce superoxide instead (Guzik, 
Mussa et al. 2002, Johansen, Harris et al. 2005). It has long been known that 
hyperglycaemia increases eNOS-dependent superoxide production (Cosentino, 
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Hishikawa et al. 1997). Xanthine oxidase and dehydrogenase are interconvertible 
enzymes involved in purine metabolism, converting hypoxanthine to xanthine and then 
uric acid, thereby generating NADH and superoxide, which under basal conditions is 
converted to hydrogen peroxide. Activity of these enzymes, and therefore reductive and 
oxidative stress, is increased in diabetics and associated with diabetic peripheral 
neuropathy and gout (Aliciguzel, Ozen et al. 2003, Maiuolo, Oppedisano et al. 2016, 
Miric, Kisic et al. 2016). The increased purine metabolism likely results from excessive 
nutrition, but is also related to vascular dysfunction, disrupted hepatic metabolism, 
increased adipose tissue and pro-inflammatory mediators (Miric, Kisic et al. 2016). In 
similar fashion, cyclooxygenase (COX) pathway is also involved in the pathogenesis of 
diabetic peripheral neuropathy, and other complications. Specifically, COX-2 is 
upregulated by high glucose and subsequently prostaglandins function is impaired, 
activating downstream inflammatory events (Kellogg, Cheng et al. 2008). 
The conversion of superoxide to hydrogen peroxide under stress-free conditions is just 
one of the complex endogenous antioxidant defence mechanisms to keep ROS, normally 
required for basal redox and signalling functions, under control. Superoxide dismutase 
converts superoxide to hydrogen peroxide (H2O2) and then cytosolic/lysosomal catalase 
or mitochondrial glutathione peroxidase catalyses the detoxification of H2O2 to water and 
oxygen. The latter reaction uses glutathione regenerated by glutathione reductase 
forming the glutaredoxin system. Catalase also binds NADPH to prevent its own 
oxidation. Disposal of H2O2 and reactive compounds, and redox signalling, is 
additionally mediated by the peroxiredoxins, which also reduce organic hydroperoxides 
and peroxynitrite; the thioredoxin system, which includes thioredoxin reductase and 
NADPH regenerates active thioredoxin after reducing protein disulfides. Moreover, 
glutathione S-transferases catalyse the conjugation of glutathione to various xenobiotics 
for detoxification and haem oxygenase catalyses the degradation of haem. Carotenoids, 
vitamins, uric acid, α-lipoic acid, trace elements and glutathione itself all have roles as 
antioxidants too. Changes in the ratios of these redox systems, for example during high 
glucose-induced oxidative stress, can activate transcription factors such as NFκB, 
hypoxia-inducible factor 1 and activator protein 1, which induce expression of 
inflammatory and antioxidant genes, and regulate proliferation and apoptosis (Arner and 
Holmgren 2000, Maritim, Sanders et al. 2003, Birben, Sahiner et al. 2012, Hanschmann, 
Godoy et al. 2013). Nuclear respiratory factor (erythroid-derived 2)-like 2 (Nrf2) is a 
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central transcription factor to the antioxidant response element (ARE) of many genes, 
capable of inducing many of the antioxidant proteins. It is stimulated by several drugs 
and phytonutrients and recent findings that suggest a key role in regulating mitochondria 
and energy metabolism (Vomhof-Dekrey and Picklo 2012). 
When oxidative stress exceeds the limits of the cellular antioxidant defence system, the 
enzymes and signalling pathways of the system themselves become targets of oxidation. 
Shortcomings and a lack of plausible evidence from clinical trials with antioxidant 
interventions suggests that further research into such therapies is required (Johansen, 
Harris et al. 2005, Matough, Budin et al. 2012), or, rather than targeting ROS directly, a 
better approach may be to modulate the systems that instigate the stress in the first place, 
such as promoting caloric restriction and increasing physical activity, or looking for 
compounds that help lower overproduction of ROS and restore the redox balance. 
Excessive energy intake leads to obesity and metabolic diseases, with high glucose and 
lipid cellular influx both resulting in an oxidative stress caused by superoxide generation 
and a redox imbalance from the conglomeration of enzymatic, glycolysis-branching 
pathways and over-flux through mitochondria, which overrides the cellular antioxidant 
defence systems, as discussed. Disproportion between NADH and NAD+ levels, referred 
to as a reductive stress, contributes in part to oxidative stress but the primary direct source 
of ROS is the mitochondria. Elevated cellular ROS can impact on a number of targets 
through (per)oxidation of proteins, lipids and modifications of deoxyribonucleic acid 
(DNA), as well as acting as a signalling molecule itself and influencing cellular redox 
status. Mechanisms affected include metabolic pathways, signalling cascades, gene 
expression, pro-inflammatory processes, proliferation and cell death and, as such, 
chronic oxidative stress has been implicated in a number of syndromes including cancer, 
neurodegeneration, CVD and metabolic disorders, besides playing a central role in the 
onset of diabetes. Specifically in diabetes, ROS impair insulin synthesis and secretion in 
the β-cells and induce insulin resistance in the peripheral tissues (Sakai, Matsumoto et 
al. 2003, Kim, Wei et al. 2008, Tangvarasittichai 2015). In support, oxidative stress 
biomarkers are increased in individuals with impaired β-cell function (Sakuraba, 
Mizukami et al. 2002, Butler, Janson et al. 2003) and/or insulin resistance (Urakawa, 
Katsuki et al. 2003, Katsuki, Sumida et al. 2004). And at the centre of these 
pathophysiological mechanisms is mitochondrial dysfunction. 
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1.2.2 Mitochondrial dysfunction and insulin resistance 
Although mitochondria are a source of oxidative stress, they are also a principal target of 
attack by ROS themselves and by RNS (reactive nitrogen species) (Starkov 2008, Kang 
and Pervaiz 2012). The impairment of complex I, as a principal source of mitochondrial 
superoxide alongside CoQ10 and complex III, together accounting for approximately 
60% of total superoxide generation in rat skeletal muscle mitochondria, (Brand 2010), is 
arguably the initiator of oxidative stress in diabetes. Overproduction of ROS by complex 
I and the damage on complex I by ROS results in dysfunction across the mitochondria 
that exacerbates the stress further in a downward spiral linked with the perturbations in 
cellular glucose and lipid metabolism, insulin resistance and impaired insulin secretion, 
and ultimately chronic hyperglycaemia and diabetes (Sivitz and Yorek 2010, Blake and 
Trounce 2014, Luo, Li et al. 2015). Cells try to prevent the increased ROS caused by the 
overflux of NADH by lowering insulin-stimulated glucose uptake and preventing 
substrate entry into the mitochondria, via the inhibition of fatty acid oxidation for 
example, which increases cellular FFAs and consequently lowers GLUT4 translocation, 
further inducing insulin resistance in muscle and adipose (Rudich, Tirosh et al. 1998, 
Tretter and Adam-Vizi 2000, Ceriello and Motz 2004). Mitochondrial dysfunction is also 
implicated in β-cell damage and endothelial dysfunction, relating to impaired insulin 
secretion and CVD, but as this work focuses on liver and muscle, only insulin resistance 
shall be discussed further in this context. 
Increased ROS damages mitochondrial proteins and lipid membranes, lowers 
mitochondrial biogenesis and leads to mutations in both mitochondrial and nuclear DNA, 
leading to mitochondrial dysfunction. This in turn further increases ROS and lowers β-
oxidation, aerobic respiration and ATP production, with increased compensatory 
glycolytic activity. Mitochondrial DNA (mtDNA) is particularly prone to mutagenic 
stress, given its proximity to the ROS source and the absence of protective histones, and 
it contains only coding sequences so most mutations will have a genotypic output (Kim, 
Wei et al. 2008). Mitochondrial capacity for oxidative phosphorylation (OXPHOS) is 
determined by expression and function of the ETS complexes (Ritz and Berrut 2005) and 
since some subunits of these complexes are encoded for by mitochondrial DNA, this is 
a potential mechanism for the mitochondrial dysfunction in insulin resistance. Fewer and 
smaller mitochondria are found in the skeletal muscle of obese and diabetic individuals 
(Ritov, Menshikova et al. 2005). Mitochondrial biogenesis is centrally regulated by 
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peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1α), the 
expression of which is increased with cellular ATP demand (Lehman, Barger et al. 2000, 
Finck and Kelly 2006) (Fig. 1.2) but generally decreased in insulin-resistant and diabetic 
humans (Patti, Butte et al. 2003). Adenosine monophosphate-activated protein kinase 
(AMPK) directly activates PGC-1α to increase mitochondrial proteins in coordination 
with NAD+-dependent deacetylase sirtuins (especially SIRT1 and SIRT3) (Winder, 
Holmes et al. 2000, Jager, Handschin et al. 2007, Canto, Gerhart-Hines et al. 2009, 
Carling 2017). AMPK and SIRTs are activated by increases in AMP and NAD+ and 
therefore also in line with ATP demand (Fig. 1.2). Decreased expression and activity of 
PGC-1α is likely the reason for the decrease in mitochondria in diabetes, and with excess 
nutrition the rise in reductive stress will account for the lowered activity. A study 
investigating respiratory output in skeletal muscle biopsies from healthy and diabetic 
subjects found no difference in mitochondrial function, but attributed the lower 
respiration to the lower mitochondrial content assessed by mtDNA and citrate synthase 
activity (Boushel, Gnaiger et al. 2007). However, Ritov et al. showed that ETS activity 
was in fact lower in diabetic muscle and only partly attributable to fewer mitochondria 
(Ritov, Menshikova et al. 2005), suggesting mitochondrial function and content are 
mutually important. Age and inherited genotype also play important roles in 
mitochondrial dysfunction (Kim, Wei et al. 2008) but the focus here shall remain on diet-
induced stress and decline. 
Mitochondrial dysfunction, caused by oxidative stress, fewer/injured mitochondria, 
depleted/mutated mtDNA, decreased oxidative function and OXPHOS protein 
expression, results in lower ATP synthesis, impaired β-oxidation, intracellular lipid 
accumulation and increased glycolysis in liver and muscle; in turn alterations in the 
insulin signalling cascade are induced and result in insulin resistance. Such changes are 
seen early in diabetes pathogenesis (Morino, Petersen et al. 2005). Insulin signalling 
pathways are initiated by insulin binding to the insulin receptor, causing a conformational 
change that activates the intrinsic tyrosine kinase activity of the receptor, resulting in 
autophosphorylation and the phosphorylation of insulin receptor substrates. 
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Figure 1.2: The PGC-1α/AMPK/SIRT axis. An increase in the intracellular AMP/ATP 
ratio activates AMPK, which phosphorylates PGC-1α. A corresponding increase in 
cellular NAD+/NADH activates SIRT1, which deacetylates PGC-1α, a 
transcriptional coactivator regulating various genes involved in mitochondrial and 
cellular metabolism. 
Phosphatidylinositol 3-kinase (PI3K) is activated and phosphorylates PI 4,5-
bisphosphate to PI 3,4,5-triphosphate, stimulating a range of downstream serine kinases 
including PI-dependent kinase-1, Akt, atypical PKC (Boucher, Kleinridders et al. 2014). 
Key pleiotropic metabolic effects of this PI3K branch include GLUT4 translocation in 
muscle and adipose (via PKCδ); the activation of glycogen synthase (glycogen synthase 
kinase is phosphorylated by Akt and inactivated, preventing it from inhibiting glycogen 
synthase) and inhibition of gluconeogenesis (downstream of the forkhead box O (FOXO) 
proteins) in liver (Saltiel and Kahn 2001); stimulation of mitochondrial respiration and 
upregulation of mitochondrial proteins (FOXO) in liver and muscle; and vasodilation in 
the vascular system via eNOS (Stump, Short et al. 2003, Kim, Wei et al. 2008, Cheng, 
Tseng et al. 2010, Boucher, Kleinridders et al. 2014). FOXO and the mitogen-activated 
protein kinase (MAPK) branch of insulin signalling regulate cell survival, proliferation 
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and differentiation and, in addition, insulin stimulates ROS detoxification functions via 
NOS (Kim, Wei et al. 2008, Yu, Gao et al. 2011). There are numerous other physiological 
actions of insulin, and many other convergent signalling pathways with effects on 
glucose metabolism, which are beyond the scope of this review. 
Various sites of the insulin signalling pathway have been implicated in the causes of 
insulin resistance. A principal mechanism is the increased serine phosphorylation of IRS 
proteins, which prevents them from interacting with the receptor and leads to their 
degradation. This can be triggered by endoplasmic reticulum stress, FFA-induced pro-
inflammatory signals via c-Jun N-terminal kinase (JNK) and inhibitor of nuclear factor 
κB kinase-β (IKK-β), and by ROS (Kim, Wei et al. 2008, Boucher, Kleinridders et al. 
2014). Accumulation of DAG activates PKCs to also increase serine phosphorylation of 
IRS (Itani, Ruderman et al. 2002) and ceramide inhibits Akt (Schmitz-Peiffer, Craig et 
al. 1999). Increased activity of phosphatases involved in the negative regulation of the 
pathway and decreased activation of molecules such as Akt may also play a role, but 
mitochondrial dysfunction and the associated lipid accumulation is a primary contender. 
Certainly interventions that improve mitochondrial function such as drugs, exercise and 
calorie restriction also restore insulin sensitivity (Kim, Wei et al. 2008). Furthermore, 
insulin regulates mitochondrial function through FOXO1 and FOXO3a, targets of SIRT1 
and this puts insulin on the AMPK metabolic regulation axis (Canto, Gerhart-Hines et 
al. 2009). Likewise, under normal conditions ROS act as signalling molecules in the 
insulin pathway and enhance insulin sensitivity, so insulin signalling and mitochondria 
feedback to each other and regulate metabolism concurrently. 
There are a plethora of recent reviews detailing the links between mitochondrial 
dysfunction and diabetes pathophysiology, and the exact cause-effect relationship 
between mitochondrial dysfunction and insulin resistance is still debated (Cheng, Tseng 
et al. 2010, Boucher, Kleinridders et al. 2014, Montgomery and Turner 2015, 
Tangvarasittichai 2015), but they clearly occur simultaneously as a result of the chronic 
high glucose and lipid stress. Regardless of the mechanism, the outcome is elevated 
oxidative stress and impaired insulin signalling, resulting in perturbed hepatic 
metabolism and impaired post-prandial glucose uptake into skeletal muscle. Dietary 
(poly)phenols have been shown to play a beneficial role in managing these and other 
features of diabetes development. 
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1.3 (Poly)phenols and their health benefits 
A large group of plant-derived organic compounds, (poly)phenols have been the focus 
of many epidemiological, animal, human intervention and in vitro studies. This is due to 
the increasing evidence for beneficial effect to human health when consumed regularly 
in our diet. This group of naturally occurring phytochemicals exist in plants (Bravo 1998, 
Manach, Williamson et al. 2005), sharing the basic structure of an aromatic ring and 
attached hydroxyl groups. Based on further specific structural features, they have been 
grouped into a classification system (Tsao 2010). The most intensively studied 
compounds include isoflavones, phenolic acids, stilbenes and the flavonoids, a subgroup 
comprising flavonols, flavanones, anthocyanins and flavanols (see Fig. 1.1). An ongoing 
collaborative project has produced, and is continually updating, an online database, 
Phenol-Explorer, of more than 500 (poly)phenols (Rothwell, Perez-Jimenez et al. 2013). 
Foods and beverages rich in (poly)phenols include teas, coffee, cocoa, fruit, vegetables, 
wine, cereals, oils, herbs, spices, seeds, nuts, pulses and soy (Manach, Scalbert et al. 
2004). 
The proclaimed benefits of the bioactive compounds in these foods vary hugely and such 
claims led to the explosion of research interest in this area. Antioxidant activity has 
probably been the most publicised over the last few decades and therefore received the 
most interest, with around 10,000 hits currently on PubMed, which were reviewed as 
early as 1987 by Fraga et al. (Fraga, Martino et al. 1987) and by Rice-Evans et al. (Rice-
Evans, Miller et al. 1996) and Landete more recently (Landete 2013). Nevertheless, there 
is now much evidence to suggest that these so-called antioxidant effects are not acting 
directly to remove free radicals and prevent oxidative stress in vivo (Hollman, Cassidy 
et al. 2011, Kerimi and Williamson 2016), and that actually it is the effects exerted on 
proteins, genes and metabolites, and even on the expression of micro ribonucleic acids 
(Milenkovic, Jude et al. 2013), having a functional impact through signalling pathways. 
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Figure 1.3: Classification of the main (poly)phenols. 
Boxed classes and sub-classes comprise compounds investigated in the present study. 
Adapted from (Pimpão 2014). 
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Another significant property is their ability to affect enzymes. On a molecular basis, 
together with ‘antioxidant’ activity, this effectively accounts for almost all the other 
(poly)phenol biological effects. For example, green tea (poly)phenols (specifically (-)-
epigallocatechin-3-gallate (EGCG)), curcumin and ellagic acid) are attributed as 
anticarcinogenic, with the proposed mechanisms of action discussed being primarily the 
enhancement of antioxidant and phase II metabolic enzymes (Stoner and Mukhtar 1995). 
Some of the earliest potential (poly)phenol benefits were seen in their effect on enzyme 
activity (Cochet, Feige et al. 1982), which ranges from enzymes on the physiological 
level, such as in the digestive tract (de la Garza, Milagro et al. 2011, Williamson 2013) 
to enzymes at the cellular level (Frezza, Schmitt et al. 2011). Other effects include 
neuroprotection (Spencer, Vauzour et al. 2009, LoPachin, Gavin et al. 2011), resistance 
against chronic diseases including cancer (Surh 2003, Ramos 2007, Arts 2008, Darvesh 
and Bishayee 2013, Gonzalez-Vallinas, Gonzalez-Castejon et al. 2013), CVDs (Arab, 
Liu et al. 2009, Kishimoto, Tani et al. 2013, Khan, Khymenets et al. 2014, Larsson 2014) 
and diabetes; there is even evidence for antimicrobial properties, for instance in an 
anticariogenic capacity (Ferrazzano, Amato et al. 2011, Goenka, Sarawgi et al. 2013). 
Despite the mass of evidence for the many health claims, the exact mechanisms of action 
are still not proven. There are numerous epidemiological and human intervention studies 
that suggest positive roles for (poly)phenols in the diet, but the physiological and 
molecular ‘truth’ is much more complex and specific in vitro investigations are required 
to elucidate the mechanisms, and compounds, responsible. It is important to support in 
vivo data with appropriate in vitro data and vice versa. It was formerly thought that all 
(poly)phenols were beneficial for simply exerting a general antioxidant effect, however 
this is no longer the consensus (Sies 2007, Cooper, Donovan et al. 2008, Fraga, Galleano 
et al. 2010, Kim, Quon et al. 2014), as work focuses on the wider array of cellular effects 
and molecular interactions. Furthermore, researchers are starting to use physiologically 
relevant metabolites in the lower micromolar range, rather than high doses of the parent 
compounds, which is more representative of the in vivo scenario. Following ingestion of 
(poly)phenol aglycones and plant metabolites, compounds undergo extensive 
biotransformation before and after absorption into the circulation, with subsequent phase 
II metabolism in enterocytes, by the colonic microbiota and upon reaching the liver 
(Williamson and Clifford 2017). 
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1.3.1 (Poly)phenol metabolism and bioavailability 
The biotransformation (i.e. conjugation, metabolism and degradation), cellular uptake 
and biological activity of many dietary (poly)phenols and their metabolites needs to be 
further ascertained (Manach, Scalbert et al. 2004, Yang, Sang et al. 2008). A range of 
possible modifications exists both in the foods and once absorbed, including conjugation 
with glucuronic acid, sulfation and methylation (O'Leary, Day et al. 2003, Williamson, 
Barron et al. 2005). Additionally, depending on chemical structure and any attached 
moiety such as sugars, many (poly)phenols will pass through the small intestine 
unabsorbed and are metabolised by the microflora in the colon, producing lower 
molecular weight catabolites, which are then absorbed here (Williamson and Clifford 
2010). The link between in vitro data for potential benefits and realistic effects in vivo 
becomes harder to prove. Various flavonoids have shown promise in preventing 
pathways leading to cancer for example, but, without the knowledge on how to improve 
bioavailability, their full potential as therapeutic/‘nutraceutic’ agents will remain 
unknown (Nambiar and Singh 2013). 
With such a broad range of dietary (poly)phenols available in the diet and huge 
complexities in their biotransformations and true bioavailabilities, it is reasonable at this 
point to focus just on those compounds that have been well characterized both in vitro 
and in vivo and form the focus of this project. The choice of compounds was centred on 
existing knowledge of their antidiabetic effects, and on them being sourced in frequently 
consumed (poly)phenol-rich foods (see Chapter 3, Table 3.1). Quercetin is a flavonol 
found in various foods, such as onions and apples (Rothwell, Perez-Jimenez et al. 2013), 
that may help modulate glucose digestion and metabolism (Nomura, Takahashi et al. 
2008, Nyambe-Silavwe, Villa-Rodriguez et al. 2015). It is also known for its widespread 
effects on mitochondrial physiology (de Oliveira, Nabavi et al. 2016) and thus, with these 
pleiotropic effects, it has been well studied for its potential in managing the development 
of type 2 diabetes (Haddad and Eid 2016). Kaempferol is another flavonol and can 
stimulate glucose uptake in order to lower hyperglycaemia (Fang, Gao et al. 2008). 
Ferulic acid is a major hydroxycinnamic acid (phenolic acid) in wheat and its conjugates 
are also found in circulation following coffee consumption (Lempereur I 1997, Stalmach, 
Mullen et al. 2009). Ferulic acid reduces lipid-induced insulin resistance in skeletal 
muscle cells and rats (Gogoi, Chatterjee et al. 2014) and increases glucose uptake in 
myotubes (Bhattacharya, Christensen et al. 2013). The stilbene resveratrol, found in 
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grape seed, is well-documented for its anticancer properties, but also more recently its 
effects on diabetes and glucose uptake, which may in fact contribute to its anticancer 
properties (Leon, Uribe et al. 2017). Finally, anthocyanins such as cyanidin 3-O-
glucoside are metabolised to form protocatechuic acid and other downstream 
(poly)phenols; and these, together with the metabolites of gallic acid (hydroxybenzoic 
acid, a phenolic acid), are all found in circulation following the consumption of berries 
(Pimpao, Ventura et al. 2015) [Pimpão PhD thesis, 2014], as well as other fruits, beans 
and cinnamon (Rothwell, Perez-Jimenez et al. 2013). Several recent human intervention 
studies have shown improved insulin responses and/or attenuated glycaemia following 
both acute and chronic consumption of berries (Stull, Cash et al. 2010, Torronen, 
Kolehmainen et al. 2013, Nyambe-Silavwe and Williamson 2016), and (poly)phenol 
compounds from berries were recently shown to improve glucose uptake and metabolism 
in liver and muscle cells in vitro (Nachar, Eid et al. 2017). The problem with the existing 
literature is that these studies have all been done using the parent compounds, or are 
interventions with whole foods without in vitro mechanistic follow-up; the metabolic 
profile of the plasma rarely includes the aglycone compounds, or does so in very small 
amounts, and thus the effects of circulating metabolites need assessing. 
1.3.1.1 Quercetin 
Quercetin present in food is typically attached to sugar moieties, such as quercetin 3-O-
glucoside (isoquercetin), 3,4′-O-diglucoside, 3-O-rutinoside (rutin), 3-O-galactoside 
(hyperin) and 3-O-rhamnoside (quercitrin) (Rhodes and Price 1996, Lommen, 
Godejohann et al. 2000). After ingestion, the glucosides are rapidly absorbed in the small 
intestine following hydrolysis by the brush border enzyme lactase phloridzin hydrolase, 
though the rutinoside is only absorbed in the colon after hydrolysis by the microbiome. 
Quercetin aglycone passively diffuses into enterocytes and is metabolised by 
sulfotransferase (SULT), UDP glucuronosyltransferase (UGT) and catechol-O-methyl 
transferase (COMT) before entering the circulation, or returning to the intestinal lumen, 
via multidrug-resistant protein (MRP) transporters. In the colonocytes quercetin 
undergoes methylation or glucuronidation, but not sulfation, although most is subjected 
to bacterial ring fission to form hydroxyphenylacetic acid catabolites. Circulating 
metabolites are numerous and primarily include sulfates and glucuronides, with most 
having a short elimination half-life (T½) before being removed from the bloodstream. 
Metabolites excreted in urine are more complex, indicative of phase II metabolism in the 
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liver and kidneys (Del Rio, Rodriguez-Mateos et al. 2013, Williamson and Clifford 
2017). 
Metabolites can enter cells and peripheral tissues, glucuronides passively and sulfates via 
organic anion transporters (OATs) (Wong, Akiyama et al. 2012), where they may be 
deconjugated and/or further metabolised (Kawai, Nishikawa et al. 2008, Ishisaka, Mukai 
et al. 2014). Kawai et al., found the aglycone form was more bioactive intracellularly in 
macrophages (Kawai, Nishikawa et al. 2008), though it is important to note that this may 
not be the case in all cells, under all conditions, nor for all biological effects or all 
(poly)phenols. For example, there were comparatively different effects on intracellular 
ROS by quercetin and quercetin 3-O-glucuronide in the study by Shirai et al. (Shirai, 
Yamanishi et al. 2002). More research has been done on aglycones; treating cells with 
aglycone may result in bioactive derivatives intracellularly, just as the metabolites can 
be deconjugated to produce the aglycone. 
1.3.1.2 Kaempferol 
Kaempferol is also a flavonol and follows similar digestion, absorption and metabolic 
pathways (DuPont, Day et al. 2004, Serra, Macià et al. 2012). Kaempferol may be better 
absorbed than quercetin, or quercetin is more efficiently metabolised to other forms 
and/or excreted (de Vries, Hollman et al. 1998). Up to 80% of the circulating kaempferol 
following consumption of endive soup was identified as kaempferol 3-O-glucuronide 
(DuPont, Day et al. 2004). Plasma metabolites following ingestion of capers included 
kaempferol 3-O-glucuronide and 7-O-sulfate, of which the former accounted for 95% 
(Kerimi, Jailani et al. 2015). 
1.3.1.3 Ferulic acid 
Ferulic acid is a metabolite of the chlorogenic acids, such as caffeoylquinic acid, found 
at high levels in coffee. Small amounts of ferulic acid itself are also present in coffee, but 
it is found at much higher levels (though often bound to fibre) in wheat and other cereals, 
plus various fruits and vegetables (Zhao and Moghadasian 2008). Some hydrolysis by 
esterases in the small intestine removes the quinic acid moiety from the coffee 
chlorogenic acids, releasing the phenolic acids; free caffeic acid is then absorbed into the 
enterocytes and sulfated to form caffeic acid 3′-O-sulfate or, in the presence of 
methylation, ferulic acid-4′-O-sulfate, both rapidly appearing in the plasma within 30 
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minutes (Williamson and Clifford 2017). Most of the chlorogenic acid esters are not 
hydrolysed and so reach the colon, where the phenolic acids are released by the gut flora 
esterases (Plumb, Garcia-Conesa et al. 1999). Here they are further converted by the 
bacteria to dihydrocaffeic and dihydroferulic acids and these circulate as sulfates, or as a 
free form in the case of dihydroferulic acid. A recent study in our lab demonstrated that 
short-chain fatty acids derived from dietary fibre via the gut microbiome metabolism can 
modulate the transport and conjugation of ferulic acid, indicating that the microbiome 
has a complex role in the metabolism of ferulic acid, and other (poly)phenols (Van 
Rymenant, Abranko et al. 2017). These conjugates reach much higher concentrations in 
the plasma than ferulic acid sulfate after drinking coffee (Stalmach, Mullen et al. 2009). 
When ferulic acid itself is ingested, it follows a different metabolic pathway. Ferulic acid 
is the most abundant phenolic compound in wheat, though its intestinal release from the 
indigestible polysaccharide matrix of the grain is low. This can be enhanced by 
bioprocessing, making the ferulic acid and other (poly)phenols more accessible (Mateo 
Anson, Aura et al. 2011). Following ingestion of 300 g of a control or bioprocessed (yeast 
fermentation and enzyme treatment) bread, the maximum plasma concentration (Cmax) in 
humans increased to 2.7 µM in the latter, up from 0.9 µM in the control. For both, the 
time at which Cmax was reached (Tmax) was less than 2 hours, implying digestion and 
absorption of free ferulic acid occurs predominantly in the small intestine. The authors 
of this study suggested some of the absorbed ferulic acid was metabolised to vanillic acid 
and various benzoic acid conjugates by the liver, in agreement with other literature (Zhao 
and Moghadasian 2008). Most of the ferulic acid, though, was passed to the colon and 
entered the circulation mainly as 3-hydroxyphenylpropionic and phenylpropionic acids, 
the latter of which can be further metabolised to benzoic acid by β-oxidation and then to 
hippuric acid in the liver (Mateo Anson, Aura et al. 2011). Ferulic acid conjugates are 
also among the numerous metabolites present in plasma following ingestion of berries 
(Pimpao, Ventura et al. 2015) (see 1.3.1.5). 
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1.3.1.4 Resveratrol 
Resveratrol is a stilbene that occurs as cis and trans isomers, as well as other derivatives 
in nature, including the 3-O-glucoside, trans-piceid. It is found in grape seed and best 
known for its presence in red wines, although it is usually present in much lower 
concentrations than other (poly)phenols (Crozier 2010). In fact, its presence in wine is 
so low that its credit for the health benefits of drinking red wine, such as in the review 
by Yang et al. (Yang, Li et al. 2014), could be completely misplaced. However, there 
may be benefits from circulating metabolites, especially over the course of a lifetime. 
Many studies tend to focus instead on its potential pharmaceutical capacity, rather than 
dietary. Bioavailability of free resveratrol is very low and this is because it is rapidly 
metabolised to its glucuronide and sulfate conjugates (Brown, Patel et al. 2010). This 
was demonstrated in two pharmacokinetic studies, where pharmacological doses of 
resveratrol were administered to humans either in a single dose or daily for a whole 
month, and the metabolites reached plasma concentrations in the micromolar range. The 
Tmax was typically within 1-2 h, suggesting intestinal metabolism and absorption 
(Boocock, Faust et al. 2007, Brown, Patel et al. 2010). This is in line with other 
bioavailability studies, generally detecting the sulfates as predominant in plasma and 
urine (Del Rio, Rodriguez-Mateos et al. 2013). Some resveratrol is further metabolised 
by the gut microbiota to dihydroresveratrol and its phase II metabolites (Rotches-Ribalta, 
Urpi-Sarda et al. 2012). 
Many of the bioavailability experiments on resveratrol have been done in rat models or 
cell models in vitro and thus may not be as relevant to the in vivo situation as performing 
pharmacokinetic interventions. It is well-known that the expression of transporters and 
enzymes, and in particular the gut microbiome composition, has large inter-individual 
variability (Tomas-Barberan, Selma et al. 2016), as well as inter-species variation, so it 
is unknown how useful such studies may be. Furthermore, there is some uncertainty over 
the metabolism of resveratrol in various peripheral tissues and the identity of compounds 
responsible for the biological effects. Resveratrol metabolites, specifically 3-O-sulfate, 
have been shown to inhibit the proliferation of colon cancer cells (Aires, Limagne et al. 
2013), which may be due to enzymatic release of the aglycone intracellularly (Miksits, 
Wlcek et al. 2009). It was recently demonstrated that the metabolites lower lipid 
accumulation and adipokine expression, and enhance lipid metabolism in murine 
adipocytes (Lasa, Churruca et al. 2012, Eseberri, Lasa et al. 2013). In contrast, an earlier 
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study attributed the biological effects solely to the aglycone, with no impact reported for 
the metabolites (Kenealey, Subramanian et al. 2011), and also a recent study showed that 
only deconjugated resveratrol had an antilipolytic effect in human adipocytes (Gheldof, 
Moco et al. 2017). However, considering positive effects following resveratrol 
administration, resveratrol still holds its promise as a therapeutic, although it is important 
to determine the specific metabolites responsible in order to improve targeting and 
efficacy. The same applies to all (poly)phenols. 
1.3.1.5 Berry (poly)phenol metabolism 
The final group of compounds investigated in this project were chosen based on the 
results from a human intervention study done previously in our lab (Pimpao, Dew et al. 
2014, Pimpao, Ventura et al. 2015). A range of metabolites were detected and quantified 
in plasma following ingestion of a mixed fruit berry purée containing blueberry, 
blackberry, raspberry, strawberry and Portuguese crowberry. Phenolic sulfates, resulting 
mostly from colonic metabolism, reached high concentrations (up to 20 µM), though for 
many of them biological activities have not been reported. It was suggested that the 
metabolites, such as the conjugates of catechol and vanillic acid, were catabolites of 
protocatechuic acid and originated predominantly from the cyanidin 3-O-glucoside 
parent compound (Pimpao, Ventura et al. 2015) [Pimpão PhD thesis, 2014], though they 
have also been shown as derivatives of chlorogenic acids, B-type proanthocyanidins and 
other flavonoids such as quercetin glycosides (Xie, Lee et al. 2016). Other major phenolic 
sulfates present in the plasma after the berry meal were conjugates of gallic acid. Of these 
compounds that were investigated here, only 4-methylgallic 3-O-sulfate was not a 
colonic catabolite, as established by its lower Tmax (Pimpao, Ventura et al. 2015). 
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Figure 1.4: Chemical structures of the (poly)phenol metabolites investigated here 
for potential roles in modulating glucose uptake and metabolism in human 
skeletal muscle. Derivatives of ferulic acid (A); flavonol conjugates (B); 
resveratrol conjugates (C); phenolic sulfates in circulation after the consumption of 
berries (D). Boxed compounds originate from colonic microbiota metabolism, 
unboxed in the small intestine.  
 
 
- 24 - 
1.3.1.6 Pharmacokinetic data 
The pharmacokinetic data suggests the body treats many (poly)phenols in a similar way 
to pharmaceutical drugs; intake, which in itself can be low to start with, is followed by 
rapid excretion due to the conjugation reactions. Therefore bioavailability is lower than 
that of the (poly)phenol doses employed in most in vitro investigations. On the other 
hand, as continuing research unfolds finer details of the metabolic transformations, 
absorption may be higher than first thought, due to some metabolites initially being 
missed in the detection. Understanding the distribution and accumulation of metabolites 
in tissues around the body can be limited by disproportionate reliance on in vitro cell 
models, which may express different levels of transporters and enzymes, and a different 
physiology in response to (poly)phenol treatments. Table 1.1 summarises some of the 
pharmacokinetic data for the (poly)phenols of interest, compiled from a comprehensive 
search of relevant human studies using PubMed, and helps to build a picture of the 
metabolite composition in the plasma following the consumption of (poly)phenol-rich 
foods or (poly)phenol supplements. It is worth noting that there are currently no 
pharmacokinetic data for isovanillic acid 3-O-sulfate exclusively, but data for vanillic 
acid 4-O-sulfate is included and so are data for total vanillic acid sulphates and the 
precursor protocatechuic acid. Furthermore, there is one study for the parent isovanillic 
acid compound, which is likely in circulation in lower concentrations than the sulfated 
compounds. 
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Table 1.1: Pharmacokinetics of (poly)phenol metabolites in humans. 
Metabolite 
Parent 
Compound/ 
Aglycone 
Dose Administered in Human Study Tmax in 
plasma 
(h) 
Mean Cmax 
in plasma 
Half 
Life 
(h) 
AUC 
(µM*h) * 
Cumulative 
Urine 
Excretion 
Remaining in 
Plasma 
Reference 
Ferulic acid 
4-O-sulfate 
Ferulic acid 
200 ml instant coffee (N = 11) (335 µM ferulic acids) 0.6 70 nM 4.9 467 
11.1 µmol 
after 24 h 
35 nM after 6 h, 
none after 24 h 
(Stalmach, Mullen 
et al. 2009) 
350 ml PP-rich a drink (N = 10) (149 µM phenolic acids) - - - - 
3.6 µmol 
after 24 h 
- 
(Borges, Mullen et 
al. 2010) 
500 ml fruit purée c (N = 9) (see (Pimpao, Dew et al. 
2014) for quantification) 
1 188 nM - - 
Mostly 0-2 h 
but some still 
8-24 h 
S55 nM after 6 h 
(Pimpao, Dew et al. 
2014, Pimpao, 
Ventura et al. 2015) 
350 ml coffee (N = 13) 1 226 nM 0.62 - - - 
(Lang, Dieminger et 
al. 2013) 
300 g red raspberries (N = 9) (292 µmol anthocyanins) 1 47 nM - - 
6.5 µmol 
after 48 h 
None after ~12 h 
(Ludwig, Mena et 
al. 2015) 
450 ml cranberry juice 
(N = 10) 
3.6 2.27 µM - 11.5 
731 nmol 8 h, 
1055 after 24 
h 
600 nM after 24 h 
(Feliciano, Boeres et 
al. 2016) 
Dihydro-
ferulic acid 
4-O-sulfate 
Dihydroferulic 
acid 
200 ml instant coffee as above 4.8 140 nM 4.7 1193 
12.4 µmol 
after 24 h 
130 nM after 6 h, 
none after 24 h 
(Stalmach, Mullen 
et al. 2009) 
350 ml PP-rich drink as above - - - - 
680 nmol 
after 24 h 
- 
(Borges, Mullen et 
al. 2010) 
500 ml fruit purée (see above) 
< LOD after 6 h – likely 
present in plasma later 
- - 
Almost all 
8-24 h 
- 
(Pimpao, Dew et al. 
2014, Pimpao, 
Ventura et al. 2015) 
350 ml coffee (N = 13) ≥ 8 878 nM - - - - 
(Lang, Dieminger et 
al. 2013) 
450 ml cranberry juice 
(N = 10) 
6.8 197 nM - 2.04 
512 nmol 8 h, 
1001 after 24 
h 
- 
(Feliciano, Boeres et 
al. 2016) 
400 ml coffee (N = 9) 10 300 nM - - - - 
(Redeuil, Smarrito-
Menozzi et al. 2011) 
Dihydro-
ferulic acid 
Dihydroferulic 
acid 
4g instant coffee + hot water (N = 1) (900 µg chlorogenic 
acids) 
8 1.2 µM - - - 90 nM after 24 h 
(Guy, Renouf et al. 
2009) 
Two artichoke leaf extracts; A containing 107 mg caffeic 
acids, B containing 154 mg caffeic acids (N = 14) 
6.34 (A) 
6.21 (B) 
140 nM (A) 
202 nM (B) 
2.91 (A) 
2.48 (B) 
147 (A) 
207 (B) 
- 
~81 nM (12 h), 
~54 nM (24 h) 
(Wittemer, Ploch et 
al. 2005) 
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350 ml coffee (N = 13) ≥ 8 94 nM (8 h) - - - - 
(Lang, Dieminger et 
al. 2013) 
450 ml cranberry juice 
(N = 10) 
6.1 304 nM - 3.24 
457 nmol 8 h, 
524 after 24 h 
- 
(Feliciano, Boeres et 
al. 2016) 
400 ml coffee (N = 9) 10 820 nM - - - - 
(Redeuil, Smarrito-
Menozzi et al. 2011) 
(Ferulic 
acid) 
Ferulic acid 
500 mg bolus of 13C5-cyanidin-3-O-glucoside (N = 8) 11.3 940 nM 51.6  
21.2 
(0-48 h) 
Max 1.5 µM 
after 48 h b 
560 nM (24 h) b 
(Czank, Cassidy et 
al. 2013) 
Two artichoke leaf extracts (as above) 
0.77 (A) 
0.98 (B) 
46 nM (A) 
79 nM (B) 
6.35 (A) 
5.23 (B) 
355 (A) 
544 (B) 
- 
~26 nM (12 h) 
and ~11 nM 
(24 h) (for both) 
(Wittemer, Ploch et 
al. 2005) 
Quercetin 
3′-O-sulfate 
Quercetin 
270 g fried red onions (N = 6) (1.02 µmol/g flavonols) 0.75 660 nM 1.71 - Trace in urine 
425 nM after 3 h, 
80 nM after 6 h 
(Mullen, Edwards et 
al. 2006) 
Meal incl. pickled capers, blackcurrants and propolis 
supplements (N = 8) 
1.9 62 nM - - - - 
(Kerimi, Jailani et 
al. 2015) 
Quercetin 
3-O-
glucuronide 
270 g fried red onions (N = 6) (1.02 µmol/g flavonols) 0.6 350 nM 2.33 - 
912 nmol 
after 9 h 
110 nM after 3 h, 
80 nM after 6 h 
(Mullen, Edwards et 
al. 2006) 
300 ml enriched tomato juice (N = 6) (40 µM quercetin 
3-O-rutinoside) 
4.7 10 nM 5.7 - 
250 nmol 
after 
8 h, 271 nmol 
after 24 h 
10 nM after 4 h, 
none by 8 h 
(Jaganath, Mullen et 
al. 2006) 
450 ml cranberry juice 
(N = 10) 
1.8 156 nM - 0.91 
79 nmol 8 h, 
108 after 24 h 
17 nM after 24 h 
(Feliciano, Boeres et 
al. 2016) 
Kaempferol 
3-O-
glucuronide 
Kaempferol 
450 ml cranberry juice 
(N = 10) 
2.1 13 nM - 0.118 
145 nmol 8 
h, 180 after 
24 h 
- 
(Feliciano, Boeres 
et al. 2016) 
Capers, blackcurrants, propolis as above (N = 8) 3 360 nM - - - 
100 nM after 
8 h 
(Kerimi, Jailani et 
al. 2015) 
300 g endive soup (N = 8) (8.65 mg kaempferol) 0.9, 5.8 50, 100 nM - 0.75 
560 nmol 
after 24 h 
20 nM after 
24 h 
(DuPont, Day et al. 
2004) 
(Total 
Quercetin)   
Quercetin 
1095 mg quercetin d aglycone (N=16) 6.1 1.43 µM 11.4 17.7 - - 
(Guo, Mah et al. 
2014) 
Sautéed onion equiv. to 1 mg quercetin/kg bw 1.5 1 µM - - - - 
(Nakamura, 
Murota et al. 2014) 
160 g stewed onion (100 mg quercetin) (N = 12) 0.7 7.6 µM 10.9 32.1 
6.4 % after 
48 h 
Cleared within 
24 h 
(Graefe, Wittig et 
al. 2001) 
          
 
 
- 27 - 
trans-
Resveratrol 
4′-O-
glucuronide 
trans-
Resveratrol 
300-600 ml various red wines (N = 2-10) (8.8 µM total 
trans-resveratrol) 
1 265 nM - - - None after 2 h 
(Vitaglione, Sforza 
et al. 2005) 
85.5 mg piceid e/70 kg body weight + 500ml milk 
(N = 9) 
6 190 nM - - 
4.7 µmol after 
12 h; no more 
99 nM after 8 h, 
none after 10 h 
(Burkon and 
Somoza 2008) 
Single doses of resveratrol caplets ranging from 0.5 g to 
5 g (N = 10 for each dose); will look at 0.5 and 5 g data. 
Also, two glucuronides measured but not identified 
0.5 g: 
(1) 2 
(2) 1.5 
5.0 g: 
(1) 2 
(2) 2.5 
0.5 g: 
(1) 1 µM 
(2) 915 nM 
5.0 g: 
(1) 3.18 µM 
(2) 4.29 µM 
0.5 g: 
(1) 2.85 
(2) 3.09 
5.0 g: 
(1) 7.90 
(2) 5.83 
0.5 g: 
(1) 4.75 
(2) 3.19 
5.0 g: 
(1) 24.5 
(2) 21.1 
All excreted 
after 12 h 
Still present after 
24 h with the 
5.0 g dose 
(Boocock, Faust et 
al. 2007) 
As above but daily doses for 29 consecutive days 
0.5 g: 
1.27 
5.0 g: 
1.5 
0.5 g: 
820 nM 
5.0 g: 
10.2 µM 
0.5 g: 
3.78 
5.0 g: 
7.55 
0.5 g: 
3.29 
5.0 g: 
49.4 
- 
All excreted by 
12-24 h 
(Brown, Patel et al. 
2010) 
trans-
Resveratrol 
3-O-sulfate 
Single doses as above 
0.5 g: 
1.5 
5.0 g: 
2.05 
0.5 g: 
3.68 µM  
5.0 g: 
13.93 µM 
0.5 g: 
3.21  
5.0 g: 
7.71 
0.5 g: 
13.14  
5.0 g: 
100.2 
All excreted 
after 12 h 
Still present 
after 24 h with 
0.5 g dose 
(Boocock, Faust et 
al. 2007) 
As above but daily doses for 29 consecutive days 
0.5 g: 
1.04 
5.0 g: 
1.25 
0.5 g: 
2.47 µM 
5.0 g 
18.3 µM 
0.5 g: 
3.09 
5.0 g: 
7.98 
0.5 g: 
11.54 
5.0 g: 
126.2 
- 
All excreted by 
12-24 h 
(Brown, Patel et al. 
2010) 
trans-
Resveratrol 
3-O-
glucuronide 
Single doses as above (two glucuronides measured, not identified); given the pharmacokinetic data below it is likely that this was (2) 
(Boocock, Faust et 
al. 2007) 
As above but daily doses for 29 consecutive days 
0.5 g: 
1.27 
5.0 g: 
1.5 
0.5 g: 
810 nM 
5.0 g: 
17.1 µM 
0.5 g: 
4.98 
5.0 g: 
5.19 
0.5 g: 
2.16 
5.0 g: 
54.6 µM 
- 
All excreted by 
12-24 h 
(Brown, Patel et al. 
2010) 
Catechol-
O-sulfate 
Catechol from 
protocatechuic 
acid f 
350 ml coffee (N = 13) 0.75 2.469 µM 0.65 - - - 
(Lang, Dieminger 
et al. 2013) 
500 ml fruit purée (above) 6 12.2 µM - - 
Mostly 8-24 
h 
All 4-6 h 
(Pimpao, Dew et 
al. 2014, Pimpao, 
Ventura et al. 
2015) 
450 ml cranberry (above) 7.1 24.6 µM - 346 
4.67 µmol 8 
h, 10.5 after 
24 h 
6.4 µM after 
24 h 
(Feliciano, Boeres 
et al. 2016) 
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4-Methyl-
catechol-O-
sulfate 
500 ml fruit purée (above) 
6 
(N = 7) 
636 nM - - All 8-24 h 
Mostly 4-6 h, 
some participants 
earlier 
(Pimpao, Dew et al. 
2014, Pimpao, 
Ventura et al. 2015) 
450 ml cranberry (above) 7.7 3.5 µM - 54 
564 nmol 8 h, 
1625 after 24 
h 
- 
(Feliciano, Boeres et 
al. 2016) 
Pyrogallol 
O-sulfate g 
Gallic acid, 
pyrogallic acid 
500 ml fruit purée (above) 
6 (1/2) 
(N = 7/8) 
(1) 652 nM 
(2) 11.4 µM 
- - 
Some 4-8 h, 
mostly 8-24 h 
At 4 and 6 h, 
more in the latter 
esp for (2) 
(Pimpao, Dew et al. 
2014, Pimpao, 
Ventura et al. 2015) 
450 ml cranberry (above) 
(1) 8.7 
(2) 6.2 
(1) 199 nM 
(2) 339 nM 
- 
(1) 3.4 
(2) 3.0 
(1) 34, 146 
nmol (2) 127, 
302 nmol 
- 
(Feliciano, Boeres et 
al. 2016) 
4-Methyl-
gallic 3-O-
sulfate 
Gallic acid 
500 ml fruit purée (above) 2 2 µM - - 
Max 2-4 h; 
still 50% max 
during 8-24 h 
Still ~800 nM 
after 6 h 
(Pimpao, Dew et al. 
2014, Pimpao, 
Ventura et al. 2015) 
450 ml cranberry (above) 2.1 275 nM - 2.2 
206 nmol 8 h, 
297 after 24 h 
- 
(Feliciano, Boeres et 
al. 2016) 
Vanillic 
acid 4-O-
sulfate 
Vanillic acid/ 
Protocatechuic 
acid 
500 ml fruit purée (above) 
4 
(N = 6) 
1.3 µM - - 
Some 2-4 h, 
mostly 4-24 h 
All 4-6 h; peak at 
4 h but 
statistically > 
baseline at 6 h 
(Pimpao, Dew et al. 
2014, Pimpao, 
Ventura et al. 2015) 
30 ml virgin olive oil (N = 5) (400 mg/kg total 
polyphenols) 
1 50 nM - - - 40 nM after 2 h 
(Suarez, Romero et 
al. 2009) 
450 ml cranberry (above) 2.1 1.05 µM - 11.8 
128 nmol 8 h, 
288 after 24 h 
200 nM after 24 h 
(Feliciano, Boeres et 
al. 2016) 
Total 
vanillic 
acid 
sulfates 
500 mg bolus of 13C5-cyanidin 3-O-glucoside (N = 8) 
(VA4S and IVA3S) 
30.1 430 nM NQ h 10.7 
1.7 µM 
VA4S, 
822 nM 
IVA3S after 
3-4 h 
Still present 
after 48 h 
(de Ferrars, Czank 
et al. 2014) 
(Protocat-
echuic 
acid) i 
500 mg bolus of 13C5-cyanidin 3-O-glucoside (total 
protocatechuic acid metabolites, NOT just IVAS) (N = 8) 
13.4 
2.4 µM 
(cumulative 
5 µM after 6 
h, still there 
at 48 h 
29.5 
44 
(0-48 h) 
Max 6 µM 
after 24 h; 40 
µM tracer 
after 48 h 
Metabolites 
mainly in serum 
and urine in first 
6 h, peaking at 24 
h and still present 
in both after 48 h 
(Czank, Cassidy et 
al. 2013) 
(Isovanillic 
acid) 
450 ml cranberry (above) 9.9 220 nM - 3.1 
481 nmol 8 h, 
1.24 µl 24 h 
- 
(Feliciano, Boeres et 
al. 2016) 
 
 
- 29 - 
Bold font indicates colonic metabolites 
* AUC – area under the curve 
a PP-rich, (poly)phenol-rich 
b Total phenylacetic/ phenylpropenoic acid metabolites 
c fruit purée contained 100 g of each of the following Portuguese berries: blueberry, blackberry, raspberry, strawberry and crowberry and was consumed with a breakfast containing no other  
  (poly)phenols, consisting of bread with ham or cheese, yogurt and biscuits 
d Typical quercetin daily intake is only 16 mg, as stated in this paper 
e piceid aka resveratrol 3-O-glucoside  
f As suggested in (Pimpão 2014, Pimpao, Ventura et al. 2015) 
g Roughly a 50/50 mix of -1-O-sulfate and -2-O-sulfate when synthesised by Rui 
h Still present after 48 h so half-life not quantifiable from this experiment 
i No studies with explicit isovanillic acid-3-O-sulfate data 
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1.3.2 The antidiabetic properties of (poly)phenols 
(Poly)phenols, and their plant-derived metabolites or conjugates, may play a beneficial 
role in glucose homeostasis through mechanisms that slow digestion and absorption to 
modulate glycaemic index; once further metabolised and absorbed into the bloodstream, 
they may prevent the loss in number and function of pancreatic β-cells and enhance 
insulin synthesis and secretion; improve insulin sensitivity, glucose uptake and reduce 
inflammation in skeletal muscle and adipose tissue; modulate glucose and lipid 
metabolism in the liver and systemically; and alleviate cellular oxidative stress and the 
effects on associated signalling pathways. There are a plethora of recent reviews that 
detail the potential antidiabetic effects of (poly)phenols based on epidemiological, in 
vitro, animal model and human intervention data (Pandey and Rizvi 2009, Hanhineva, 
Torronen et al. 2010, de Bock, Derraik et al. 2012, Babu, Liu et al. 2013, Bahadoran, 
Mirmiran et al. 2013, Williamson 2013, Amiot, Riva et al. 2016, Kim, Keogh et al. 2016). 
The relevant knowledge on the (poly)phenols of interest shall be summarised briefly 
here, with more in-depth discussions in the corresponding Results chapters. 
1.3.2.1 Quercetin and its conjugates 
Quercetin is one of the most widely distributed flavonoids in the diet and unquestionably 
the most-studied. It has been reported to act on many targets in the gut, pancreas, liver, 
muscle and adipose tissue to control systemic glucose metabolism (Haddad and Eid 
2016), as well as in endothelium in cardiometabolic pathologies (Kunasegaran, Mustafa 
et al. 2017). Quercetin is an inhibitor of α-amylase (Nyambe-Silavwe, Villa-Rodriguez 
et al. 2015) and GLUT2 (Kwon, Eck et al. 2007), suggesting it may reduce carbohydrate 
digestion and the absorption of glucose and fructose in the gut. Subsequently, a recent 
human study in our lab demonstrated that intervention with a fruit purée, rich in 
(poly)phenols including quercetin, attenuated postprandial glycaemic and insulinaemic 
responses (Nyambe-Silavwe and Williamson 2016). The Haddad research group have 
provided in vitro evidence that quercetin increases glucose uptake in murine C2C12 and 
in rat L6 myotubes via an AMPK-dependent pathway (Eid, Martineau et al. 2010, Eid, 
Nachar et al. 2015), however both studies use quercetin in excess of 25 µM, which would 
never be attainable from dietary sources. In the study by Anhê et al. the authors treated 
ob/ob obese mice with quercetin for 10 weeks and L6 myotubes with quercetin and 
palmitate or tumour necrosis factor-α (TNF-α). They reported that inflammatory 
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responses were lowered and insulin signalling and GLUT4 expression restored in both 
models, with an increase in glucose uptake in the muscle cells; this was also at 25 µM 
(Anhê, Okamoto et al. 2012). There are contrasting reports on the effects of quercetin on 
glucose uptake in adipocytes, as reviewed recently by Eid et al. (Haddad and Eid 2016). 
Although quercetin inhibited glucose uptake in normal murine 3T3-L1 adipocytes, when 
under inflammatory conditions induced by macrophage-derived conditioned medium, 
quercetin actually rescued the cells from insulin resistance, and it was demonstrated that 
these divergent effects were regulated via AMPK (Xu, Hu et al. 2014). In the same Eid 
et al. review, several studies are highlighted for demonstrating that quercetin has similar 
effects to the antidiabetic drug metformin on liver glucose metabolism, by inhibiting 
glucose 6-phosphatase-mediated gluconeogenesis, again involving AMPK activation, 
but without stimulating glycogenesis (Haddad and Eid 2016). Furthermore, in mice fed 
with a high fat diet, quercetin lowered lipid accumulation and steatosis-inducing gene 
expression in the liver, as well as circulating lipids and body weight (Hoek-van den Hil, 
van Schothorst et al. 2014). 
The research on quercetin conjugates to date is mostly related to a potential benefit in 
CVD prevention. High glucose-induced apoptosis in human umbilical vein endothelial 
cells (HUVECs) was dose-dependently inhibited by sulfate and glucuronide conjugates 
prepared from the serum of rats administered with quercetin (Chao, Hou et al. 2009). In 
aortic rings isolated from rats, incubation with quercetin 3′-O-sulfate and 3-O-
glucuronide partially recovered the oxidative stress-impaired nitric oxide response and 
at higher micromolar concentrations inhibited NADPH oxidase superoxide generation 
(Lodi, Jimenez et al. 2009). A more recent study revealed that both quercetin and its 3-
O-glucuronide conjugate ameliorated palmitate-induced oxidative stress and 
inflammation in HUVECs (Guo, Zhang et al. 2013). Quercetin 3-O-glucuronide was also 
shown to accumulate in atherosclerotic lesions, but not normal aorta, with signs of 
preventing arteriosclerosis (Ishizawa, Yoshizumi et al. 2011). Other studies, however, 
demonstrate biological actions exerted by quercetin aglycone but not the conjugates; only 
quercetin had anti-inflammatory effects in rat pancreatic cells (Cho, Chang et al. 2012) 
and in human endothelial cells (Mochizuki, Kajiya et al. 2004, Winterbone, Tribolo et 
al. 2009). In a study on vascular smooth muscle cells from hypertensive or normal rats, 
quercetin 3-O-glucuronide inhibited NADPH oxidase to prevent superoxide generation, 
but the effect was absent in the presence of a β-glucuronidase inhibitor. This suggests 
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that the glucuronide is deconjugated to release the free, active quercetin (Jimenez, Lopez-
Sepulveda et al. 2015), thus lack of deconjugation could explain why activity was only 
seen for the aglycone in the previous examples. 
1.3.2.2 Effects of quercetin on mitochondria 
Quercetin rapidly diffuses into cells and accumulates in mitochondria (Fiorani, 
Guidarelli et al. 2010), where it is able to modulate mitochondrial biogenesis, membrane 
potential, respiration, redox status and apoptosis, as has been recently reviewed 
(Sandoval-Acuna, Ferreira et al. 2014, de Oliveira, Nabavi et al. 2016). One of the key 
characteristics of quercetin is its redox capacity and, because of this, it has a hormetic 
effect and biphasic dose-responses (Vargas and Burd 2010). In the low micromolar range 
(< 50 µM) quercetin upregulates the Nrf2-mediated ARE, which promotes anti-oxidative 
stress response genes (Rotblat, Grunewald et al. 2013) and anti-inflammatory pathways 
and functions (Costa, Garrick et al. 2016). However, quercetin itself has a potent 
antioxidant ability and is able to reduce ROS, becoming a semi-quinone, and quinone in 
turn, in its oxidised form, which can react with reduced GSH to deplete cellular levels 
and result in a pro-oxidative state. In particular this occurs at the higher concentrations 
(≥ 100 µM) and in cancer cells, in which ROS are continually high due to the glycolytic 
phenotype; ROS is propagated by the pro-oxidant effect of quercetin and this triggers 
apoptosis (Gibellini, Pinti et al. 2010). It has been hypothesised that this pro-oxidant 
effect is what triggers antioxidant defence at the lower doses, the small increase in ROS 
activating the ARE of the defence system genes (Vargas and Burd 2010). 
Studies on isolated mitochondria, usually from rat liver or brain, suggest that quercetin 
decreases membrane fluidity, respiration and ATPase/ATP synthase activities, while 
increasing calcium release, mitochondrial permeability transition pore (MPTP) activity 
and mitochondrial swelling (signs/triggers of autophagy and apoptosis); generally ROS 
and oxidative effects were lowered (Zheng and Ramirez 2000, Dorta, Pigoso et al. 2005, 
Dorta, Pigoso et al. 2008, De Marchi, Biasutto et al. 2009, Waseem and Parvez 2016). 
These effects were all with concentrations of ≥50 µM and with short incubation times. 
Indeed, lowering respiration would help lower the production of ROS, as would 
autophagy and mitochondria-induced apoptosis, as part of the cell’s oxidative stress 
defence mechanism. In another study, 25 µM quercetin protected cells against 
oxygen/glucose deprivation-induced mitochondrial dysfunction by regulating 
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intracellular calcium, without affecting mitochondrial membrane potential (Panickar and 
Anderson 2011); Dorta et al. also showed no effect on membrane potential (Dorta, 
Pigoso et al. 2005). 
Lagoa et al. investigated the potential effects of quercetin on the ETS and saw that 
quercetin dose-dependently prevented H2O2 production without interfering with oxygen 
consumption. This was also the case in the presence of rotenone and antimycin A, 
inhibitors of ETS complexes I and III respectively, which increases electron leakage and 
ROS, suggesting the action of quercetin was not a direct result of a direct interaction with 
ROS, but rather preventing ROS generation in the first place. The authors speculated this 
was due to inhibition of ROS generation at the ETS complexes and found this was the 
case specifically at complex I, without affecting its activity. Pre-treatment with CoQ10 
decreased the effect, indicating that quercetin may competitively bind to the quinone site 
of complex I (Lagoa, Graziani et al. 2011). In contrast, Sandoval-Acuña et al. 
demonstrated that quercetin stimulated complexes I and IV, in a CoQ-mimicking fashion, 
in Caco-2 cells and isolated mitochondria. However, this was studied as preventing 
complex I inhibition (at the CoQ-binding site) by indomethacin and other non-steroidal 
anti-inflammatories in the absence of CoQ10 (Sandoval-Acuna, Lopez-Alarcon et al. 
2012). Essentially, quercetin and CoQ10 compete for the CoQ-binding site and can work 
synergistically to block other inhibitors; when only CoQ10 and quercetin are both present, 
depending on their concentrations, quercetin may be seen to inhibit the action of CoQ10. 
These two groups used quercetin at lower concentrations than those used by others, with 
some effects seen at 5 µM. Recently, Waseem and Parvez showed that quercetin 
increased complex I activity at 50 µM and this was without CoQ10 in the assay (Waseem 
and Parvez 2016). 
In cells in vitro and in animal models in vivo, quercetin prevents or recovers stress-
induced mitochondrial dysfunction. Mechanisms are similar to those in isolated 
mitochondria, including lowered ROS and restored membrane potential, complex I and 
ATP levels (Punithavathi and Stanely Mainzen Prince 2010, Carrasco-Pozo, Mizgier et 
al. 2012, Chakraborty, Stalin et al. 2012, Karuppagounder, Madathil et al. 2013, Sandhir 
and Mehrotra 2013, Bali, Ergin et al. 2014, Ben Salem, Boussabbeh et al. 2016). In cells, 
quercetin targets signalling pathways related to mitochondrial function in addition to 
affecting the mitochondria directly. Nrf2-ARE signalling pathways are upregulated to 
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prevent oxidative stress and hepatotoxicity (Ji, Sheng et al. 2015) and apoptotic pathways 
are regulated to prevent stress-induced cell death (Carrasco-Pozo, Pastene et al. 2012, 
Bali, Ergin et al. 2014). In diabetic pathophysiology, preventing oxidative stress and 
apoptosis in the pancreatic islets preserves insulin synthesis and secretion function 
(Haddad and Eid 2016), and in the kidneys and cardiovascular system this may protect 
against diabetic complications (Blake and Trounce 2014). There are some reports of 
quercetin inducing mitochondrial biogenesis in mammalian cells and tissues via the 
AMPK-SIRT-PGC-1α axis (Davis, Murphy et al. 2009, Rayamajhi, Kim et al. 2013, 
Kim, Kwon et al. 2015, Liu, Zou et al. 2015), though the evidence is limited, with others 
reporting lack of effect (Nieman, Williams et al. 2010, Nichols, Zhang et al. 2015). 
Rayamajhi et al. detected increased mitochondrial biogenesis in HepG2 (human 
hepatocellular carcinoma, immortalised) cells with 15 µM quercetin that was dependent 
on the heme oxygenase-1 (HO-1) and carbon monoxide system (Rayamajhi, Kim et al. 
2013), and in primary murine hepatocytes , Kim et al. showed that PGC-1α was induced 
by quercetin through a Nrf-2/HO-1-dependent mechanism (Kim, Kwon et al. 2015). HO-
1 is typically a stress-induced protein and also regulates autophagy and apoptosis, via 
AMPK (Dong, Zheng et al. 2015). This suggests that AMPK-mediated pathways play a 
role in mitophagy as well as biogenesis, basically regulating a mitochondrion-recycling 
system. 
In general, evidence for the effects of quercetin on mitochondrial biogenesis, metabolic 
flux and the ETS is scarce and often conflicting. Effects are dose-dependent and reliant 
on cell type, situation and on co-treatment with a stressor and, moreover, are mostly 
limited to short treatment times or only applying quercetin to the mitochondria once 
isolated. It remains unclear how the pleiotropic effects of quercetin on mitochondria 
come together to impact cellular metabolism in the longer term, and there are no existing 
studies that have looked specifically at mitochondria in cells faced with a high glucose 
stress. Therefore the first half of this study shall focus on investigating the effects of 
quercetin on mitochondrial function in HepG2 cells in a high glucose environment, and 
whether it can alleviate the dysfunction associated with insulin resistance and diabetes. 
A secondary aim is to further elucidate the effects of quercetin in general, by combining 
assays for ETS function, metabolic flux, mitochondrial content and related gene 
expression, alongside intact cell respirometry to provide an overall picture of what a 
chronic exposure to quercetin may elicit. 
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1.3.2.3 Kaempferol and its conjugates 
There has been much less published on kaempferol than on quercetin. Both flavonols 
increased glucose uptake in 3T3-L1 adipocytes (Fang, Gao et al. 2008) and kaempferol, 
obtained as a metabolite from elderflower, dose-dependently increased uptake in porcine 
myotubes (Bhattacharya, Christensen et al. 2013). In L6 myotubes it was only effective 
at 30 µM (Kawabata, Sawada et al. 2011). A plant metabolite from hops, kaempferol 3-
O-neohesperidoside, acquired insulinomimetic status for its ability to increase glucose 
uptake and glycogen synthesis in rat soleus muscle via the PI3K-dependent pathway 
(Zanatta, Rosso et al. 2008, Cazarolli, Folador et al. 2009). However, there are no 
pharmacokinetic studies demonstrating presence of this metabolite in plasma following 
consumption, which would be a prerequisite for such effects on muscle. Thus, while the 
effects are clear, the claim regarding overall postprandial glycaemia benefits in vivo 
should be treated with caution. Similarly, Ho et al. recently demonstrated that kaempferol 
may have lasting effects on metabolism; longer incubation times with radiolabelled 
glucose in the presence of the compound lead to increases in uptake in primary human 
myotubes and HepG2 cells (Ho, Kase et al. 2017). However, the HepG2 data are not 
presented and the authors themselves highlight that it is unclear if these compounds are 
even relevant based on bioavailability in vivo, leading to scepticism in interpreting these 
data. Propolis extract, in which 4′-O-methylkaempferol (kaempferide) is a major 
compound, lowered postprandial glucose levels in mice after oral administration (Ueda, 
Hayashibara et al. 2013), which could be an indication that kaempferol metabolites in 
circulation may increase glucose disposal in vivo, but there are other flavonoids in 
propolis that could have been responsible. In a recent study in our lab, 20 µM kaempferol 
aglycone decreased deoxyglucose uptake in HepG2 cells, but increased glucose uptake 
(Kerimi, Jailani et al. 2015). The data on kaempferol are minimal and inconclusive and 
there are no published results for biological effects of the glucuronide or sulfate 
conjugates that have been identified in the few pharmacokinetic studies (Table 1.1). 
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1.3.2.4 Ferulic acid and its metabolites 
Similar to quercetin, there is some evidence for ferulic acid displaying various 
antidiabetic effects, but very little on its metabolites. Earlier studies on ferulic acid 
demonstrated its ability to lower blood pressure, cholesterol and triglyceride levels in 
hypertensive rats, prevent oxidative stress in neuronal cells and induce anti-inflammatory 
effects (Pavlica and Gebhardt 2005, Ardiansyah, Ohsaki et al. 2008, Islam, Murata et al. 
2008). A recent review by Martini et al. highlighted the effects of coffee consumption 
on lowering markers of oxidative stress in humans. However, despite the number of 
intervention studies, the authors called for more robust and well-controlled studies to 
gain more complete understanding (Martini, Del Bo et al. 2016). In recent primary 
studies, ferulic acid 4-O-sulfate, but not ferulic acid, elicited vasorelaxation and lowered 
blood pressure in mice and dihydroferulic acid exhibited a stronger inhibitory effect on 
in vitro platelet activation than its precursors; dihydroferulic acid, among other colonic 
catabolites, protected neuronal cells from oxidative stress; and both dihydroferulic acid 
and ferulic acid 4-O-sulfate were increased in plasma following prolonged orange juice 
consumption in correlation with lower markers of oxidative stress and inflammation 
(Verzelloni, Pellacani et al. 2011, Baeza, Bachmair et al. 2017, Rangel-Huerta, Aguilera 
et al. 2017, Van Rymenant, Van Camp et al. 2017). This suggests that the biological 
activities reported for ferulic acid may be accounted for by its metabolites. 
In terms of potential effects in managing glucose metabolism, Prabhakar and Doble 
showed ferulic acid increased deoxyglucose uptake in 3T3-L1 adipocytes and L6 
myotubes via a PI3K-dependent mechanism (Prabhakar and Doble 2009, Prabhakar and 
Doble 2011) and Jung et al. demonstrated that ferulic acid had hypoglycaemic effects in 
diabetic mice, decreasing blood glucose and cholesterol levels while increasing insulin 
and hepatic glycogen synthesis (Jung, Kim et al. 2007). Ferulic acid increased glucose 
uptake and insulin signalling also in other systems (Bhattacharya, Christensen et al. 2013, 
Gogoi, Chatterjee et al. 2014, Narasimhan, Chinnaiyan et al. 2015, Ho, Kase et al. 2017), 
but none of these groups tested ferulic acid metabolites. Again, there are no published 
data on the effects on glucose uptake or metabolism by circulating ferulic acid 
metabolites. 
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1.3.2.5 Resveratrol and its conjugates 
For some time, resveratrol has been known for its anticancer properties (Aggarwal, 
Bhardwaj et al. 2004) and, more recently, its conjugates have shown such activity, 
notably in the colon by resveratrol 3-O-sulfate (Aires, Limagne et al. 2013). Much like 
quercetin, resveratrol has displayed pleiotropic activities, modulating various cellular 
targets, many of which hold promise as a potential antidiabetic therapeutic. Such effects 
on glucose uptake and cellular signalling and metabolism were reviewed earlier this year 
(Leon, Uribe et al. 2017). From in vitro and in vivo studies, in both animals and humans, 
it seems that resveratrol only improves insulin sensitivity in insulin-resistant models or 
individuals (Kang, Hong et al. 2012, Poulsen, Vestergaard et al. 2013, Liu, Zhou et al. 
2014). On the other hand, an earlier study suggests that resveratrol may enhance insulin 
secretion from the pancreas, but only in normal rats and not in streptozotocin-diabetic 
rats (Chen, Chi et al. 2007). Mechanisms whereby resveratrol may improve insulin 
sensitivity are centred on AMPK-mediated pathways, rather than those that are PI3K-
dependent. Breen et al. showed that deoxyglucose uptake was stimulated by resveratrol 
at 25-100 µM in L6 myotubes and that this was prevented by AMPK or sirtuin inhibition. 
Furthermore, while resveratrol did not significantly induce translocation of GLUT4 or 
GLUT1, the GLUT4 inhibitor indinavir also blocked the resveratrol-stimulated uptake 
(Breen, Sanli et al. 2008). Another study found that GLUT4 translocation was increased 
in vivo in rats and in C2C12 myotubes. GLUT4 expression was not increased but 
caveolin-3, a protein associated with GLUT4 translocation, was upregulated via 
activation of estrogen receptor (Tan, Zhou et al. 2012). In another study resveratrol 
upregulated GLUT4, SIRT1 and activated AMPK in the muscle of diabetics, resulting in 
improved energy expenditure similar to that with increased exercise (Goh, Lee et al. 
2014). 
Clinical studies, reviewed in (Leon, Uribe et al. 2017), demonstrated that resveratrol 
improved insulin resistance and lowered glycaemia, cholesterol, oxidative stress and 
markers of diabetes. In this review the authors draw on the evidence that the anticancer 
properties of resveratrol may be attributable, at least in part, to its effects on glucose 
uptake and metabolism (Leon, Uribe et al. 2017). In cancer cell lines, resveratrol inhibits 
GLUT1 (Salas, Obando et al. 2013, Gwak, Haegeman et al. 2015) and thus disrupts the 
glycolytic-dependent metabolism. Via activation of AMPK and SIRT, FOXO1 is another 
target of resveratrol (Kulkarni and Canto 2015, Sin, Yung et al. 2015), and so is the 
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insulin signalling pathway. FOXO1 negatively regulates insulin signalling to inhibit 
glucose uptake and glycolysis via pyruvate dehydrogenase lipoamide kinase 4 (PDK4), 
and, together with SIRT1 this stimulates mitochondrial function (Canto, Gerhart-Hines 
et al. 2009, Price, Gomes et al. 2012). Carbon flux is channelled away from the glycolytic 
pathways, which is another anticancer mechanism. Higher doses of resveratrol (100 µM) 
have been shown to inhibit insulin in human adipocytes (Gomez-Zorita, Treguer et al. 
2013) and AMPK, β-oxidation and glucose metabolism in human myotubes (Skrobuk, 
von Kraemer et al. 2012), revealing its hormetic effects, akin to the dose-dependent 
effects of quercetin. 
Resveratrol is also implicated in the management of diabetic complications, including 
CVDs (Huang, Huang et al. 2010). Multiple benefits of resveratrol have been 
highlighted, with further examples provided in Chapter 3. Although, once again, all 
reports are for the aglycone and not on resveratrol conjugates. However, resveratrol is 
that is rapidly metabolised in vivo and is found circulating almost entirely in conjugated 
forms (see 1.3.1.4). So while numerous studies demonstrate that resveratrol impacts 
glucose uptake and metabolism, with implications for diabetes, cancer, or CVDs, not one 
has examined the relevance of the sulfate or glucuronide conjugates to these effects. 
1.3.2.6 Berries, anthocyanins and their phenolic sulfate metabolites 
Berries are rich in anthocyanins among other (poly)phenols and ingestion results in a 
range of plasma metabolites. Human intervention studies have found antidiabetic 
benefits to consuming berries (Castro-Acosta, Lenihan-Geels et al. 2016) possibly linked 
to these metabolites. Supplementation with blueberries twice daily for 6 weeks was found 
to improve insulin sensitivity in obese, insulin-resistant individuals (Stull, Cash et al. 
2010) and in two studies by Torronen et al. berries reduced postprandial insulin responses 
to ingestion of bread and postprandial glucose responses to sucrose, both in healthy 
subjects (Torronen, Sarkkinen et al. 2010, Torronen, Kolehmainen et al. 2013). A study 
in our lab found that for healthy subjects, consumption of a (poly)phenol-rich fruit purée 
containing apple and berries, along with green tea, also helped to attenuate postprandial 
glucose and insulin responses (Nyambe-Silavwe and Williamson 2016). Similar effects 
were seen for bilberry (Hoggard, Cruickshank et al. 2013) and strawberry lowered 
postprandial insulin and inflammatory markers (Edirisinghe, Banaszewski et al. 2011). 
The (poly)phenols found in cinnamon include caffeic acid and protocatechuic acid 
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(Rothwell, Perez-Jimenez et al. 2013) and, consequently, similar metabolites to those 
from berries may arise in the plasma following consumption. Several human studies have 
demonstrated benefits to eating cinnamon (Khan, Safdar et al. 2003, Hlebowicz, 
Hlebowicz et al. 2009, Lu, Sheng et al. 2012), for which phenolic sulfates may, at least 
in part, be accountable. Furthermore, as these metabolites have been shown to originate 
from chlorogenic acids (Xie, Lee et al. 2016), the same may apply for the beneficial 
effects of drinking coffee. 
In vitro investigations suggest the primary mechanisms for the anthocyanin effects in 
vivo are inhibition of carbohydrate digestion and absorption in the gut (Adisakwattana, 
Ngamrojanavanich et al. 2004, McDougall, Shpiro et al. 2005, Iwai, Kim et al. 2006, 
Akkarachiyasit, Charoenlertkul et al. 2010, Ifie, Marshall et al. 2016) and increased 
glucose uptake into muscle and adipose. A range of studies established that a major 
parent anthocyanin conjugate, cyanidin 3-O-glucoside, and/or its metabolite, 
protocatechuic acid, elevated deoxyglucose uptake in L6 and C2C12 myotubes and in 
3T3-L1 and human adipocytes via both insulin- and AMPK-dependent pathways 
(Yamamoto, Ueda et al. 2010, Scazzocchio, Vari et al. 2011, Chellan, Muller et al. 2012, 
Rojo, Ribnicky et al. 2012, Scazzocchio, Vari et al. 2015, Luna-Vital, Weiss et al. 2017). 
In the study by Rojo et al. the anthocyanin glucoside extract also lowered hepatic 
gluconeogenesis (Rojo, Ribnicky et al. 2012) and Luna-Vital et al. showed additional 
effects of cyanidin 3-O-glucoside in reducing adipocyte precursor differentiation, fatty 
acid synthase activity, inflammatory markers, leptin and ROS (Luna-Vital, Weiss et al. 
2017). An earlier study generated similar data, as well as showing increased gene 
expression for mitochondrial function in muscle (Matsukawa, Inaguma et al. 2015) and 
an earlier review highlighted the potential benefits of anthocyanins for hepatic lipid 
metabolism (Valenti, Riso et al. 2013). While protocatechuic acid and cyanidin 3-O-
glucoside are detected following anthocyanin ingestion, they comprise only a small 
percentage of the circulating metabolites (de Ferrars, Czank et al. 2014), so this could be 
another example of research focusing on potentially an irrelevant form of a compound 
and claiming it could account for antidiabetic effects of foods or extracts in vivo. 
Phase II metabolites, such as vanillic acid and its sulfates, circulate in much greater 
proportions (de Ferrars, Czank et al. 2014, Ludwig, Mena et al. 2015). In another study 
by Ho et al., both protocatechuic and vanillic acids, among several other anthocyanins 
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and (poly)phenols, increased glucose uptake but this study has the same drawbacks as 
the one scrutinised in section 1.3.2.3 with regard to kaempferol (Ho, Kase et al. 2017). 
Almost no tests were performed for the phase II metabolites downstream of 
anthocyanins, protocatechuic acid and gallic acid absorbed from berries. The Haddad 
group took a small step in the right direction, with their two studies on fermented 
blueberry juice, which lowered hepatic gluconeogenesis and triglyceride content in 
adipocytes while increasing hepatic glycogen synthase activity and glucose uptake in 
muscle and adipose via AMPK (Vuong, Martineau et al. 2007, Nachar, Eid et al. 2017). 
However, in the subsequent experiments to elucidate the compounds responsible, the 
authors focused on the parent compounds identified in the juice, rather than potential 
metabolites. 
The biological activities of phase II (poly)phenol metabolites from berries are practically 
unknown. Of the limited data available, most concern anti-inflammatory effects. Vanillic 
acid lowered cyclooxygenase-2 expression and NFκB activity, leading to lowered plasma 
interleukin (IL)-6 and suppressed ulcerative colitis in mice (Kim, Kim et al. 2010) and 
was shown to suppress elevated cytokine levels and improve sinusoid organisation in a 
murine liver injury model (Itoh, Isoda et al. 2009). Two recent studies by the Kay group 
highlighted the potential of anthocyanin and flavonoid metabolism to enhance vascular 
efficacy (Warner, Zhang et al. 2016, Warner, Smith et al. 2017). The metabolites, but not 
the parental compounds, inhibited vascular cellular adhesion molecules (VCAM) and 
inflammatory markers in human endothelial cells. Among the compounds tested, 
isovanillic acid and its 3-O-glucuronide metabolite lowered soluble VCAM-1 expression 
(Warner, Zhang et al. 2016) and pre-treating endothelial cells with anthocyanin 
metabolite signatures, which included (iso)vanillic acids and their glucuronide and 
sulfate metabolites, inhibited TNF-α stimulation of VCAM-1 and IL-6 secretions 
(Warner, Smith et al. 2017). Similarly, isovanillic acid and its 3-O-glucuronide conjugate 
have been shown to reduce lipopolysaccharide-induced TNF-α secretion in monocytes 
(di Gesso, Kerr et al. 2015) and a mixture of blueberry anthocyanin metabolites, which 
included vanillic acid 4-O-sulfate and isovanillic acid 3-O-sulfate, ameliorated 
palmitate-induced cell adhesion and inflammation in endothelial cells (Cavalcanti, 
Begaye et al. 2015). There are no published data for biological activities of other berry 
metabolites catechol-O-sulfate, 4-methylcatechol-O-sulfate, pyrogallol-O-sulfate or 4-
methylgallic acid 3-O-sulfate. 
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Complementary to the antidiabetic effects, recent investigations have exhibited 
promising results for the consumption of anthocyanin-rich beverages or anthocyanin 
extract supplementation to aid skeletal muscle performance in athletes. A blackcurrant 
extract given to healthy men for 7 days, in a randomised, double-blind, crossover 
intervention, lowered blood pressure and muscle oxygen saturation while increasing 
cardiac output, femoral artery diameter and enhancing muscle activity (Cook, Myers et 
al. 2017). An açai beverage increased time to exhaustion in athletes running on a 
treadmill, while attenuating metabolic stress induced by the exercise (Carvalho-Peixoto, 
Moura et al. 2015). Moreover, six weeks of daily supplementation with 100 mg 
anthocyanin tablets significantly increased VO2 max in athletes, though no changes in 
body composition or muscle damage were observed (Yarahmadi, Askari et al. 2014). A 
recent review of several studies that investigated the effects of cherry consumption on 
exercise-induced muscle damage found that typically the cherry juices prevented 
soreness and improved muscle recovery, while lowering or unchanging biomarkers of 
oxidative stress and inflammation (Coelho Rabello Lima, Oliveira Assumpcao et al. 
2015). Further work is required, however, to elucidate specific mechanisms of action and 
compounds responsible and the anthocyanins do not always produce measureable effects, 
for example cherry juice had no effect on water polo players, though this could also 
indicate a dependence on the type of exercise involved and habitual diets of the 
participants (McCormick, Peeling et al. 2016). It would be interesting to investigate the 
physiological effects of anthocyanin metabolites on skeletal muscle both in vivo and in 
vitro. 
1.3.2.7 Skeletal muscle cell models for studying glucose uptake and metabolism 
The majority of in vitro analyses of the effects of parent (poly)phenol compounds on 
glucose uptake and metabolism have been done on rat or mice cell models, with some 
experiments in primary human cells. Primary cells from biopsies, ideally taken during 
the course of a disease, are important because they closely match the genotype of muscle 
in vivo, though only for the specific donor. However, this model relies on the availability 
of samples, there can be substantial variation in cells between cultures, even from the 
same donor, and they have a limited lifespan. The advantage of using an immortalised 
muscle cell line is that experiments can be easily seeded for with consistent preselected 
myoblast densities, multiple treatments across different dishes and allow for numerous 
biological (and technical) replicates of reproducible monolayer cultures. Use of an 
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immortalised clone enables a pure myogenic culture, free from contamination of other 
cells such as fibroblasts in an ex vivo or primary system, which is readily propagated to 
provide an unlimited source of cells of the same genetic background. Suitable markers 
of muscle differentiation are essential however, because proliferating myocytes 
eventually lose myogenic characteristics and become fibroblastic, and the degree of 
fusion and differentiation can vary (Miranda 2014). 
While established rodent cell lines such as L6 or C2C12 for skeletal muscle, or 3T3-L1 
in the case of adipose tissue, are useful tools for probing the effects of compounds on 
glucose uptake and metabolism, the mechanisms in play and the extent to which changes 
are induced may differ to those in human cells, thus caution should be taking when 
interpreting data from such models. In a recent study, cultured murine and human 
satellite cells were compared and divergence in the myogenic genetic programming were 
highlighted, indicating that the mechanisms regulating differentiation between the 
species are not all the same, and there were differences in inflammatory signalling in 
response to cytokine stimulation (Bareja, Holt et al. 2014). Differences between mouse 
and human at the transcriptome level are dependent on the muscle tissue type (Kho, Kang 
et al. 2006, Breschi, Gingeras et al. 2017). Expression of myosin heavy chain varies 
between muscle type and species (human, rat and mouse) at the tissue level (Bloemberg 
and Quadrilatero 2012) and glycosylation of proteins at the plasma membrane of 
differentiated myotubes in vitro also varies between mouse and human (McMorran 
2017). Important to the context of this research project, an earlier review on the GLUT 
family highlighted the difference between rat and human glucose transport kinetics in 
response to insulin in vitro and the variation in GLUT4 expression between a diabetic 
mouse model and diabetic humans (Gould and Holman 1993). 
Taking this information into account, in the present study, the immortalised human 
skeletal muscle cell line, LHCN-M2 (human skeletal myoblasts immortalised with lox-
hygro-hTERT ("LH") and Cdk4-neo ("CN"), well-differentiating subclone M2) (Zhu, 
Mouly et al. 2007), is characterised as a model to explore the unknown effects of relevant 
(poly)phenol metabolites on glucose uptake and metabolism. Regardless of the pros and 
cons of different cell models, this is the first study on the effects of any (poly)phenol 
compounds on glucose in immortalised human myotubes. 
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1.4 Concluding remarks and project aims 
Type 2 diabetes is a global endemic caused primarily by overnutrition and lack of 
physical activity. This results in a perturbation in glucose and lipid metabolism with 
increased systemic oxidative stress and mitochondrial dysfunction, elevated 
inflammation, and a loss of insulin sensitivity in liver, adipose tissue and skeletal muscle. 
(Poly)phenol-rich foods have been linked to the prevention and management of this 
disease and information from the literature suggests that this is, in part, via the prevention 
of oxidative stress and improvements in postprandial glucose uptake. However, most of 
the mechanisms remain to be ascertained or clarified in detail. 
Quercetin in particular has shown promise in restoring mitochondrial function and yet 
there have been no studies investigating its effects in a high glucose environment. 
Furthermore, a greater understanding is required of its pleiotropic mechanisms of action 
and how its hormetic effects on the mitochondria may affect cellular metabolism in 
general, and glucose and lipid metabolism in the liver specifically. To this end, the well-
established HepG2 cell line is utilised to investigate the mitochondrial dysfunction 
caused by high glucose and any effects that quercetin may have in ameliorating this. A 
combination of ETS activity assays and whole cell respirometry are used, together with 
markers for redox status and mitochondrial content and function, providing detail on 
numerous aspects of mitochondrial physiology. 
A range of human intervention, animal and in vitro studies demonstrate that 
(poly)phenols may improve postprandial glycaemia and specifically uptake into skeletal 
muscle, but the effects of relevant metabolites that would be found in the plasma in vivo 
are unknown. Berries are one source of (poly)phenols for which trials have demonstrated 
the ability to affect postprandial glycaemia, insulinaemia and sensitivity and 
inflammation. The consumption of berries gives rise to a range of diverse plasma 
metabolites, but knowledge on the biological activity of specific compounds is unknown, 
in particular relating to their potential effects on glucose uptake. As such, the LHCN-M2 
myoblast cell line shall be characterised and used as a model for human skeletal muscle 
to research the effects of glucose, insulin and (poly)phenol metabolites on glucose uptake 
and cellular metabolism. 
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Here is an outline of the specific aims for this project: 
 Determine novel effects of high glucose and oxidative stress on mitochondrial 
function in HepG2 cells. 
 Explore the acute and chronic effects of quercetin on mitochondrial physiology in 
HepG2 cells grown in a physiologically normal or high glucose concentration. 
 Propose the mechanism(s) of action for the potential protective role of quercetin 
against high glucose-induced mitochondrial dysfunction. 
 
 Characterise the LHCN-M2 cell line and establish appropriate biomarkers to assess 
its use as a model of human skeletal muscle specifically for metabolic studies. 
 Investigate the effects of glucose and insulin on cellular metabolism and muscle 
characteristics such as myotube differentiation, metabolic phenotype and insulin-
stimulated glucose uptake. 
 Analyse the potential effects of relevant (poly)phenol metabolites, which can be 
found in circulation in vivo after the consumption of common parent compounds, 
on glucose uptake and metabolism in differentiated myotubes. 
 Elucidate the mechanism(s) of action through which any effects may be elicited, 
such as expression of the GLUTs and interaction with insulin signalling. 
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Chapter 2  
Quercetin preserves electron transfer system efficiency and 
redox status and stimulates mitochondrial function in high 
glucose-stressed HepG2 cells. 
2.1 Abstract 
Hyperglycaemia results in enhanced intracellular ROS, leading to mitochondrial damage 
and increased risk of developing insulin resistance and type 2 diabetes. Quercetin 
accumulates in mitochondria and by affecting various molecular targets it may 
beneficially impact cellular metabolism. The aim here was to investigate whether 
quercetin could reverse chronic high glucose-induced oxidative stress and mitochondrial 
dysfunction. HepG2 cells were cultured in normal (5.5 mM) or high (25 mM) glucose 
for 4 days and treated with various concentrations of quercetin. After culturing in high 
glucose, complex I activity in isolated mitochondria was significantly decreased, but this 
was concentration-dependently recovered by quercetin treatment. In addition, cellular 
ROS generation was lowered by quercetin in both high and low glucose. Respirometry 
data showed that quercetin reversed the detrimental increase in IMM proton leakage in 
high glucose. Oxidative respiration was also increased by quercetin, owing to elevated 
net mitochondrial respiration despite a decrease in ETS capacity, and lower non-ETS 
oxygen consumption. Furthermore, quercetin stimulated increases in cellular 
NAD+/NADH and subsequently in PGC-1α mRNA (messenger ribonucleic acid), a well-
established marker of mitochondrial biogenesis and function. These results suggest that 
quercetin may restrict high glucose-induced mitochondrial stress by increasing cellular 
NAD+/NADH and activating PGC-1α-mediated pathways to increase mitochondrial 
oxidative function. The key outcome of this is lowered ROS generation and an 
improvement in complex I activity and ETS coupling efficiency after quercetin 
treatment, where the oxidative stress generated by high glucose is diminished and 
ultimately mitochondrial integrity is enhanced. 
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2.2 Introduction 
Hyperglycaemia is a typical biomarker of obesity, type 2 diabetes and metabolic 
syndrome (Krentz and Hompesch 2016), since high levels of glucose in the blood lead 
to intracellular oxidative stress in tissues involved in glucose metabolism (Murphy 2009, 
Yan 2014, Gero, Torregrossa et al. 2016). Although mitochondria are a source of 
oxidative stress, they are also a principal target of attack by reactive oxygen and nitrogen 
species themselves (Starkov 2008, Kang and Pervaiz 2012). The resulting mitochondrial 
dysfunction exacerbates the stress further in a downward spiral linked with a perturbation 
in glucose and lipid metabolism, insulin resistance, and ultimately hyperglycaemia, and 
the onset of type 2 diabetes (Sivitz and Yorek 2010, Blake and Trounce 2014, Luo, Li et 
al. 2015, Chow, Rahman et al. 2016, Zaccardi, Webb et al. 2016). The cause-effect 
relationship between mitochondrial dysfunction and insulin resistance is still debated 
(Montgomery and Turner 2015), but it is likely they both occur as a result of the high 
glucose stress. 
Quercetin is a flavonoid that accumulates in mitochondria (Fiorani, Guidarelli et al. 
2010) and affects their function directly and indirectly through various signalling 
pathways, such as those associated with biogenesis, metabolic flux, respiration, 
mitochondrial membrane potential and apoptosis (Fiorani, Guidarelli et al. 2010, 
Sandoval-Acuna, Ferreira et al. 2014, de Oliveira, Nabavi et al. 2016). Quercetin and 
other flavonoids may have beneficial effects in modulating glucose digestion and 
absorption (Nomura, Takahashi et al. 2008, Williamson 2013, Nyambe-Silavwe, Villa-
Rodriguez et al. 2015) and metabolism, through affecting expression of glycolysis-
involved genes (Leiherer, Stoemmer et al. 2016) and the aforementioned effects on 
mitochondria. In streptozotocin-induced diabetic rats, quercetin dose-dependently 
decreased blood glucose, cholesterol and triglyceride levels, as well as increasing hepatic 
glucokinase activity (Vessal, Hemmati et al. 2003) and decreasing hepatic oxidative 
stress markers (Chis, Muresan et al. 2016). Activities on mitochondrial function and 
glucose homeostasis make quercetin a widely-studied compound for its potential uses in 
the prevention and management of type 2 diabetes (Akash, Rehman et al. 2014, Haddad 
and Eid 2016), however details of its pleiotropic mechanisms require further elicitation, 
not least that studies are lacking in considering these mechanisms in a high glucose 
environment. 
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The mechanisms of action of quercetin on mitochondria in hepatic cells, grown 
chronically in high or normal glucose (to model hyperglycaemia versus 
normoglycaemia), were explored in light of its potential to prevent oxidative stress, 
mitochondrial damage and subsequent diabetes pathophysiology at the cellular level. The 
majority of previous in vitro studies looking at the effects of quercetin on mitochondria 
have often employed acute treatments (several minutes or hours) directly to isolated 
organelles in a kinetic experiment setup (Lagoa, Graziani et al. 2011, Sandoval-Acuna, 
Lopez-Alarcon et al. 2012, Waseem and Parvez 2016), but in the present study it was 
assessed as to how intracellular mitochondrial function was affected by prolonged 
quercetin exposure. Complex I of the electron transfer system (ETS) was focussed on, as 
it is known to be a major source and target of mitochondrial superoxide generation (Hirst 
and Roessler 2016) and thus is central to high glucose-induced oxidative stress (Blake 
and Trounce 2014, Yan 2014), with the hypothesis that quercetin may have an alleviating 
role. Surplus glucose and thus NADH can overload complex I and cause excess 
superoxide generation and Luo et al. suggested if there was a compound that would allow 
complex I to be bypassed in the ETS it would dissipate the ROS generated (Luo, Li et al. 
2015); quercetin may do just that. Lagoa et al. found that quercetin lowered hydrogen 
peroxide production and inhibited complex I in isolated rat brain mitochondria, with the 
latter being reversed by addition of CoQ10 (Lagoa, Graziani et al. 2011). Sandoval-Acuña 
et al. added quercetin to mitochondria isolated from rat duodenum and found it protected 
complex I from inhibition by non-steroidal anti-inflammatory drugs, suggesting a CoQ-
like function for the flavonoid (Sandoval-Acuna, Lopez-Alarcon et al. 2012). This could 
be a chronic mechanism by which quercetin acts when complex I is faced with high 
glucose oxidative stress. 
 
Likewise, the impact of quercetin on cellular and mitochondrial respiration in intact cells 
was investigated, and how respiration may be controlled via cellular oxidative status, 
drawing comparisons between high and normal glucose-treated cells. There is evidence 
of quercetin improving mitochondrial bioenergetics, increasing respiration coupling 
efficiency in rat pancreatic cells (Carrasco-Pozo, Tan et al. 2016) and increasing 
respiratory capacity and cell survival in primary cortical neuronal cells (Nichols, Zhang 
et al. 2015). Quercetin has also been shown to stimulate mitochondrial metabolic 
signalling pathways (Nichols, Zhang et al. 2015). Rayamajhi et al. and Kim et al. showed 
that quercetin increases PGC-1α, NRF-1 and mitochondrial transcription factor A 
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(TFAM) mRNA in HepG2 cells and mouse primary hepatocytes respectively 
(Rayamajhi, Kim et al. 2013, Kim, Kwon et al. 2015), but this has not yet been tested in 
a human in vitro system with a high glucose stress and chronic quercetin treatment. 
Presented here for the first time are the dose-dependent chronic (≥ 24 h) effects of 
quercetin on intracellular complex I activity and mitochondrial respiration in cells 
stressed by chronic high glucose, and with this a proposed mechanism by which quercetin 
exerts these effects, directly and via gene expression and oxidative signalling pathways. 
 
2.3 Materials and Methods 
2.3.1 Chemical compounds and reagents 
All cell culture medium components and all other reagents were purchased from Sigma-
Aldrich (Gillingham, UK) unless otherwise stated. High purity (18.2 MΩ cm-1) water 
supplied by a MilliQ system (Merck Millipore UK, Watford, UK) was used throughout 
this work. 
2.3.2 Cell culture 
HepG2 cells were derived originally from adolescent human hepatocellular carcinoma 
and is a well-established cell line (Knowles 1983) of the American Type Culture 
Collection (HB-8065, LGC Promochem, Teddington, UK). The cells were maintained in 
Eagle’s minimum essential medium (MEM) containing 5.5 mM glucose and 
supplemented with 10% (v/v) heat-inactivated foetal bovine serum, 100 U/ml penicillin, 
100 mg/ml streptomycin, 2% (v/v) non-essential amino acids, and 1% (v/v) sodium 
pyruvate, in a humidified atmosphere of 5% CO2/95% air. Medium was changed at least 
every two days while sub-culturing and cells were used for experiments during passages 
83-91, for which they were seeded in 75 cm2 flasks, 6-well, 24-well or 48-well plates (all 
from Appleton Woods, Birmingham, UK), or 100 mm2 dishes (Greiner Bio-One, 
Stonehouse, UK) at a density equivalent to 8 x 104 cells cm-2. Medium was supplemented 
with additional glucose for cells grown in 25 mM glucose for experiments but was 
otherwise unchanged. Cells were monitored and images acquired using the Leica DM IL 
LED (Milton Keynes, UK) inverted microscope. For experiments, N/n values indicate 
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the number of independent biological passages (N) and the number of technical replicates 
(n) from which the data were acquired. 
2.3.3 Trypan Blue exclusion cell viability assay 
HepG2 cells were seeded into T75 flasks or 6-well plates and maintained in MEM 
containing 5.5 mM (NG) or 25 mM (HG) glucose for 96 h. Medium was changed 48 h 
after seeding and then again for the final 24 h but FBS was removed and 10 or 20 µM 
quercetin (Extrasynthese, Genay, France) (or DMSO controls) added. After the 24 h 
treatment cells were lifted with 0.25% trypsin-EDTA or TrypLE Express (Thermo Fisher 
Scientific, Warrington, UK), resuspended in 1 ml medium and an aliquot mixed 1:1 (v/v) 
with 0.4% Trypan Blue-PBS. Resuspended cells were counted and assessed for Trypan 
Blue exclusion as done previously (Strober 2001), but using a TC10 automated cell 
counter (Bio-Rad Laboratories, Hercules, CA, USA). Viable cells excluding Trypan Blue 
were given as a percentage of total cells counted. 
2.3.4 Isolation of mitochondria 
An important aspect to this work was optimising the mitochondrial isolation process to 
gain viable and intact mitochondria. HepG2 cells were seeded into T75 flasks and grown 
in normal or high glucose medium for 96 h; for the final 24 h without FBS but with 2.5, 
5, 10 or 20 µM quercetin (or DMSO controls) added. Cells were scraped into 1 ml PBS 
supplemented with 1% (v/v) protease inhibitor cocktail P8340, centrifuged at 210 g, 4oC 
for 5 min and snap-frozen in ethanol over dry ice. Cell pellets were stored at -80oC until 
required for mitochondrial isolation. Mitochondria were prepared from thawed cell 
pellets by homogenisation and differential centrifugation (see Fig. 2.1) using the reagents 
and Dounce homogeniser from the Mitochondria Isolation Kit for Cultured Cells (ab 
110171, Abcam, Cambridge, UK). The manufacturer’s protocol guidelines were 
followed, but adapted with an extra 1000 g, 5 min centrifugation step added at the end 
for a purer preparation. 
 
 
- 50 - 
 
 
Cell pellets were thawed then frozen-thawed twice more and whole cell pellet protein 
determined by absorbance at 280 nm on the NanoDrop ND-1000 (Thermo Scientific, 
Wilmington, DE, USA). Cells were resuspended at 5 mg/ml in the ‘Reagent A’ 
(containing triethanolamine, Tris, digitonin, EDTA) provided, incubated on ice for 10 
min and homogenised in the pre-cooled 2 ml glass Dounce homogeniser, with 30 strokes 
of pestle B. The homogenate was centrifuged at 1000 g, 4oC for 10 min (SPIN 1a) and 
the supernatant recovered. The pellet was resuspended in ‘Reagent B’ (containing Tris, 
digitonin, EDTA) in the same volume as used of Reagent A, and the incubation, 
homogenisation and centrifugation (SPIN 1b) repeated and the supernatant recovered, 
this time the pellet was discarded. The supernatants from SPINs 1a and 1b were 
combined and centrifuged at 12,000 g, 4oC for 15 min (SPIN 2) and the pellet collected. 
The pellet, crude mitochondrial isolate, was resuspended in 0.5 ml 250mM sucrose/10 
mM HEPES/50mM Tris buffer, pH 7.4 and centrifuged once more at 1000 g, 4oC for 5 
min (SPIN 3). The final mitochondrial pellets were resuspended in 250 mM sucrose/10 
mM HEPES/50 mM Tris, pH 7.4, supplemented with 1% (v/v) protease inhibitor cocktail 
P8340, snap-frozen and stored at -80oC until used for complex I and Western analyses. 
Figure 2.1: Isolation of mitochondria from HepG2 cells. Several homogenisation and 
differential centrifugation steps were used. Mitochondrial fraction was resuspended 
in 250 mM sucrose/10 mM HEPES/50 mM Tris buffer and spun again to remove 
any remaining debris. 
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2.3.5 Western blot assessment of mitochondrial isolation process 
Aliquots from throughout the mitochondrial isolation process, of the initial cell lysate, 
supernatants, resuspended pellets and the final mitochondrial isolates, (see 2.3.4) were 
taken and snap frozen and stored in -80oC to analyse by Western blot at a later date. Once 
thawed, total protein in each aliquot was determined by absorbance at 280 nm on the 
NanoDrop and 10µg of each were incubated with 4x Laemmli sample buffer (Bio-Rad 
Laboratories, Hemel Hempstead, UK) at 37oC for 15 min. Standard sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) procedures were followed 
using a Mini-PROTEAN TGX Stain-Free Precast Gel (Bio-Rad Laboratories, UK) and 
then subsequent transfer to polyvinylidene fluoride (PVDF) membranes. After blocking, 
membranes were probed with mouse anti-NDUFB8 (ab110242, Abcam) (subunit of 
complex I) primary antibody followed by 1:10,000 horseradish peroxidase-conjugated (-
HRP) secondary antibody (Bio-Rad Laboratories, UK). Immunoreactive proteins were 
visualised using Clarity Western ECL Substrates (Bio-Rad Laboratories, UK) luminol 
and peroxide (1:1 mix) and then developed and fixed onto photographic film (Fig 2.2). 
2.3.6 Western analysis of mitochondrial fraction purity 
Total protein in aliquots of the initial cell lysate and the isolated mitochondrial fraction 
of HepG2 cells was determined by absorbance at 280 nm on the NanoDrop and prepared 
for running on the ProteinSimple Wes automated western blot system (Bio-Techne, 
ProteinSimple, San Jose, CA, USA) using reagents supplied in the system kit according 
to the manufacturer’s guidelines. Samples were denatured at 37oC for 20 min and loaded 
onto the pre-filled assay plate at 4.8 mg/ml mitochondrial protein, with 1:100 primary 
mouse anti-NDUFB8 and the supplied anti-mouse secondary. Chemiluminescence was 
detected in high dynamic range (HDR) mode and the peaks seen at 27 kDa converted to 
traditional Western-like bands. This confirmed increased mitochondrial protein 
(NDUFB8) in the mitochondrial isolate, as seen with the traditional Western Blot (Fig. 
2.2). 
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Figure 2.2: Western blot showing the expression of mitochondrial protein complex 
I subunit NDUFB8 in aliquots taken throughout mitochondrial isolation 
process. Protein samples were subjected to SDS-PAGE procedures with 
subsequent transfer to PVDF membranes. After blocking, membranes were probed 
with mouse anti-NDUFB8 primary antibody followed by HRP-conjugated 
secondary antibody. Immunoreactive proteins were visualised using luminol and 
peroxide and developed and fixed onto photographic film. 1 – whole HepG2 cell 
lysate; 2 – supernatant after first centrifugation; 3 – supernatant after second 
centrifugation; 4 – supernatant after third centrifugation, containing little to no 
mitochondrial material; 5-7 – resuspended mitochondrial isolates following high-
speed centrifugation of combined first and second supernatants. 
2.3.7 Complex I activity assay 
Mitochondria from HepG2 cells grown in normal or high glucose for 96 h and treated 
with varying concentrations of quercetin (or DMSO controls) for the final 24 h were 
isolated in 250 mM sucrose/10 mM HEPES/50 mM Tris, pH 7.4, and assayed for 
complex I specific activity spectrophotometrically in 96-well plates on a PheraSTAR FS 
microplate reader (BMG LabTech, Ortenberg, Germany) at 37oC. 10 µg isolated 
mitochondria (as determined by NanoDrop) were mixed with 150 µM NADH (VWR, 
Lutterworth, UK) and 50 µM coenzyme Q1 (CoQ1, analog of CoQ10) and the decrease in 
absorbance at 340 nm followed for 60 min, as done previously (Ragan 1987, Janssen, 
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Trijbels et al. 2007, de Wit, Scholte et al. 2008, Usta, Kreydiyyeh et al. 2009, Oliveira, 
Kiyomoto et al. 2013) and optimised for sample mass and NADH/CoQ1 concentrations 
(see 2.3.7.1). Specific activity was calculated by converting rate of absorbance change 
into rate of NADH decrease per mg of total protein and then normalised to the normal 
glucose controls. 
2.3.7.1 Optimising the complex I assay 
Complex I enzyme activity was assayed spectrophotometrically using the isolated 
HepG2 mitochondria with various reaction conditions and protocol variants evaluated. 
After initial trials, the assay was tried with varied mitochondrial preparation amounts 
(enzyme concentration) and it was deemed that 10 µg mitochondria was sufficient to give 
a linear rate in NADH oxidation over 60 min, while allowing for plenty of material from 
each cell pellet. Varying NADH (substrate) concentrations of 150 µM, 500 µM, 750 µM 
and 1500 µM were assayed. ≥750 µM gave absorbance measurements of ≥2.0 and 
therefore could not be used and while 500 µM and 750 µM gave good rates, the original 
150 µM NADH concentration gave the most reproducible and linear data. Furthermore, 
>150 µM NADH showed too much non-mitochondria-specific oxidation. Plotting 
complex I activity against NADH concentration gives a linear curve up to 500 µM and 
reaches Vmax at >500 µM; complex I is saturated with substrate. 
Linalool was added to the assay, as done by Usta et al. (Usta, Kreydiyyeh et al. 2009), at 
concentrations of 5 µM and 20 µM against an ethanol control in the hope of being able 
to use linalool as a negative control. However, across several assays it was shown to 
inhibit complex I activity in the initial rate of reaction but then the activity recovered, 
suggesting a reversible inhibition. By the end of the assay complex I activity with 20 µM 
was actually greater than that of the control; it may also be that the ethanol in the control 
is more detrimental than the linalool, despite the data published in the literature. 
Coenzyme Q1 (CoQ1) was added to the assay as an analog of coenzyme Q10 (ubiquinone), 
with and without linalool (1 µl of linalool was added neat, giving a final concentration 
of 27 mM, which was >1000x greater than previously used so any effect linalool was 
having would potentially be clearer). The CoQ10 was tried at 50 µM and 100 µM as has 
previously been published (Ragan 1987, Usta, Kreydiyyeh et al. 2009) and had a 
dramatic effect on the rate of NADH oxidation. There was a 500% increase in activity 
when 50 µM CoQ1 was present in the assay and a ~900% increase with 100 µM CoQ1, 
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compared to no CoQ1 (with the volume of CoQ1 replaced with buffer) (Fig 2.3). 
Furthermore, the linalool showed an inhibitory effect previously unseen when the CoQ1 
was present, and when the linalool was at lower concentrations. In the absence of CoQ1 
linalool had no effect on activity compared with the ethanol control, but with 50 µM 
CoQ1 activity was decreased by 64% (Fig. 2.3). CoQ1 acts as a final electron acceptor 
from the oxidation of NADH by complex I and therefore allows the reaction to progress 
at a quicker rate. The fact that inhibition is seen only with CoQ1 present indicates that 
the linalool has an effect on the mechanism involved in complex I reducing the 
ubiquinone analog. Linalool could be used in future work as a negative control, however 
with such a high concentration required for complex I inhibition it may have other unseen 
detrimental effects and rotenone-inhibited controls are sufficient for the investigations 
here. 
 
 
Figure 2.3: NADH oxidase activity of complex I in isolated HepG2 mitochondria. 
The effect of varying coenzyme Q1 (CoQ1) (A) and of CoQ1 on linalool inhibition 
(B) on the complex I activity in 10 µg mitochondria, isolated from HepG2 cells 
grown for 96 h in 5.5 mM glucose, assessed with NADH (150 µM), corrected for 
non-mitochondrial oxidation by blank and rotenone-inhibited (2 µM) controls.  
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2.3.8 DCFH-DA ROS assay 
HepG2 cells were grown in 6-well plates for 96 h in normal or high glucose and treated 
for the final 2, 12 or 24 h with 2.5, 5, 10 or 20 µM quercetin (or DMSO controls). The 
DCFH-DA assay was used for assessing oxidative stress as previously (Wang and Joseph 
1999), but with modifications described as follows. Cells were washed with PBS, 
incubated with 10 µM DCFH-DA in PBS, 37oC, 20 min in darkness, washed again and 
fluorescence of DCF was measured on a PheraSTAR FS (Ex/Em = 485/530 nm). Cells 
were then scraped into and lysed in CellLytic M supplemented with 1% (v/v) P8340 
protease inhibitor cocktail and total protein measured using the Bradford assay (Pierce 
Coomassie (Bradford) Protein Assay Kit #23200, Thermo Fisher Scientific) as described 
previously (Bradford 1976, Ernst and Zor 2010). DCF fluorescence was corrected for 
protein and data normalised to a relative total ROS percentage of the controls. 
2.3.9 MitoOrange fluorescence and confocal microscopy 
The cytopainter ‘MitoOrange’ (ab176831, Abcam) was used to probe for mitochondria 
in live HepG2 cells grown on 48-well plates in normal or high glucose or galactose. The 
manufacturer’s protocol was followed; the 500X MitoOrange was diluted to 1X in 20 
mM HEPES in Hank’s Balanced Salt buffer and added to the cells with medium 1:1 (v/v) 
for 30 min in the incubator. The MitoOrange-containing buffer/medium was aspirated, 
the cells washed with the buffer and medium only added. The labelled cells were 
subsequently viewed under the Zeiss LSM 700 confocal laser scanning microscope (Fig. 
2.4) as well as assayed for fluorescence intensity (Ex/Em 540/590) on the PheraSTAR 
FS plate reader. When the cells were treated with quercetin, it was found that the 
flavonoid interfered with the uptake of the MitoOrange antibody and thus this was not 
pursued further; the citrate synthase activity assay provided a more accurate, and 
quantitative, measurement of mitochondrial content. 
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Figure 2.4: Confocal micrograph of HepG2 cells. HepG2 cells grown for 96 h in 5.5 
mM glucose were stained with mitochondrial marker MitoOrange (red) and DAPI 
(nuclei, blue) and image acquired using the Zeiss LSM 700 confocal microscope, 
magnification 20X. 
2.3.10 Citrate synthase activity assay 
Cells were grown in T75 flasks in normal or high glucose for 96 h, with 10 or 20 µM 
quercetin (or DMSO controls) for the final 24 h. Cell pellets, prepared as for when 
isolating mitochondria, were lysed in CellLytic and assayed for citrate synthase activity, 
a recognised marker for total mitochondrial content (Larsen, Nielsen et al. 2012), using 
reagents from the Citrate Synthase Assay Kit (CS0720, Sigma-Aldrich) and following 
the manufacturer’s instructions. Briefly, the formation of the 5-thio-2-nitrobenzoic acid 
colorimetric reaction product was measured on the PheraSTAR FS at 412 nm, 30oC for 
5 min and again following addition of oxaloacetic acid. Citrate synthase activity was 
calculated by correcting for the first reaction rate, a baseline of endogenous 
thiol/deacetylase levels, and for total protein, as measured optically at 280 nm 
(NanoDrop) prior to the assay. 
25 µM 
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2.3.11 High-resolution respirometry 
HepG2 cells, treated as for the citrate synthase assay, were washed in PBS and lifted 
from T75 flasks using TrypLE Express and resuspended in serum-free medium at 1.5 x 
106 cells/ml (after counting on the TC10 cell counter); this cell density was optimised for 
based on adequate material to provide distinguishable oxygen flux measurements in the 
various states and for oxygen in the sealed chamber to sustain the whole experiment. 
Oxygen concentration and flux was continuously measured as 2 ml of the cell 
suspensions were added to each chamber of the Oxygraph-2k (Oroboros Instruments, 
Innsbruck, Austria), maintained at 37oC, and a phosphorylation control protocol followed 
(Gnaiger 2014). Routine respiration was recorded first; Leak was measured following 
the addition of 250 nM oligomycin; ETS capacity was titrated by several additions of 5 
µM FCCP (carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone); and 1.25 µM 
rotenone and 2.5 µM antimycin A were both added at the end of the experiment to 
measure residual oxygen consumption (ROX) (see Fig. 2.5). These inhibitor and 
uncoupler concentrations were also optimised in preliminary experiments. 
The advantage of the O2k system is the precise measurement of oxygen flux in each 
respiratory state, but the disadvantage is the low throughput; one control and one 
treatment per respirometer. Each experiment took 96 h cell growth plus ~6 h experiment 
time to allow for 5.5. mM glucose versus 5.5. mM glucose + quercetin in one 
respirometer, 5.5 mM glucose versus 25 mM glucose in another, and 25 mM glucose 
versus 25 mM glucose + quercetin in a third experiment; the output from such an 
experiment is just four data points for each respiratory state. An extensive amount of 
time was spent optimising the protocol to account for cell density; too low and 
differences in flux owing to cell treatments are smaller, too high and the oxygen in the 
chamber is exhausted. HepG2 cells were very sensitive to oligomycin; adding too much 
resulted in the collapse of the ETS and effective cell death and again adding too little 
resulted in Leak not being achieved. Furthermore, the amount of FCCP required to 
uncouple ETS varied marginally in each experiment, hence the titration approach, and 
thus all of this combined lead to the need for a lot of experimental replicates to gain 
enough data for a realistic biological insight. 
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Figure 2.5: The electron transfer system and respirometry protocol. NADH is 
oxidised by complex I at the matrix side of the IMM and the donated electrons are 
transferred in turn through the redox complex to CoQ10 (QH2 and Q), complex III, 
cytochrome c (cyto c), complex IV and the final acceptor, O2 (white arrows). 
Simultaneously, protons are transferred to the IMS by the complexes (solid black 
arrows ↑), contributing to the proton gradient that couples the ETS to OXPHOS of 
ADP to produce ATP at ATP synthase (solid black arrow ↓ at complex V). Some 
electrons leak back from the IMS to the matrix through the IMM (dashed black 
arrows ↓). This is known as state 3 respiration and is measured in the respirometer 
during Routine (A). When oligomycin is added to the respirometer, ATP synthase 
is inhibited and ETS may only continue by dissipating the proton gradient via the 
natural electron leak back across the IMM; the Leak measurement indicates how 
‘leaky’ the IMM is and is indicative of mitochondrial dysfunction (B). FCCP 
uncouples the ETS completely by picking up protons in the IMS, diffusing across 
the IMM and releasing them in the matrix; effectively the unlimited reverse of the 
ETS complexes and thus electrons may flow without the rate-limiting step of proton 
transfer, providing the ETS maximal capacity measurement (C). Finally when 
rotenone and antimycin A, inhibitors of complexes I and III respectively, the ETS 
is completely inhibited and only non-ETS-specific residual oxygen consumption 
(ROX) occurs (D). 
 
Additional experiments were conducted whereby quercetin (10-100 µM) was titrated 
directly into the respirometer chamber containing a HepG2 cell suspension, followed by 
an FCCP positive control, to assess if quercetin was acting as a direct ETS uncoupler. As 
a control for the effect of quercetin reacting directly with oxygen, quercetin (10-200 µM) 
was also titrated into cell-free medium. 
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2.3.12 Cellular NAD+/NADH assay 
Cells were grown in 24-well plates and treated as for the DCFH-DA assay. Cells were 
washed in PBS, lysed and collected, and NAD+/NADH measured using the NAD/NADH 
Assay Kit (Fluorometric) (ab 176723, Abcam), in which enzymes specifically recognise 
NAD+ or NADH in an enzyme recycling reaction. The manufacturer’s instructions were 
followed; lysates were incubated with either a NADH or NAD+ extraction solution at RT 
for 15 min in a black, clear-bottomed 96-well plate (Greiner Bio-One), then the opposite 
solution added and, after a final incubation at RT for 60 min, the signals were read on 
the PheraSTAR FS plate reader (Ex/Em = 540/590 nm). Each of the signals from the 
NAD+-specific wells were divided by each signal of the NADH-specific wells to give 
the ratio. 
2.3.13 RNA isolation and cDNA synthesis 
HepG2 cells were grown in normal or HG in 100 mm2 dishes for 60 h. At 60 h cells were 
treated with medium ± FBS for 12 h (72 h after seeding) before treatment with 20 µM 
quercetin (or DMSO controls) for up to 24 h. Samples were collected after 1, 3, 6, 12 and 
24 h, with additional samples taken at 60 h (-12 h) and 72 h (time 0) in order to assess 
whether the FBS had an effect on mRNA expression. Total RNA was isolated using the 
Aurum Total RNA Mini Kit (#732-6820, Bio-Rad Laboratories, UK) and following the 
manufacturer’s instructions. RNA content was determined spectrophotometrically at 260 
nm (NanoDrop) and cDNA was synthesised by reverse transcription from 1 µg RNA 
using the High Capacity RNA-to-cDNA master mix kit (Applied Biosystems, Thermo 
Fisher Scientific), again following the manufacturer’s protocol, and this was stored at -
20oC for later polymerase chain reaction (PCR) analyses. 
2.3.14 Droplet digital PCR analysis 
The QX100 Droplet Digital PCR system (Bio-Rad Laboratories, USA) was used to 
quantify changes in gene expression of PGC-1α and TBP (housekeeping gene) as 
previously described (Tumova, Kerimi et al. 2016). FAM-labelled PPARGC-1α-specific 
Taqman primer (Hs01016719_m1) was mixed with VIC-labelled TBP Taqman primer 
(Hs00427620_m1) and each 20 µl assay contained 1 µl of each primer, 10 µl of ddPCR 
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Supermix and 9 µl of cDNA diluted with MilliQ water corresponding to 19 ng of mRNA, 
assuming 1:1 reverse transcription efficiency. The mixtures were dispersed into oil 
droplets using the QX100 Droplet generator and then transferred to a C1000 Touch 
thermal cycler (Bio-Rad Laboratories, USA). Droplet-containing mixtures were 
incubated for 10 min at 95oC, followed by 40 cycles of 30 sec at 94oC and 1 min at 
57.8oC, and then finished with 10 min incubation at 98oC. Products were maintained at 
12oC before analysis on the QX100 Droplet Reader. The QuantaSoft software (Kosiche, 
Slovakia) was used to analyse the data and determine concentrations of the target DNA 
in copies per µl from the fraction of positive reactions using Poisson distribution analysis. 
All reactions were performed in duplex mode with data collected independently for each 
target (PGC-1α and TBP) and presented as fold change of control treatment. 
2.3.15 Statistical analyses 
Data are expressed as means ± standard error of the mean. The significance of differences 
between groups of quercetin treatments was analysed by one-way ANOVA and post hoc 
Tukey’s (for unequal sample sizes), Dunnett’s (comparing multiple treatments to a single 
control) or two-tailed t-tests accordingly, with variance checks using Levene’s test, and 
with Bonferroni correction where multiple treatments were compared, using SPSS 24 
and presenting the data in Origin 2016. p < 0.05 was considered as statistically 
significant. 
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2.4 Results 
 
Figure 2.6: HepG2 cells in culture. Cells were maintained in Eagle’s MEM 
supplemented with 10% FBS. Images were acquired using the Leica DM IL LED 
inverted microscope at 10X magnification 12 h (A) and 96 h (B) after seeding, at 
which point cells were confluent. 
2.4.1 Mitochondrial isolation and complex I activity assay were optimised 
The isolation process was optimised before preparing mitochondria for complex I assays 
on HepG2 cells grown in normal or high glucose and treated with quercetin. Initially, the 
resuspension of cells and pellets was improved, an extra centrifugation step was 
introduced at the end to improve mitochondrial purity and remove remaining cellular 
debris from the resuspended mitochondrial pellet and the whole procedure streamlined 
by removing an unnecessary protein assay step after SPIN 1a, instead keeping the 
volumes of reagent A and B consistent (see 2.3.4). Further optimisation was carried out 
by investigating the effect of variables in the protocol on the complex I activity 
mitochondrial protein yield/quality through protein assay and Western analysis. This 
included varying the number of homogenisation strokes, SPIN 2 speeds and the number 
of SPIN 2 centrifugations (trying three spins versus the one); reagent incubation times 
before both homogenisation steps, the speed of the final centrifugation, and checking the 
effect of freeze-thaw cycles on the mitochondrial isolate. The finalised protocol yielded 
the highest and purest yield i.e. highest complex I activity and cleanest peak signal on 
the ProteinSimple Wes system (Fig. 2.7A). It was clear that the isolation process had to 
be strictly adhered to for the lysate of each treatment to avoid unnecessary variation and 
risk masking minor changes in complex I activity. 
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Various conditions for the complex I activity assay were evaluated. 10 µg mitochondria 
was sufficient to give a steady rate of NADH oxidation over the 60 min assay and allowed 
for plenty of material from each cell pellet. Varying NADH concentrations were assayed 
(see 2.3.7.1) and 150 µM gave data with the highest reproducibility and linearity. CoQ1 
was added to the assay at 50 µM as previously been published (Ragan 1987, Usta, 
Kreydiyyeh et al. 2009) and had a dramatic effect on the rate of NADH oxidation, with 
a 500% increase in activity. Linalool was tested during preliminary assays, as 
investigated by Usta et al. (Usta, Kreydiyyeh et al. 2009). It inhibited complex I as 
expected, with a 64% decrease against an ethanol control, confirming the assay was valid 
and responsive to stimulation/inhibition. Linalool only showed an inhibitory effect in the 
presence of CoQ1, with the higher basal activity. CoQ1 accepts electrons from complex 
I as ubiquinone does in vivo and therefore was necessary to allow the reaction to progress 
with high linearity (see 2.3.71 and Figs. 2.3 and 2.7B). Blanks (no mitochondria) and 
controls for non-mitochondrial oxidation by rotenone inhibition were assayed alongside 
mitochondria from treated cells. 
2.4.2 Quercetin recovers complex I activity lost with chronic high glucose 
The complex I activity assay was put to use for assessing mitochondria in HepG2 cells 
grown under different conditions and with quercetin treatments. Complex I activity 
decreased with high glucose treatment by 11% (p < 0.001) after 24 h and by 19% (p < 
0.001) after 96 h. Both hydrogen peroxide and serum removal also lowered the activity, 
whereas growing in galactose increased it (Fig. 2.7 C-D). In normal glucose, quercetin 
treatment caused a small decrease in complex I activity. However, in high glucose, 
quercetin up to 10 µM dose-dependently attenuated the high-glucose induced damage, 
up to 94% with 10 µM (p < 0.001), although at 20 µM the effect was less pronounced 
(Fig. 2.7E). 
  
 
 
- 64 - 
 
 
 
 
 
- 65 - 
Figure 2.7: Quercetin dose-dependently recovered complex I activity decreased by 
high glucose in HepG2 cells. Purity of isolated mitochondrial fraction (imt). 
Protein expression of complex I subunit NDUFB8 increased when compared to the 
whole cell lysate (WCL), assessed by ProteinSimple automated Western, with 
traditional Western blot and pherogram views (A). Complex I activity in 10 µg imt 
assessed with NADH (150 µM) in the presence of coenzyme Q1 (50 µM), and 
corrected for non-mitochondrial oxidation by blank and rotenone-inhibited (2 µM) 
controls. Lines of best fit for mean activity ± SEM (B). Complex I activity in cells 
grown in normal glucose (NG) medium supplemented with 10% serum for 72 h 
and then treated for 24 h with high glucose (HG), 0.5 mM hydrogen peroxide 
(H2O2) or serum-free medium. Complex I activity was normalised to the NG 
control (13.7 ± 0.8 nmol/min/mg) and data are expressed as mean percentages ± 
SEM (N/n = 3/9). ***p < 0.001 vs NG control (C). Complex I activity in cells 
grown for 96 h in NG, HG or 10 mM galactose (Gal); data are expressed as mean 
percentages of NG ± SEM (NG = 8.9 ± 0.9 nmol min-1 mg-1) (N/n = 5/15). *p < 
0.05, *** p < 0.001 vs NG control (D). Complex I activity in cells grown for 96 h 
in NG or HG and treated for the final 24 h (in the absence of serum) with various 
concentrations of quercetin (or DMSO controls). Data are mean percentages of the 
NG control ± SEM (NG = 8.6 ± 0.3 nmol/min/mg) (N/n = 6/18). *p < 0.05, ***p < 
0.001 vs NG control; #p < 0.05, ### < 0.001 vs HG control (E). 
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Figure 2.8: Quercetin decreased the relative DCF fluorescence in normal and high 
glucose cells. Cells were grown for 96 h in normal (NG) or high (HG) glucose and 
then incubated with 10 µM DCFH-DA for 20 min and DCF fluorescence measured 
and corrected for total protein (A). Cells grown in NG or HG for 96 h were treated 
with quercetin (or DMSO control), in the absence of serum, for the final 2 h (B), 
12 h (C) or 24 h (D) and DCF fluorescence measured in the same way. All data are 
mean values expressed as (%) of the NG or HG controls accordingly ± SEM (N/n 
= 4/12). **p < 0.01, ***p < 0.001 vs NG controls; #p < 0.05, ##p < 0.01, ###p < 0.001 
vs HG controls; NS = not significant. 
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2.4.3 Quercetin lowers ROS in HepG2 cells in normal and high glucose 
DCF fluorescence, as an indicator of intracellular ROS, was increased by 10% (p < 0.01) 
when cells were grown in high glucose for 96 h (Fig. 2.8A). This increase in ROS was 
attenuated dose-dependently in both normal and high glucose following quercetin 
treatment at all time points up to 24 h (Fig. 2.8 B-D). The effect of quercetin was most 
pronounced at earlier time points, with relative ROS lowest in normal glucose (53%, p 
< 0.001) and high glucose (57%, p < 0.001) after treatment with 20 µM quercetin for 2 
h (Fig. 2.8B). Quercetin was less effective in high glucose, notably after 12 and 24 h 
(Fig. 2.8 C-D). 
2.4.4 Quercetin decreases mitochondria while increasing cell viability 
Growing cells in normal or high glucose did not affect citrate synthase activity, a 
mitochondrial matrix marker, whereas quercetin significantly lowered citrate synthase 
activity after 24 h in normal glucose, and in high glucose with 20 µM, by 5-7% (p < 
0.05) (Fig. 2.9A). Cell viability, assessed by Trypan Blue exclusion, was also not affected 
by glucose but concentration-dependently increased with quercetin, by up to 5% in high 
glucose (p < 0.001) (Fig. 2.9B). 
2.4.5 Quercetin lowers high glucose-induced IMM proton leak and 
increases oxidative respiration 
IMM proton ‘Leak’, as assessed by respirometry, was increased by high glucose 
treatment by 21% (p < 0.05), but with no significant changes in the basal ‘Routine’ 
respiration, the non-coupled ‘ETS’ capacity nor the non-ETS ‘ROX’ (Fig. 2.10B). 
Quercetin treatment concentration-dependently almost entirely reversed the high 
glucose-induced proton leak (p < 0.01). In high glucose, treatment with 10 µM quercetin 
also increased oxidative respiration; both the cellular Routine and net ETS respiration 
(calculated from (Routine-Leak)/ETS) were elevated (p < 0.01), though not with 20 µM 
(Fig. 2.10D). Respiration in normal glucose was unaffected by quercetin, but again Leak 
was lowered dose-dependently (p < 0.01) (Fig. 2.10C). In general with quercetin 
treatments ETS capacity was unchanged or lowered and ROX was dose-dependently 
decreased (Fig. 2.10 C-D). 
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Figure 2.9: Quercetin decreased mitochondrial content and increased cell viability. 
Mitochondrial content (citrate synthase activity) in cells grown for 96 h in normal 
(NG) or high (HG) glucose and treated for the final 24 h with 10 or 20 µM quercetin 
(or DMSO control). All data are mean values expressed as (%) of the NG ± SEM 
(NG = 43.8 ± 0.5 nmol min-1 mg-1) (n = 6 for 10 µM; 9 for 20 µM; 15 for controls). 
*p < 0.05 vs NG control; #p < 0.05 vs HG control (A). Cells treated in the same 
way were assessed for plasma membrane integrity using the Trypan Blue exclusion 
test. Data are mean values of cells that excluded Trypan Blue expressed as (%) of 
total cells ± SEM (N = 6 for 10 µM; 13 for 20 µM; 19 for controls). **p < 0.01 vs 
NG control; ##p < 0.01 vs HG control; ###p < 0.001 vs HG control (B). 
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Figure 2.10: Quercetin decreases high glucose-induced IMM proton leak and 
increases oxidative respiration. Typical oxygen flux trace on the OROBOROS 
O2k high-resolution respirometer (grey line – [O2]; black line – O2 flux). Intact 
HepG2 cells were added to the respirometer and, in turn, the following states were 
measured: ‘Routine’ respiration after equilibration; IMM proton ‘Leak’ after 
addition of oligomycin (250 nM); electron transfer system capacity (ETS) in the 
non-coupled state induced by FCCP (5 µM) titration; and non-ETS residual oxygen 
consumption (‘ROX’) with the addition of rotenone (1.25 µM) and antimycin A 
(2.5 µM). Routine, Leak and ETS were all ROX-corrected (A). Respirometry data 
for cells grown in normal (NG) or high (HG) glucose for 96 h. Net R/E is the net 
routine flux control ratio, calculated as ((Routine-Leak)/ETS). Data shown are 
mean values and expressed as (%) of the NG control ± SEM (N/n = 9/16). *p < 
0.01 vs NG (B). Cells grown in NG (C) or HG (D) for 96 h were treated with 10 or 
20 µM quercetin (Q) (or DMSO control) for the final 24 h. Data are mean values 
and expressed as (%) of the NG or HG control accordingly ± SEM (N/n = 5/8 for 
10 µM; 9/9 for 20 µM; 14/17 for controls). *p < 0.05, **p < 0.01, ***p < 0.001 vs 
respective controls. See Table 2.1 for control values. 
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Table 2.1: Control values for respirometry. O2 flux values (pmol s
-1 10-6 cells) ± SEM. 
NG – normal glucose; HG – high glucose. 
  Routine Leak ETS Net R/E ROX 
Fig. 2.10B (NG Ctrl) 32.9 ± 1.2 8.1 ± 0.6 95.3 ± 6.5 0.25 ± 0.02 4.9 ± 0.9 
Fig. 2.10C (NG Ctrl) 28.2 ± 1.5 10.3 ± 0.4 97.3 ± 4.2 0.19 ± 0.02 4.6 ± 0.6 
Fig. 2.10D (HG Ctrl) 29.8 ± 1.5 11.2 ± 0.6 93.1 ± 6.4 0.21 ± 0.02 4.9 ± 0.6 
 
 
 
Fig 2.11: Quercetin reacts with oxygen and is rapidly taken up by HepG2 cells, 
without uncoupling ETS. Oxygen ‘flux’ trace for cell-free medium when titrated with 
quercetin (10-200 µM final) in the OROBOROS O2k (A). Intact HepG2 cells were added 
to the respirometer and quercetin (10-100 µM) was titrated in, followed by a single 
addition of FCCP (5 µM) as a positive control. Grey line – [O2]; black line – O2 flux; Q 
followed by number indicates cumulative quercetin concentration (µM) (B). 
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2.4.6 Quercetin is rapidly taken up by HepG2 cells without uncoupling 
mitochondrial respiration 
When added directly to cell-free medium in the respirometer, quercetin dose-dependently 
reacted with oxygen (Fig. 2.11A). When added to HepG2 cells already in suspension and 
equilibrated in the respirometer chamber, the increase in oxygen consumption was no 
longer evident, indicating the quercetin was rapidly taken up by the cells quicker than it 
could react with oxygen in the medium. Quercetin did not act as a direct ETS uncoupler, 
unlike FCCP (Fig. 2.11B). 
2.4.7 Quercetin reverses increased NADH in high glucose cells within 2 h 
High glucose increased cellular NADH (p < 0.001) (Fig. 2.12A), but this effect had 
diminished at later time-points. Quercetin dose-dependently increased NAD+/NADH in 
high glucose after 2 h (p < 0.01), but not in normal glucose, to reverse the increased 
NADH (Fig. 2.12A). NAD+/NADH was elevated after 12 h with 10 µM quercetin in both 
normal and high glucose (p < 0.001) (Fig. 2.12B) and this effect was maintained in 
normal glucose up to 24 h (p < 0.001) (Fig. 2.12C). In high glucose, an effect was evident 
with 20 µM quercetin at 24 h (p < 0.05) (Fig. 2.12C). 
2.4.8 Quercetin increases PGC-1α mRNA in normal and high glucose 
Without serum PGC-1α gene expression was increased under both normal and high 
glucose conditions. Following 12 h in serum-free medium (t0) PGC-1α increased by 1.7-
fold (p < 0.001) and remained stable for 12 h in normal glucose; in the presence of high 
glucose a further increase was evident at 6 h (2-fold, p < 0.001). At 24 h mRNA levels 
were significantly lower than in control cells (Fig. 2.13 A, C). Treatment with 20 µM 
quercetin increased PGC-1α gene expression within 3 h in normal glucose and within 6 
h in high glucose (both p < 0.001). A maximal effect was reached at 6 h in both (Fig. 
2.13 E, G). TBP (housekeeping reference) was mildly affected by the absence of serum 
and high glucose but these changes did not affect the PGC-1α measured gene expression 
(Fig. 2.13 B, D, F, H). The ddPCR determines the absolute number of mRNA molecules 
in the reaction, so the use of a stably expressed reference gene is not essential but was 
used to account for variations in the sample preparation. 
 
 
- 72 - 
 
Figure 2.12: Quercetin reverses the high glucose-increased NADH. HepG2 cells 
grown in NG or HG for 96 h were treated with NG or HG plus various 
concentrations of quercetin (or DMSO controls) for the final 2 h (A). NG and HG 
cells were treated with 10 or 20 µM quercetin (or DMSO controls) for the final 12 
h (B) or the final 24 h (C). All data are expressed as mean NAD+/NADH ± SEM 
(N/n = 6/36). ***p < 0.001 vs NG control; #p < 0.05, ##p < 0.01, ###p < 0.001 vs HG 
control.  
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2.5 Discussion 
Type 2 diabetes and metabolic syndrome are manifested by high glucose-induced 
oxidative stress that leads to mitochondrial dysfunction, insulin resistance and continued 
hyperglycaemia (Yang, Jin et al. 2011). Quercetin is known for its potential health 
benefits, particularly in relation to mitochondrial dysfunction and metabolic diseases 
(Eid, Martineau et al. 2010, Kim, Kwon et al. 2015, Chis, Muresan et al. 2016, de 
Oliveira, Nabavi et al. 2016, Haddad and Eid 2016). Numerous studies have 
demonstrated that quercetin protects against oxidative stress in mitochondria, either 
through restriction of ROS generation locally or enhancement of oxidative defence 
mechanisms (Moskaug, Carlsen et al. 2005, Vargas and Burd 2010, Lagoa, Graziani et 
al. 2011, Ji, Sheng et al. 2015, Jimenez, Lopez-Sepulveda et al. 2015). It may also impact 
metabolism through interacting with proteins, regulating genes that control metabolic 
pathways and promoting mitochondrial biogenesis or mitophagy (Sandoval-Acuna, 
Ferreira et al. 2014, de Oliveira, Nabavi et al. 2016). Mechanisms by which quercetin 
affects mitochondrial function were reviewed by de Oliveira et al. (de Oliveira, Nabavi 
et al. 2016), but there is still a lack of understanding when it comes to the specifics 
involved with lowering mitochondrial dysfunction caused by oxidative stress, especially 
in cells grown in a high glucose environment. In the present study the latter was 
investigated against a normal glucose control. Beneficial effects were seen in HepG2 
cells when exposed to quercetin in the low micromolar range, reversing the high glucose-
induced stress in a dose-dependent manner, and higher concentrations of quercetin were 
used to probe the mechanisms of action further. 
ETS complex I activity was lowered by H2O2 incubation or removal of serum, as means 
of inducing oxidative stress (Takeda, Akao et al. 2006, Jiang, Yu et al. 2014), and was 
increased when growing the cells in galactose, known for increasing oxidative 
phosphorylation fuelled by glutamine and fatty acids in vitro (Reitzer, Wice et al. 1979, 
Robinson, Petrova-Benedict et al. 1992, Marroquin, Hynes et al. 2007, Andrzejewski, 
Gravel et al. 2014). The decreased complex I activity in high glucose was likely a result 
of oxidative stress, supported by the increased DCF fluorescence; free radicals attack the 
ETS protein complexes, particularly prone as the principal sites of generation, and 
mitochondrial DNA, leading to additional defects in the complexes (Starkov 2008, Kang 
and Pervaiz 2012, Guo, Sun et al. 2013, Hirst and Roessler 2016). 
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Figure 2.13: Quercetin induced PGC-1α transcription in normal and high glucose. 
Cells were seeded in NG or HG media and after 60 h (-12 h) the medium was 
changed to medium ± serum (F – with FBS). Cells were treated again at 72 h (t = 
0) ±FBS and samples were collected at 6, 12 and 24 h (A-D). Cells were treated 
with 20 µM quercetin (Q) at 72 h (T=0) (or DMSO controls) and samples were 
collected at 1, 3, 6, 12 and 24 h (E-H). RNA was extracted, cDNA synthesised and 
expression quantified by droplet digital PCR analysis. Data are mean values of 
fold-change of PGC-1α or TBP (housekeeping) ± SEM (n/N = 18/6). *p < 0.05, 
**p < 0.01, *** p < 0.001 vs control accordingly. See Appendix 1 for PGC-1α data 
normalised to TBP housekeeping gene. 
 
The diminished complex I activity in high glucose was dose-dependently recovered by 
quercetin to the level in the normal glucose mitochondria when also treated with 
quercetin. Cells grown in normal glucose had universally lowered complex I activity 
when treated with all concentrations of quercetin, suggesting quercetin has a potentially 
detrimental effect on complex I when not already faced with the stress of chronic high 
glucose, but a beneficial effect against when it is. Conversely, relative ROS levels were 
dose-dependently lowered in both normal and high glucose by quercetin, as seen 
previously (Bali, Ergin et al. 2014), suggesting the lower complex I activity in normal 
glucose cells was not a result of increased oxidative stress; quercetin can itself act as a 
pro-oxidant depending on the environment, but usually at higher concentrations 
(Laughton, Halliwell et al. 1989, de Oliveira, Nabavi et al. 2016). Previous studies on 
complex I suggest that quercetin may competitively inhibit the complex at the CoQ-
binding site, preventing inhibition by other agents (Carrasco-Pozo, Mizgier et al. 2012), 
and/or act as a CoQ mimic, allowing electron transfer to continue from NADH to 
complex III (Hodnick, Bohmont et al. 1987, Lagoa, Graziani et al. 2011, Sandoval-
Acuna, Lopez-Alarcon et al. 2012), two possible reasons as to why this phenomenon was 
seen. A third possibility is that quercetin oxidised NADH itself (Chan, Galati et al. 1999, 
Buss, Constantin et al. 2005), increasing the NAD+/NADH ratio. This decreased pool of 
NADH led to consequently lower complex I activity (Niklas, Nonnenmacher et al. 2012, 
Santidrian, Matsuno-Yagi et al. 2013) in the normal glucose cells wherein the pool of 
reducing substrates will have been lower than in high glucose. 
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DCF fluorescence was generally lowered more in normal glucose as there were less ROS 
in those cells to begin with and the high glucose cells had more NADH to be oxidised by 
quercetin. Furthermore, these data show that the effect of quercetin in (directly and/or 
indirectly) lowering the relative ROS levels wore off with time during 24 h, an indication 
that the quercetin is consumed and/or metabolised, and more so in high glucose. 
Hashimoto et al. studied the effect of hyperglycaemia on quercetin metabolism and found 
that quercetin was almost fully metabolised within 4 h of treatment and that phase II 
metabolism was attenuated by high glucose in HepG2 cells, with less quercetin aglycone 
and metabolites combined in the cells and media (Hashimoto, Blumberg et al. 2016). 
This may help explain the time-dependence of the DCFH-DA data, but also the differing 
effects of quercetin in cells grown in normal or high glucose due to its differing 
metabolism. Likewise, previous work on HepG2 cells in our lab showed that 5 µM 
quercetin lowered glucose metabolism and uptake over 12 h (Kerimi, Jailani et al. 2015) 
(only tested in normal glucose) so quercetin may have lowered cellular NADH and 
lessened the high glucose burden in this manner. The DCF data are indicative that 
quercetin may push metabolism in a certain direction, with the shift in redox balance 
producing lesser ROS, which will have little relevance physiologically from one dose of 
quercetin, but continued chronic exposure, say even over a lifetime, may help maintain 
the redox shift. 
Citrate synthase activity, a marker of mitochondrial content (Lanza and Nair 2009, 
Larsen, Nielsen et al. 2012), was lowered in the normal glucose cells akin to the complex 
I activity, but in high glucose too, a sign that the mitochondria that are present following 
quercetin treatment are more functional and their oxidative output more efficient. The 
Trypan Blue data suggest cells are more viable overall 24 h after adding quercetin, with 
improved plasma membrane integrity. Changes in citrate synthase activity and plasma 
membrane integrity were small and not as physiologically relevant as the changes 
observed in the respirometry data for example. Other studies have suggested a role for 
quercetin in membrane integrity (Modriansky and Gabrielova 2009, Margina, Gradinaru 
et al. 2013, Sanver, Murray et al. 2016) and as such the quercetin-attenuated proton Leak 
across the IMM was caused by an improvement in the IMM directly, as well as indirectly 
by the lowered oxidative stress. The lower Leak in high glucose cells further enhanced 
mitochondrial respiration by improving coupling efficiency, shown by the increased 
Routine respiration and net respiration/ETS flux control ratio (net R/E). The latter was 
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due to a combination of lowered Leak but also lowered ETS, in line with the citrate 
synthase activity. The increase in net R/E was only present in the cells treated with 10 
µM quercetin; at 20 µM there was a decrease in routine respiration adding to the notion 
that at 20 µM complex I may have been inhibited. Previous studies have shown quercetin 
improves mitochondrial bioenergetics (Nichols, Zhang et al. 2015, Carrasco-Pozo, Tan 
et al. 2016) and this was shown here for the first time in an intact HepG2 system, and 
notably that these improvements are enhanced when in high glucose. 
Another key finding from the respirometry data was in the non-ETS residual oxygen 
consumption (ROX) measurements. This was dose-dependently decreased by quercetin 
and is indicative of a lower dependence on glycolysis, NADH oxidation by quercetin and 
inhibition of ATPase enzymes such as those involved in trans-plasma membrane electron 
transport (tPMET); ROX is the amalgamated effect of oxygenase redox enzymes (Brand 
and Nicholls 2011, Banh, Iorio et al. 2016, Kerimi and Williamson 2016) and cell surface 
oxygen consumption via tPMET (Herst and Berridge 2007). The dependence on 
glycolysis is lowered because ATP is generated instead by quercetin-enhanced 
mitochondrial respiration and this includes substrates via glutamate and fatty acid 
metabolism (Gnaiger 2014). Furthermore, quercetin was shown previously to inhibit 
glucose-6-phosphatase in insulin-resistant HepG2 cells, effectively helping to reverse the 
effects of insulin resistance and allow glycolysis to continue towards pyruvate (Teng, 
Chen et al. 2016). Direct NADH oxidation by quercetin (Chan, Galati et al. 1999, Buss, 
Constantin et al. 2005, Niklas, Nonnenmacher et al. 2012) also allows glycolysis to 
continue without the need for tPMET (Herst and Berridge 2007), and quercetin has long 
been known to inhibit ATPases (Lang and Racker 1974, Davis, Middleton et al. 1983, 
Racker 1986, Gasparin, Salgueiro-Pagadigorria et al. 2003). 
Previous studies suggested that quercetin (≥ 25 µM) uncoupled ETS and oxidative 
phosphorylation while inhibiting mitochondrial respiration in mitochondria isolated from 
rat kidney or liver (Dorta, Pigoso et al. 2005, Ortega and Garcia 2009). Quercetin also 
caused partial uncoupling in the low nanomolar range in rat heart mitochondria 
(Trumbeckaite, Bernatoniene et al. 2006). This was tested in intact cells, H9c2 rat 
cardiomyocytes, whereby quercetin increased Leak and partially protected complex I 
respiration, but only following hypoxia. Short-term incubation with quercetin (< 50 µM) 
did not induce uncoupling however, demonstrating that the effects seen in isolated 
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mitochondria are attenuated in whole cells (V. Zholobenko, Mouithys-Mickalad et al. 
2017). Supporting evidence for this is provided here, as quercetin ≥ 100 µM did not act 
as an uncoupler in intact HepG2 cells. Quercetin reacted with oxygen when cells were 
not present, as shown previously (Morales, Günther et al. 2012), but it was taken up 
rapidly into the cells, also seen previously in Jurkat cells (Fiorani, Guidarelli et al. 2010), 
and oxygen consumption was not increased. 
NADH oxidation by quercetin was also demonstrated by the general increases in 
NAD+/NADH. Elevated NADH in high glucose cells is an indication of the reductive 
stress that leads to oxidative stress (Yan 2014). There was a decrease in this NADH pool 
following addition of quercetin, lasting up to 24 h in when treated 20 µM. The increase 
in NAD+/NADH was seen too in cells grown in normal glucose but not when treated with 
20 µM quercetin, nor for the dose-response at 2 h; further evidence of complex I 
inhibition, which was overridden by the high glucose-induced excess NADH. The 
increased NAD+/NADH for 24 h is an effect that is temporally beyond direct oxidation 
alone and thus the lasting effect was due to the increased mitochondrial respiration in an 
environment with less oxidative stress resulting from the pleiotropic effects of quercetin 
combined. In accordance with this, Niklas et al. postulated that improved channelling of 
pyruvate into the mitochondria could result from a quercetin-induced increase in 
NAD+/NADH ratio (Niklas, Nonnenmacher et al. 2012) and other studies have suggested 
that quercetin affects this (Buss, Constantin et al. 2005, Dorta, Pigoso et al. 2005, de 
Oliveira, Nabavi et al. 2016). 
An increased pool of cellular NAD+ activates NAD+-dependent deacetylase sirtuins 
involved in the signalling network that governs central metabolism. The AMPK-SIRT-
PGC-1α axis in particular regulates mitochondrial function and can increase 
mitochondrial biogenesis or ultimately lead to cell death (Canto, Gerhart-Hines et al. 
2009, Austin and St-Pierre 2012, Tang 2016). Quercetin has been shown previously to 
activate these pathways (Ahn, Lee et al. 2008, Chung, Yao et al. 2010, Kim, Kwon et al. 
2015, Haddad and Eid 2016, Leiherer, Stoemmer et al. 2016, Liu, Mei et al. 2016) and 
may be primarily via NADH oxidation (directly and/or indirectly). PGC-1α transcription 
was measured as a biomarker of mitochondrial biogenesis and oxidative function (Austin 
and St-Pierre 2012, Sugden and Holness 2012). PGC-1α mRNA was increased in 
response to transient starvation when FBS was removed from the media (Rodgers, Lerin 
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et al. 2005, Sen, Satija et al. 2011, Austin and St-Pierre 2012, Sugden and Holness 2012). 
Serum was removed 12 h earlier so any changes instigated by quercetin specifically were 
detectable. PGC-1α mRNA was not dependent on glucose concentration, however when 
quercetin was added to the serum-starved cells PGC-1α expression was increased further 
and in doing so may promote increased mitochondrial functionality. An increase in 
mitochondrial biogenesis was not seen according to the citrate synthase biomarker after 
24 h, which is consistent with other reports on biogenesis; it is dependent upon cell type 
and quercetin concentration (Nichols, Zhang et al. 2015, de Oliveira, Nabavi et al. 2016). 
However, the increased PGC-1α mRNA and activation will have nonetheless affected 
the intrinsic oxidative nature of the cells, further boosting oxidative respiration (Austin 
and St-Pierre 2012, Rayamajhi, Kim et al. 2013). Autophagy is also induced by this and 
other signalling pathways regulated by quercetin (see 1.3.2.2) and thus damaged 
mitochondria may be disposed of and replaced with regenerated mitochondria more 
oxidative in function, enhancing the overall efficiency per mitochondrion. Increases in 
PGC-1α mRNA levels corroborates with the increased NAD+ in cells treated with 10 µM 
quercetin; NAD+-dependent SIRT1 activates PGC-1α, which in turn promotes its own 
transcription (Nelson, Valentine et al. 2012, Sugden and Holness 2012). The effects of 
quercetin are similar to those seen by metformin (Sugden and Holness 2012) and it has 
been shown previously that quercetin enhances oxidative metabolism via heme 
oxygenase-1 in obese mice (Kim, Kwon et al. 2015). Increased PGC-1α also helps to 
manage ROS (Baldelli, Aquilano et al. 2014) and suppresses glycolytic gene 
transcription (Rodgers, Lerin et al. 2005), shifting metabolic dependence towards the 
mitochondria. 
Quercetin lowers local ROS generation and promotes antioxidant cellular defences to 
lower oxidative stress. It has been suggested that the principal mechanisms involve 
modulation of proteins and genes, such as those of the mitochondrial electron transfer 
system and involved in metabolic signalling pathways, as well as lipid membrane 
integrity, maintaining membrane-bound protein function and proton gradients. In the 
present study the data suggest that several such mechanisms are involved and have 
particular beneficial effects on reversing the high glucose-induced mitochondrial 
dysfunction in HepG2 cells (Fig. 2.14). Cellular ROS levels were lowered by quercetin 
as expected and this was both a cause and effect of other findings. It is proposed that 
quercetin forms a dimer quinone structure (which can be pro-oxidant and toxic itself at 
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higher concentrations) within the cell and mitochondrion (Metodiewa, Jaiswal et al. 
1999, Buss, Constantin et al. 2005, Boots, Li et al. 2007, Lagoa, Graziani et al. 2011, 
Carrasco-Pozo, Mizgier et al. 2012, Sandoval-Acuna, Ferreira et al. 2014), accumulating 
in the latter (Fiorani, Guidarelli et al. 2010). Here it competitively inhibits complex I at 
the CoQ-binding site, but simultaneously oxidises NADH and transfers electrons to 
complex III (Sandoval-Acuna, Lopez-Alarcon et al. 2012) at the Q-junction, as well as 
those from FADH2 and the electron transfer flavoprotein (Rosca, Vazquez et al. 2012, 
Gnaiger 2014), allowing OXPHOS to continue, while superoxide generation at complex 
I is impeded. Global oxidation of NADH lowers the substrate pool available to complex 
I and this adds to the overall effect on complex I and lowered ROS. The NAD+/NADH 
ratio rises and leads to promotion of NAD+-dependent enzymes and associated 
mitochondrial signalling pathways, seen by a transient increase in PGC-1α transcription 
to promote mitochondrial respiration and reprogrammed cellular metabolism in the 
longer term. Through direct incorporation of quercetin and/or indirect lowering of 
oxidative stress, the integrities of the inner mitochondrial and plasma membranes are 
enhanced and the heightened proton leak across the IMM in high glucose is attenuated, 
maintaining the proton gradient and efficient coupling, and mitochondrial respiration is 
increased. Non-ETS respiration is lowered through NADH oxidation in the cytosol and 
mitochondria and is indicative of a lesser dependence on glycolysis. The ultimate 
outcome of these effects is lowered oxidative stress induced by chronic high glucose and 
improved mitochondrial functionality, resulting in a net increase in complex I activity 
and respiration 24 h after a single dose of quercetin. 
The positive effects of quercetin on mitochondrial bioenergetics in cells grown in high 
glucose have not been demonstrated previously and existing studies on the effects and 
mechanisms of quercetin on mitochondrial function have often employed an acute kinetic 
experiment setup on isolated mitochondria, but here the outcome following a chronic 
treatment to the cells has been presented, whereby the effects of a single dose of quercetin 
on metabolism, redox signalling and gene expression up to 24 hours later have been 
demonstrated concurrently. The differences between normal and high glucose helped to 
elucidate the specific mechanisms of action (Fig. 2.14). If quercetin is consumed on a 
daily basis, longer lasting pools may accumulate in the hepatic mitochondria and lead to 
a chronic effect to alleviate the stresses of hyperglycaemia and help to prevent insulin 
resistance in vivo. Proteomics studies have revealed that complex I is lowered in diabetic 
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patients (Peinado, Diaz-Ruiz et al. 2014), thus a greater understanding of these quercetin 
mechanisms of action in mitochondria and on cellular metabolism in a high glucose 
environment gives hope to the potential for nutraceutical or, with the use of nano-
technology and optimised concentrations (de Oliveira, Nabavi et al. 2016), 
pharmaceutical applications to help absolve metabolic syndromes.  
 
 
- 82 - 
 
 
 
- 83 - 
Figure 2.14: Mechanisms of action of quercetin in mitochondria in HepG2 cells 
chronically exposed to high glucose. Elevated glucose leads to elevated NADH 
and overproduction of superoxide (O2
•-) at complex I of the electron transfer system 
(A). Quercetin inhibits complex I at the coenzyme Q10-binding site (CoQ), 
suppressing superoxide generation while oxidising NADH and allowing electron 
transfer to continue to complex III, and attenuates the high glucose-induced proton 
leak across the inner mitochondrial membrane. This results in more efficient 
coupling with ATP synthesis. The NAD+/NADH is increased in parallel with 
induction of PGC-1α gene expression by quercetin; mitochondrial function is 
promoted and metabolic flux shifted to mitochondrial respiration, leading to lower 
oxidative stress and attenuation of high glucose-induced mitochondrial 
dysfunction, with increased net respiration and recovered complex I activity. PDH 
– pyruvate dehydrogenase, TCA cycle – tricarboxylic cycle, Acetyl CoA – acetyl 
coenzyme A.  
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Chapter 3  
(Poly)phenol metabolites increase glucose uptake in human 
skeletal muscle: gut microbiome metabolite isovanillic acid 3-
O-sulfate upregulates GLUTs and activates insulin signalling. 
3.1 Abstract 
Epidemiological, animal and human intervention studies have revealed that consumption 
of (poly)phenols such as quercetin, ferulic acid and resveratrol has antidiabetic effects 
and this may be via increased postprandial glucose uptake in the skeletal muscle. Some 
in vitro studies have shown aglycone compounds can stimulate GLUT4 translocation, 
however these are limited to rat or mouse cells models and relevant (poly)phenol 
metabolites that are in circulation in vivo are yet to be tested. The immortalised myoblast 
line, LHCN-M2, was characterised as a human skeletal muscle model comprising 
myotubes differentiated in normal or high levels of glucose and insulin. This model was 
used to investigate the effects of a range of sulfated and glucuronidated (poly)phenol 
conjugates on glucose uptake and metabolism. Compounds were selected and grouped 
based on the known metabolite profiles following the consumption of parent compounds 
and (poly)phenol-rich foods. Derivatives of ferulic acid, resveratrol and anthocyanins 
increased glucose uptake and metabolism, notably in high glucose and insulin-treated 
myotubes, as evidenced by increased short-term intracellular transport of 2-[1-14C(U)]-
deoxy-D-glucose and decreased longer-term D-[14C(U)]-glucose uptake respectively, 
assessed by liquid scintillation counting. When tested individually, isovanillic acid 3-O-
sulfate (IVAS), a colonic microbiome catabolite of cyanidin 3-O-glucoside, stimulated a 
dose-dependent increase in 2-[1-14C(U)]-deoxy-D-glucose transport and involved a 
PI3K-dependent mechanism, as confirmed by wortmannin and indinavir inhibition. 
Western analyses showed that IVAS upregulated GLUT1, GLUT4 and PI3K p85α, and 
increased phosphorylated Akt. This is the first time such metabolites have been shown 
to improve glucose uptake in human skeletal muscle, with promising effects on insulin 
signalling and GLUT expression, notably in myotubes exposed to a high glucose/insulin 
stress. 
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3.2 Introduction 
Skeletal muscle accounts for at least 40% of the human body mass and is the primary 
site of postprandial glucose disposal (Tremblay, Dubois et al. 2003, Lauritzen and 
Schertzer 2010). Glucose uptake is facilitated by glucose transporters encoded by the 
SLC2 genes, with tissue-specific expression of different isoforms (Cura and Carruthers 
2012, Mueckler and Thorens 2013). GLUT1 and GLUT4 are the major glucose 
transporters in skeletal muscle tissue and the latter is dominantly expressed in mature 
muscle in vivo and activated by translocation from internal vesicles to the plasma 
membrane, in response to insulin (Huang and Czech 2007, Cura and Carruthers 2012, 
Mueckler and Thorens 2013). In insulin-resistant tissues, insulin-stimulated GLUT4 
glucose uptake is compromised (Kahn, Rosen et al. 1992, Saltiel and Kahn 2001, 
Deshmukh 2016). Insulin resistance therapies, including exercise, nutra-
/pharmaceuticals and diet-related changes (Collier, Bruce et al. 2006, Oberg, Yassin et 
al. 2011, Stanford and Goodyear 2014, Alvim, Cheuhen et al. 2015, Kouzi, Yang et al. 
2015, Cheng, Villani et al. 2017, Wu, Horowitz et al. 2017), lower postprandial 
glycaemia by restoring skeletal muscle uptake and enhancing metabolism. Glucose 
homeostasis is maintained without causing oxidative stress (Chapter 2), as glucose is 
converted to glycogen for storage (Saltiel and Kahn 2001), or some glucose may be 
metabolised aerobically through transduction of AMPK-mediated pathways (Jager, 
Handschin et al. 2007, Canto, Gerhart-Hines et al. 2009, Timmers, Konings et al. 2011). 
Conserving insulin sensitivity in skeletal muscle is imperative to reducing chronic 
hyperglycaemia and preventing or reversing the diabetic phenotype. 
Diets high in (poly)phenols have been correlated with a lower incidence of type 2 
diabetes (Kim, Keogh et al. 2016) and as such this has led to investigations in vivo and 
in vitro into how these compounds may help regulate glucose homeostasis. Mechanisms 
studied include the inhibition of carbohydrate digestion and absorption in the gut 
(Williamson 2013), stimulation of glucose uptake into muscle and adipose, improvement 
in pancreatic function and hepatic glucose metabolism, as well as lowering obesity-
induced inflammation and oxidative stress (Hanhineva, Torronen et al. 2010, Babu, Liu 
et al. 2013, Williamson 2013, Kim, Keogh et al. 2016) (see 1.3.2). (Poly)phenols, or 
(poly)phenol-rich extracts or foods, have been shown to affect the expression and activity 
of the GLUTs. A cinnamon (poly)phenol extract was shown to increase GLUT1 
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expression in murine macrophages to help enhance their immune function (Cao, Urban 
et al. 2008), while phloretin, commonly found in apples, inhibits GLUT2 and induces 
cell cycle arrest in colorectal tumour cells (Lin, Tu et al. 2016). Recently, data were 
published from our lab that demonstrated green and chamomile teas inhibit GLUT2 in 
Caco-2 cells and Xenopus oocytes, and chamomile also inhibits GLUT5 (Villa-
Rodriguez, Aydin et al. 2017). There are reports of (poly)phenols enhancing GLUT4-
mediated transport into muscle via increased GLUT4 expression and/or via the insulin- 
or AMPK-mediated pathways. Citrus flavonoids hesperidin and naringin upregulated 
GLUT4 expression in the adipose of diabetic mice, as well as improving hepatic glucose 
metabolism, systemic lipid metabolism and lowering hyperlipidaemia (Jung, Lee et al. 
2006). Grape seed procyanidin extract lowered hyperglycaemia in streptozotocin-
induced diabetic rats and stimulated glucose uptake in L6 myotubes and 3T3-L1 
adipocytes via increased GLUT4 translocation dependent on the insulin signalling 
pathways (Pinent, Blay et al. 2004). The same effects were elicited by an anthocyanin-
rich bilberry extract in diabetic mice, but via stimulation of AMPK (Takikawa, Inoue et 
al. 2010). 
However, the literature is lacking in vitro studies testing (poly)phenol metabolites that 
can be found in circulation in vivo. In the animal studies described, the effects on 
glycaemia and lipidaemia may have been caused by conjugates and catabolites of the 
(poly)phenols that were administered. More attention should be given to matching the 
compounds and their doses to the tissue in question i.e. gut cells in vivo are exposed to 
relatively higher concentrations of the compounds in their aglycone and plant metabolite 
forms, while hepatic, adipose and muscle cells will see mostly conjugates in the 
nanomolar to low micromolar range (Del Rio, Rodriguez-Mateos et al. 2013, Bohn, 
McDougall et al. 2015). Notably, there is less information on how catabolites of the 
colonic microbiome may play a role and yet the majority of (poly)phenols in circulation 
are metabolised in this way before absorption (Cardona, Andres-Lacueva et al. 2013, 
Williamson and Clifford 2017). Colonic metabolites are of particular interest because 
they can be present in the blood at high concentrations, similar to those tested in vitro, 
and remain so for long periods of time, increasing their bioavailability (Williamson and 
Clifford 2010). 
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Studies using combinations of metabolites would also be useful in mimicking the in vivo 
situation, because it is unlikely for tissues to be exposed to single compounds, and it has 
been shown previously that (poly)phenols may affect the metabolism and biological 
activity of others; several flavonoids are known to inhibit SULT for example and 
therefore will in turn affect the conjugation of other compounds (Huang, Chen et al. 
2009). Even after taking a single supplement, ingestion of phytochemical(s) can yield 
tens of circulating metabolites; de Ferrars et al. reported the pharmacokinetic profiles of 
17 metabolites in plasma, 31 in urine and 28 in faeces following ingestion of a single 
13C-labelled anthocyanin (de Ferrars, Czank et al. 2014). A recent study showed that 
resveratrol 3-O-sulfate inhibited colon cancer cell proliferation, which was more so than 
unconjugated resveratrol, and its activity was synergistically increased when in 
combination with resveratrol glucuronide conjugates despite they themselves exerting no 
effects. Moreover, the resveratrol metabolites, individually and in combination, 
synergised with chemotherapeutic drugs to induce cell death (Aires, Limagne et al. 
2013). Further in vitro studies demonstrating the synergistic effects of natural 
compounds, including quercetin, and chemotherapeutics on cancer cells were reviewed 
recently (Aung, Qu et al. 2017). 
Another challenge is the choice of model. There are scarcely any reported studies on 
(poly)phenols and glucose uptake in human skeletal muscle cells, either primary or 
immortalised. One recent study investigating the effects of epigallocatechin-3-gallate in 
increasing insulin sensitivity used both murine and primary human myotubes 
(Pournourmohammadi, Grimaldi et al. 2017) and a recent review looked at human studies 
with resveratrol intervention and subsequent muscle biopsy analyses (Sin, Yung et al. 
2015). However, the rat L6 or murine C2C12 immortalised cell lines are favoured for 
their ease of culture, differentiation potential, accessibility (Cheng, El-Abd et al. 2014) 
and likely the abundant existing documentation to support new research, but it is 
important to acknowledge that mechanisms that occur in rodent muscle cells may not be 
the same as those in human. Such differences include the myogenic programming that 
regulates differentiation (Bareja, Holt et al. 2014), glucose transport kinetics in response 
to insulin and GLUT4 expression (Gould and Holman 1993). 
The aim of this part of the project was to determine the LHCN-M2 myoblast line as a 
suitable human skeletal muscle cell model to study the effects of (poly)phenol 
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metabolites on glucose uptake and metabolism. A normal and diabetic-mimicking 
(hyperglycaemic and hyperinsulinaemic) model was established to compare metabolite 
activities between the two contexts. A recent study examining the effects of quercetin on 
glucose disposal in mice and C2C12 myotubes found that quercetin suppressed insulin-
mediated glucose uptake under normal conditions, but rescued the impaired uptake under 
inflammatory conditions (Liu, Mei et al. 2016). Before testing the metabolites in the 
present study, the degree of differentiation, respiratory status, GLUT expression and 
insulin responses were characterised to confirm the muscle phenotype and evaluate the 
effects of differentiating the myoblasts in normal and high glucose/insulin. 
Hyperglycaemia and hyperinsulinaemia are classic biomarkers of diabetes (Wilcox 2005, 
Krentz and Hompesch 2016) and the effects of glucose and insulin on muscle glucose 
transport have been studied previously in human primary cells (Ciaraldi, Abrams et al. 
1995), providing a reference for the model here. 
(Poly)phenol metabolites were chosen based on their origins in frequently-consumed 
(poly)phenol-rich foods that have previously shown promise in regulating glycaemia in 
vivo and/or associated compounds or extracts have affected muscular glucose uptake in 
vitro (Table 3.1). Based on achievable plasma concentrations in vivo, ascertained from 
Cmax values in pharmacokinetic studies, a dose of 2 µM was chosen for most metabolite 
compounds. This was slightly higher than that detected previously for dihydroferulic acid 
(DHFA) and its sulfate conjugate, and for the flavonol conjugates, but these values were 
recorded after a single dose, such as one cup of coffee or a portion of fried onions for 
example, so it is plausible that plasma concentrations could reach several micromolar 
from habitual consumption and following several meals in a day. The combination of 
phenolic sulfates was chosen on the back of a pharmacokinetic study done previously in 
our lab, with the identification (and subsequent synthesis) of these metabolites circulating 
in plasma following the consumption of a mixed berry purée (Pimpao, Ventura et al. 
2015). Higher doses of 5 µM were chosen for these metabolites because they are mostly 
colonic microbiome catabolites with higher plasma concentrations achieved (Table 3.1) 
and generally have longer circulation times (Table 1.1). This is the first study to 
investigate the effects of such conjugates on glucose uptake and metabolism in human 
skeletal muscle, and with comparisons between myotubes differentiated in a normal or 
high glucose/insulin environment. 
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Table 3.1: (Poly)phenol metabolites selected for the present study, with reference to articles evidencing antidiabetic effects for parent/precursor 
compounds, or associated extracts or foods (more detail in 3.5). 
(Poly)phenol Metabolite 
Profile (Metabolites) 
Food Sources 1 [Plasma] Achieved in 
pharmacokinetic studies 
Antidiabetic in vivo studies 2 Antidiabetic in vitro studies 3 
Ferulic Acid 
Ferulic acid 4-O-sulfate 
(FA4S) 
Dihydroferulic acid 4-O-
sulfate (DHFA-4S) 
Dihydroferulic acid 
(DHFA) 
Coffee, wheat, 
dark chocolate, 
dates, herbs, 
olive, berries, 
cinnamon 
FA4S > 4.9 µM (Feliciano, 
Mills et al. 2017) 
DHFA-4S > 0.9 µM (Lang, 
Dieminger et al. 2013) 
DHFA > 1.2 µM (Guy, 
Renouf et al. 2009) 
(Johnston, Clifford et al. 2003, 
Khan, Safdar et al. 2003, Thom 
2007, Andersen, Koehler et al. 
2008, Hlebowicz, Hlebowicz et al. 
2009, van Dijk, Olthof et al. 2009, 
Lu, Sheng et al. 2012, Bozzetto, 
Annuzzi et al. 2015) 
(Roffey, Atwal et al. 2006, 
Prabhakar and Doble 2009, 
Prabhakar and Doble 2011, 
Chellan, Muller et al. 2012, 
Tsuda, Egawa et al. 2012, 
Bhattacharya, Christensen et 
al. 2013, Gogoi, Chatterjee et 
al. 2014, Ho, Kase et al. 2017) 
Flavonols 
Quercetin 3′-O-sulfate 
(Q3S) 
Quercetin 3-O-β-D-
glucuronide (Q3G) 
Kaempferol 3-O-β-D-
glucuronide (K3G) 
Capers, onion, 
apple, tea, 
elderberry, 
endive, wine, 
beans, propolis 
Q3S > 0.7 µM (Mullen, 
Edwards et al. 2006) 
Q3G ≥ 0.6 µM (Cialdella-
Kam, Nieman et al. 2013)  
K3G > 0.4 µM (Kerimi, 
Jailani et al. 2015) 
(Johnston, Clifford et al. 2002, 
Bozzetto, Annuzzi et al. 2015, 
Nyambe-Silavwe and Williamson 
2016) 
 
(Fang, Gao et al. 2008, 
Zanatta, Rosso et al. 2008, Eid, 
Martineau et al. 2010, 
Kawabata, Sawada et al. 2011, 
Bhattacharya, Christensen et 
al. 2013, Ueda, Hayashibara et 
al. 2013, Xu, Hu et al. 2014, 
Eid, Nachar et al. 2015, Liu, 
Mei et al. 2016, Ho, Kase et al. 
2017) 
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Resveratrol 
trans-Resveratrol 4′-O-β-
D-glucuronide (R4G) 
trans-Resveratrol 3-O-
sulfate (R3S) 
trans-Resveratrol 3-O-β-
D-glucuronide (R3G) 
Wine, grape 
seed and various 
berries 
R4G > 10.2 µM (Brown, 
Patel et al. 2010) 
R3S > 18.3 µM (Brown, 
Patel et al. 2010) 
R3G > 17.1 µM (Brown, 
Patel et al. 2010) 4 
(Brasnyo, Molnar et al. 2011, 
Timmers, Konings et al. 2011, 
Bhatt, Thomas et al. 2012, 
Crandall, Oram et al. 2012, 
Movahed, Nabipour et al. 2013, 
Goh, Lee et al. 2014, Zare Javid, 
Hormoznejad et al. 2017) 
(Park, Kim et al. 2007, Breen, 
Sanli et al. 2008, Deng, Hsieh 
et al. 2008, Minakawa, 
Kawano et al. 2011) 
Phenolic sulfates 
Catechol-O-sulfate (CS) 
4-Methylcatechol-O-
sulfate (MCS) 
Pyrogallol-O-sulfate 
(PGS) 
4-Methylgallic 3-O-
sulfate (MGS) 
Vanillic acid 4-O-sulfate 
(VAS) 
Isovanillic acid 3-O-
sulfate (IVAS) 
Berries, cherry, 
olive, plum, 
coffee, 
cinnamon, black 
soybeans 
CS > 24.6 µM (Feliciano, 
Boeres et al. 2016) 
MCS > 5.0 µM (Feliciano, 
Mills et al. 2017) 
PGS > 12 µM (Pimpao, 
Ventura et al. 2015) 5 
MGS > 2 µM (Pimpao, 
Ventura et al. 2015) 
VAS > 1.6 µM (Feliciano, 
Mills et al. 2017) 
IVAS – n/a 
(PCA 6 > 2.4 µM (Czank, 
Cassidy et al. 2013)) 
(Johnston, Clifford et al. 2003, 
Khan, Safdar et al. 2003, Thom 
2007, Hlebowicz, Hlebowicz et al. 
2009, van Dijk, Olthof et al. 2009, 
Stull, Cash et al. 2010, Torronen, 
Sarkkinen et al. 2010, Edirisinghe, 
Banaszewski et al. 2011, Lu, Sheng 
et al. 2012, Hoggard, Cruickshank 
et al. 2013, Torronen, Kolehmainen 
et al. 2013, Giacco, Costabile et al. 
2014, Bozzetto, Annuzzi et al. 
2015, Nyambe-Silavwe and 
Williamson 2016) 
 
(Roffey, Atwal et al. 2006, 
Vuong, Martineau et al. 2007, 
Yamamoto, Ueda et al. 2010, 
Scazzocchio, Vari et al. 2011, 
Chellan, Muller et al. 2012, 
Rojo, Ribnicky et al. 2012, 
Tsuda, Egawa et al. 2012, 
Matsukawa, Inaguma et al. 
2015, Scazzocchio, Vari et al. 
2015, Boue, Daigle et al. 2016, 
Ho, Kase et al. 2017, Ho, Kase 
et al. 2017, Luna-Vital, Weiss 
et al. 2017, Nachar, Eid et al. 
2017) 
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1 from Phenol Explorer (Rothwell, Perez-Jimenez et al. 2013); foods not listed in any  
  particular order 
2 where glycaemia was lowered, or similar antidiabetic effects exerted, in humans 
3 where glucose uptake in muscle, or adipocytes, was stimulated 
4 all resveratrol metabolite Cmax values measured after 29 days of a daily 5 g supplement 
5 two isoforms of pyrogallol-O-sulfate combined 
6 PCA – protocatechuic acid, included as the precursor of (iso-)vanillic acid sulfates;  
  IVAS is the methylated and sulfated metabolite of PCA 
Note: lists are examples of relevant foods/studies and are not exhaustive 
 
3.3 Materials and Methods 
3.3.1 Chemical compounds and reagents 
All reagents were purchased from Sigma-Aldrich (Merck) (Gillingham, UK) unless 
otherwise stated. High purity (18.2 MΩ cm-1) water supplied by a MilliQ system (Merck 
Millipore UK, Watford, UK) was used throughout. 
3.3.2 Cell culture 
LHCN-M2 myoblasts, kindly provided by Vincent Mouly, are a cell line derived from a 
selected myogenic clone of the immortalised population of human satellite cells derived 
originally from the pectoralis major muscle of a 41-year old Caucasian heart-transplant 
donor (Zhu, Mouly et al. 2007). Myoblasts were maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) (11966-025, Gibco (Life Technologies, Thermo Fisher), 
Paisley, UK) supplemented with 5.5 mM glucose, 10% (v/v) heat-inactivated foetal 
bovine serum, 10% (v/v) heat-inactivated newborn calf serum (Gibco), 0.01 µg ml-1 
animal-free recombinant human epidermal growth factor (PeproTech, London, UK), 1 
ng ml-1 animal-origin free recombinant human basic fibroblast growth factor (Gibco) and 
0.4 µg ml-1 dexamethasone and then sterile-filtered. The composition of the growth 
medium was optimised in preliminary experiments (data not shown). Cells were 
passaged before reaching confluence to avoid terminal differentiation, at least every four 
days. For experiments, myoblasts, upon reaching ~80-90% confluence, were 
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differentiated to myotubes for 96 h after replacing growth medium with differentiation 
medium; DMEM supplemented with 5.5 or 25 mM glucose, 10 or 50 nM recombinant 
human insulin from Saccharomyces cerevisiae and 2% horse serum (Gibco) (myotubes 
differentiated in various concentrations of glucose and insulin were characterised – see 
Results) and this was changed every day. Cells were kept in a humidified atmosphere of 
5% CO2/95% air at 37
oC and used for experiments during passages 129-135. Sub-
culturing was done in 75 cm2 or 175 cm2 flasks (Appleton Woods, Birmingham, UK) 
and for experiments cells were seeded on 6-well plates (Appleton Woods), 100 mm 
dishes or 150 mm dishes (Greiner CELLSTAR, Stonehouse, UK) at a density equivalent 
to ~1.8 x 104 cells cm-2. For experiments, N/n values indicate the number of independent 
biological passages (N) and the number of technical replicates (n) from which the data 
were acquired. 
HepG2 (American Type Culture Collection HB-8065, LGC Promochem, Teddington, 
UK), Caco-2/TC7 (kindly provided by Dr. Monique Rousset, Institut national de la santé 
et de la recherche médicale, Paris, France) and Human Umbilical Vein Endothelial Cells 
(HUVEC) (C2517A, Lonza, Visp, Switzerland) cells were cultured as done previously 
in our lab (HepG2 – see 2.3.2; Caco-2/TC7 – (Villa-Rodriguez, Aydin et al. 2017); 
HUVEC – (Tumova, Kerimi et al. 2016)) and their whole cell lysates used in the 
validation of the GLUT4 antibody for Western analyses. 
3.3.3 Microscopy and cell viability checks 
Viability was assessed when seeding LHCN-M2 myoblasts for experiments using the 
Trypan Blue exclusion assay as done previously (Strober 2001). Cells were lifted with 
0.05% trypsin-EDTA, resuspended in medium and an aliquot mixed 1:1 (v/v) with 0.4% 
Trypan Blue-PBS and counted on a haemocytometer using a Leica MD IL LED inverted 
microscope; viable cells were those excluding Trypan Blue. During experiments non-
viable cells would actually detach from the plate, due to cell death or over-differentiation 
causing auto-contractions in the myotubes. If this was extensive the experiment was 
abandoned and repeated with a new passage of viable myoblasts, and if any detached 
during experiments then only viable cells were collected for analyses at the end anyway. 
Differentiation progress was monitored daily by observing the formation of elongated 
and multinucleated myotubes, and images were acquired with the same microscope. 
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3.3.4 Cell treatments with (poly)phenol conjugates 
LHCN-M2 myotubes, differentiated for 96 h in 5.5 mM glucose and 10 nM insulin or in 
25 mM glucose and 50 nM insulin, were starved of glucose and serum in the presence of 
(poly)phenol metabolites in combination, an individual compound or DMSO control for 
4 h before subsequent experiments for protein analyses or deoxy-/glucose uptake. 
Compounds were all reconstituted or diluted in DMSO. Comprising the ferulic acid 
metabolite profile were: ferulic acid 4-O-sulfate (FA4S), dihydroferulic acid 4-O-sulfate 
(DHFA-4S) (both synthesised by Dr. Nicolai Kraut in our lab previously; data 
unpublished but presented in his PhD thesis, 2015) and dihydroferulic acid (DHFA) 
(purchased from Alfa Aesar, Thermo Fisher Scientific, Warrington, UK), all at 2 µM 
when in combination or 6 µM individually. In the flavonol metabolite profile were: 
quercetin 3′-O-sulfate (Q3S) (synthesised by Dr. Dennis Wong in our lab previously 
(Wong, Botting et al. 2011)), quercetin 3-O-β-D-glucuronide (Q3G) and kaempferol 3-
O-β-D-glucuronide (K3G) (both purchased from Sigma-Aldrich), all at 2 µM when in 
combination or 6 µM individually. Resveratrol metabolites comprised: trans-resveratrol 
4′-O-β-D-glucuronide (R4G), trans-resveratrol 3-O-sulfate (R3S) and trans-resveratrol 
3-O-β-D-glucuronide (R3G) (all purchased from Bertin Pharma, Montigny-le-
Bretonneux, France), again at 2 µM in combination or 6 µM individually. The berry 
metabolite profile included the following phenolic sulfates: catechol-O-sulfate (CS), 4-
methylcatechol-O-sulfate (MCS), pyrogallol-O-sulfate (PGS), 4-methylgallic 3-O-
sulfate (MGS), vanillic acid 4-O-sulfate (VAS) and isovanillic acid 3-O-sulfate (IVAS) 
(all chemically/enzymically synthesised and characterised in our lab by Dr Rui Pimpão 
as described previously (Pimpao, Dew et al. 2014, Pimpao, Ventura et al. 2015)), all at 
5 µM in combination or 30 µM individually. IVAS was also tested further at various 
concentrations, always with the equivalent final DMSO (v/v). Isovanillic acid (Sigma-
Aldrich) (IVA) was tested individually at 30 µM to compare to the effects of IVAS. 
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3.3.5 Protein extraction and BCA total protein assay 
LHCN-M2 myotubes were differentiated for 96 h in 5.5 mM or 25 mM glucose with or 
without various concentrations of insulin and protein extracted at 96 h or at 0, 24, 48 and 
72 h time-points during differentiation. Alternatively, myotubes were differentiated for 
96 h in 5.5 mM glucose and 10 nM insulin or in 25 mM glucose and 50 nM insulin before 
being starved of glucose and serum in the presence of a (poly)phenol metabolite profile, 
individual compound or DMSO control for 4 h and then protein extracted. For analysis 
of Akt activation after incubation with IVAS, myotubes were incubated for a further 15 
min with IVAS, insulin, IVAS and insulin together, insulin and 5 µM wortmannin 
(inhibitor of PI3K of the insulin signalling pathway (Clarke, Young et al. 1994, 
Elmendorf, Damrau-Abney et al. 1995, Roffey, Atwal et al. 2006), or DMSO control. 
Following treatment, protein was extracted by washing cells twice in PBS, scraping into 
Bicine/CHAPS lysis buffer (ProteinSimple, Bio-Techne, San Jose, CA, USA) 
supplemented with 1% (v/v) protease inhibitor cocktail (P8340) and phosphatase 
inhibitor cocktail (one tablet PhosSTOP/10 ml) (#04 906 845, Roche, Sigma-Aldrich), 
centrifuging at 500 g, 4oC for 5 min, removing PBS and then snap-freezing in a dry 
ice/ethanol bath before storing pellets at -80oC. Total protein in thawed pellets was 
assayed using the colorimetric detection of bicinchoninic acid (BCA) as done previously 
(Smith, Krohn et al. 1985), with quantification on a PheraSTAR FS microplate reader 
(BMG LabTech, Ortenberg, Germany). Whole cell lysates for HepG2, Caco-2/TC7 and 
HUVEC cells, used as negative controls in the GLUT4 analysis, were prepared and 
protein measured in the same way. A positive control for GLUT4, human skeletal muscle 
whole tissue lysate (#NB820-59253, Novus, BioTechne) was diluted in Bicine/CHAPS 
and protein measured in the same way. 
3.3.6 Western protein analyses 
Whole cell lysates were prepared for running on the ProteinSimple Wes automated 
Western system (ProteinSimple, Bio-Techne) using reagents supplied in the system kit 
according to the manufacturer’s guidelines and were denatured at 37oC for 20 min before 
being added to the pre-filled assay plate along with primary antibodies accordingly. 
Primary antibodies used were: mouse anti-troponin T (cardiac) (CT3, Developmental 
Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA) as a marker of 
differentiated muscle (Gardner, Anguiano et al. 2012); mouse anti-GLUT4 (1F8, Cell 
 
 
- 95 - 
Signalling Technology, Beverley, MA, USA); rabbit anti-GLUT1 (ab115730, Abcam, 
Cambridge, UK); mouse anti-PI3K (subunit p85α) (MAB2998, Novus, BioTechne) as a 
marker of the insulin signalling pathway proteins (Clarke, Young et al. 1994); rabbit anti-
Akt (#9272, Cell Signalling Technology) and rabbit anti-phospho-Akt (Ser473) ((D9E) 
XP #4060, Cell Signalling Technology) to determine the p-Akt/Akt ratio, a marker of 
insulin signalling pathway activation (Kohn, Barthel et al. 1998); and these were 
duplexed with mouse anti-α-actinin 1 (MAB8279, Novus, BioTechne) or rabbit anti-α-
actinin ((D6F6) XP #6487, Cell Signalling Technology) (which recognises total 
endogenous α-actinin proteins) accordingly as loading controls, and run with anti-mouse 
or anti-rabbit secondary antibodies accordingly (supplied in the Wes kit). Lysate preps 
were loaded onto the Wes system at specific final protein concentrations, and 
chemiluminescence was detected after specific exposure times (or in the high dynamic 
range mode (HDR)), determined as optimal for each antibody combination: 0.4 mg/ml 
for troponin T/α-actinin 1 and after 16 s; 0.5 mg/ml for GLUT4/α-actinin 1 and after 512 
s for the former and in HDR for the latter; 0.1 mg/ml for GLUT1/α-actinin and after 16 
s; 0.4 mg/ml for PI3K p85α/α-actinin 1 and after 16 s; 0.1 mg/ml for (p-)Akt/α-actinin 
and after 512 s for the former and in HDR for the latter. See Figs. 3.2, 3.6, 3.7, 3.13, 3.14 
for full setup and validation of antibodies. Chemiluminescent peak areas were converted 
into ratios of the target protein/loading control. 
3.3.7 Uptake assays with radiolabelled 2-deoxy-D-glucose and glucose 
LHCN-M2 myotubes were differentiated and treated as described previously for protein 
extraction. Following the 4 h starvation/incubation with the (poly)phenol metabolites or 
DMSO control, or insulin (for uptake experiments only), myotubes were further 
incubated with various insulin concentrations, (poly)phenol metabolites or DMSO 
controls and 0.075 µCi/ml 2-[1-14C(U)]-deoxy-D-glucose (PerkinElmer, Beaconsfield, 
UK) in 0.55 mM 2-deoxy-D-glucose in DMEM for 30 min or 0.1 µCi/ml D-[14C(U)]-
glucose (PerkinElmer) in 0.55 mM D-glucose in DMEM for 4 h. Cells were then washed 
twice in the starvation medium (without glucose and serum), lysed in 1M NaOH, 
neutralised with 1M HCl and measured by liquid scintillation counting using a Tri-Carb 
1900 TR Liquid Scintillation Analyzer (Canberra Packard, Harwell, Oxford, UK). 
Counts per minute were corrected for total protein, measured in aliquots of the lysates 
using the Bradford assay (Pierce Coomassie (Bradford) Protein Assay Kit #23200, 
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Thermo Fisher Scientific) as described previously (Bradford 1976, Ernst and Zor 2010) 
and extrapolated to total 2-deoxy-D-glucose and glucose uptake. Uptake of both in 
response to insulin in myoblasts (at the point of confluence where medium would be 
changed for differentiation) was also investigated in this way. Later experiments with 
IVAS on the myotubes also used 5 µM wortmannin and 20 µM indinavir, a known 
inhibitor of GLUT4 (Rudich, Konrad et al. 2003, Breen, Sanli et al. 2008). 
3.3.8 High-resolution respirometry 
LHCN-M2 myotubes differentiated for 96 h in 5.5 mM glucose were washed in PBS and 
lifted from 150 mm dishes in serum-free DMEM. Oxygen concentration and flux was 
continuously measured as 2 ml of the cell suspensions were added to each chamber of 
the Oxygraph-2k (O2k) (OROBOROS Instruments, Innsbruck, Austria), maintained at 
37oC, and a phosphorylation control protocol followed (see 2.3.10) (Brand and Nicholls 
2011, Gnaiger 2014). ‘Routine’ basal respiration was recorded first, then 250 nM 
oligomycin added to measure IMM proton ‘Leak’; 5 µM FCCP was titrated in to measure 
electron transfer system (‘ETS’) capacity, and 1.25 µM rotenone and 2.5 µM antimycin 
A both added for non-mitochondrial residual oxygen consumption, ‘ROX’, for which the 
previous measurements were corrected. Cell suspensions were collected after the 
respirometry experiment was complete, spun down and pellets lysed in Bicine/CHAPS 
and measured for total protein using the BCA assay as done for the Western lysates; 
respiration values were then corrected for total protein. To compare respiration in LHCN-
M2 muscle cells to that in HepG2 hepatic cells, as part of the muscle model 
characterisation, the flux control ratios, which account for ETS capacity to enable 
comparison between cell types, were calculated from these respirometry values and 
compared to data collected for Chapter 2 (see 2.3.10 and 2.4.5). Flux control ratios were 
calculated from the measured oxygen fluxes as a factor of ETS; R/E – Routine/ETS, L/E 
– Leak/ETS, Net R/E – (Routine-Leak)/ETS, and ROX/E′ – ROX/non-ROX-corrected 
ETS. 
3.3.9 DCFH-DA ROS Assay 
LHCN-M2 myotubes differentiated in 6-well plates for 96 h in 5.5 mM or 25 mM glucose 
with 10 or 50 nM insulin or DMSO controls were assessed for relative total ROS levels 
using the DCFH-DA assay as done for the HepG2 cells (see 2.3.7) and elsewhere 
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previously (Wang and Joseph 1999). Briefly, cells were washed with PBS, incubated 
with 10 µM DCFH-DA in PBS at 37oC for 20 min in darkness, washed again and DCF 
fluorescence measured on the PheraSTAR FS plate reader (Ex/Em = 485/530 nm). Cells 
were then scraped into and lysed in CellLytic supplemented with 1% (v/v) P8340 
protease inhibitor cocktail and total protein measured using the Bradford assay. DCF 
fluorescence, in relative fluorescence units, was corrected for protein and normalised 
relative to total ROS in the 5.5 mM glucose control. 
3.3.10 Statistical analyses 
Data are expressed as means ± standard error of the mean. The significance of differences 
between groups of treatments was analysed by one-way ANOVA and post hoc Tukey’s 
(for unequal sample sizes), Dunnett’s (comparing multiple treatments to a single control) 
or two-tailed t-tests accordingly, with variance checks using Levene’s test, and with 
Bonferroni correction where multiple treatments were compared, using SPSS 24 and 
presenting the data in Origin 2016 p < 0.05 was considered as statistically significant. 
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Figure 3.1: LHCN-M2 myoblasts differentiate to myotubes in 96 h. Myoblasts were grown in medium containing 5.5 mM glucose, 20% serum, 
dexamethasone and growth factors until confluent, at which point this was replaced with medium containing 5.5 mM glucose and 2% serum only 
and the myoblasts differentiated for 96 h. Images were taken daily using a Leica MD IL LED inverted microscope at 10X magnification.
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3.4 Results 
3.4.1 Characterising the human skeletal muscle cell model 
3.4.1.1 Differentiation from myoblasts to myotubes 
LHCN-M2 myoblasts were differentiated to myotubes, identified by multinucleated 
fibres formed by fused myoblasts, for 96 h in differentiation medium (Fig. 3.1). Protein 
analysis revealed that α-actinin levels remained constant, making it a suitable loading 
control for subsequent protein analyses, but troponin T increased by an average of 50% 
every 24 h (Fig. 3.3). As expected, myotubes were responsive to insulin and respired 
aerobically (Fig. 3.4). Insulin dose-dependently increased acute 2-[1-14C(U)]-deoxy-D-
glucose (2-[1-14C(U)]-DG) uptake, up by 30% with 200 nM (p < 0.001), and D-[14C(U)]-
glucose (D-[14C(U)]-Glc) (or 14C in other metabolic forms downstream of glucose) 
retained in the cells after 4 h, up by 65% with 50 nM (p < 0.001) (Figs. 3.4A, B). Insulin 
did not stimulate 2-[1-14C(U)]-DG uptake in myoblasts (0 h differentiation) but increased 
14C in the cells after longer-term uptake with D-[14C(U)]-Glc at the precursor stage (Fig. 
3.4C). Oxidative respiration was greater in myotubes than in hepatocytes grown in 
similar conditions, particularly net mitochondrial output by 70% (p < 0.001) (Fig. 3.4D). 
3.4.1.2 Effects of glucose and insulin on myotube phenotype 
Morphological differences in myotube differentiation caused by glucose or insulin could 
not be determined by eye, as seen in the micrographs in Fig. 3.5E, however respiration 
and differentiation were affected (Figs. 3.5A-D). Differentiating in high glucose 
increased IMM proton leak by 45% (p < 0.05) (Fig. 3.5A) and relative ROS levels in 
myotubes; 10 nM insulin reversed the latter but 50 nM insulin increased it further (Fig. 
3.5B). The greatest difference in ROS was between 5.5 mM glucose with 10 nM insulin 
and 25 mM glucose with 50 nM insulin (p < 0.001). In normal glucose insulin dose-
dependently increased the degree of differentiation after 96 h (p < 0.05), but in high 
glucose this was lowered with 50 nM (p < 0.05) (Fig. 3.5C). Interestingly, troponin T/α-
actinin was the same in myotubes differentiated in 5.5 mM glucose with 10 nM insulin 
and 25 mM glucose with 50 nM insulin (Fig. 3.5C) and this was the case throughout the 
96 h (Fig. 3.5D). 
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The glucose and insulin concentration of the differentiation medium also affected 2-[1-
14C(U)]-DG and D-[14C(U)]-Glc uptake in myotubes. Acute 2-[1-14C(U)]-DG uptake 
was greater in normal glucose myotubes (Fig. 3.8A) but high glucose myotubes were 
more responsive to insulin (Fig. 3.8B). This was the same for 14C taken up and remaining 
in the myotubes after 4 h (Figs. 3.8C, D), and differentiating the cells in the presence of 
insulin generally lowered this uptake too (Figs. 3.8C, E). Increasing the differentiation 
medium insulin from 10 nM to 50 nM lowered basal D-[14C(U)]-Glc uptake/retained 14C 
in the normal glucose cells (p < 0.05) but did not affect the high glucose cells. The 
greatest difference in D-[14C(U)]-Glc uptake was observed between the 5.5 mM glucose 
with 10 nM insulin myotubes and the 25 mM glucose with 50 nM insulin myotubes (p < 
0.05 at each dose of insulin) (Fig. 3.8E). The insulin response, however, was not different 
between these two conditions and was instead heightened with increased insulin, 
particularly in the normal glucose cells (p < 0.001 across the curve for 5.5 mM glucose 
with 50 nM insulin). Adding 10 nM insulin to the cells differentiating in high glucose 
actually diminished the insulin dose-response (NS across the curve) (Fig. 3.8F). 
Protein analyses for myotubes differentiated in 5.5 mM glucose with 10 nM insulin or 
25 mM glucose with 50 nM insulin revealed that total GLUT4 was not different between 
the two (Fig. 3.8G), but GLUT1 was higher in the former (p < 0.001) (Fig. 3.8H). As the 
cells differentiated, GLUT4 protein increased (Fig. 3.8G), while GLUT1 decreased. 
GLUT1 was lower in the myotubes differentiated in 5.5 mM glucose with 10 nM insulin 
after 48 h (p < 0.05), but higher after 96 h (p < 0.01) (Fig. 3.8H). Subsequent experiments 
were performed on cells differentiated in one of these two conditions to compare a 
‘normal’ glucose/insulin environment (5.5 mM glucose with 10 nM insulin) to ‘high’ 
glucose/insulin. For ease, these shall be referred to from here simply as ‘normal’ or ‘high 
GI’ myotubes. 
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Figure 3.2: Antibody validation for Western analysis of troponin T and α-actinin 1. 
Various total protein concentrations of differentiated LHCN-M2 whole cell lysate 
were analysed with troponin T and α-actinin 1 antibodies and run in the same 
capillary on the ProteinSimple Wes automated Western system to establish 
standard curves, with electropherogram view (A) and gel-style lane view (B), for 
detection after a 16 s exposure. The peak areas taken from the pherogram were used 
to establish a standard curve for each antibody when duplexed (C). 
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Figure 3.3: Troponin T is upregulated during myocyte differentiation. LHCN-M2 
Myoblasts were grown and differentiated to myotubes over 96 h, as described in 
Fig. 3.1. Protein analysis of troponin T and α-actinin 1 was performed on the 
ProteinSimple Wes automated Western capillary system (see Fig. 3.2 for antibody 
validation and linear range of detection) using total cell lysates extracted each day 
during differentiation and loaded at 0.4 mg/ml. Chemiluminescence peaks after a 
16 s exposure can be seen in the electropherogram (A) and gel image views (B). 
The areas under these peaks were plotted and data (C-D) are shown as mean ± SEM 
(N = 3). Letters above bars (D) denote where p < 0.05 between time-points.  
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Figure 3.4: LHCN-M2 myotubes are insulin-responsive and more oxidative than 
hepatocytes. Acute uptake of 2-[1-14C(U)]-deoxy-D-glucose (2-DG) (A) and 
longer-term D-[14C(U)]-glucose uptake (or retention of 14C metabolites) (B) in 
response to insulin in myotubes differentiated for 96 h was measured. Cells were 
starved of glucose and serum for 4 h then incubated with various insulin 
concentrations and 0.15 µCi/ml 2-[14C(U)]-DG in 0.55 mM 2-DG for 30 min (A) 
or 0.2 µCi/ml D-[14C(U)]-glucose in 0.55 mM D-glucose for 4 h (B), then washed, 
lysed and measured by liquid scintillation counting and corrected for total protein. 
The same was measured in myoblasts alongside myotubes for 30 min with 2-[1-
14C(U)]-deoxy-D-glucose (DG) ± 100 nM insulin or for 4 h with D-[14C(U)]-
glucose ± 25 nM insulin (C). Mitochondrial respiration was measured in myotubes 
and in HepG2 cells, grown in 5.5 mM glucose for 96 h, using the OROBOROS 
O2k respirometer and flux control ratios calculated as a factor of ETS (see Figs. 
2.10A, 3.5A); R/E – Routine /ETS, L/E – Leak/ETS, Net R/E – (Routine-
Leak)/ETS, and ROX/E′ – ROX as a factor of non-ROX-corrected ETS. All data 
are mean ± SEM (n/N = 12/4 (A); 24/5 (B); 12/4 (C); 25/17 (HepG2) and 5/5 
(LHCN-M2) (D)). Letters denote p < 0.05 between doses (A-B). *p < 0.05 and **p 
< 0.01 vs 0 nM insulin controls (C). ***p < 0.001 vs HepG2 (D). 
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Figure 3.5: Glucose and insulin affect LHCN-M2 differentiation and myotube 
metabolism. Myotubes differentiated for 96 h in media containing 5.5 mM or 25 
mM glucose and oxygen fluxes measured using the OROBOROS O2k high-
resolution respirometer (A). Intact cells were added to the respirometer and a 
phosphorylation control protocol followed as for the HepG2 cells in Chapter 2 (see 
2.3.10). Data were corrected for total protein and are expressed as mean 
percentages of the 5.5 mM glucose controls ± SEM (N = 5) (A). Relative ROS 
levels were assayed, by incubating with 10 µM DCFH-DA in PBS for 20 min and 
measuring DCF fluorescence, in myotubes differentiated in media with various 
glucose and insulin concentrations and data expressed as mean ROS relative to the 
5.5 mM glucose + 0 nM insulin control ± SEM (n/N = 18/3) (B). Troponin T/α-
actinin 1 protein in total cell lysates of myotubes differentiated in media with 
various glucose (Glc) and insulin (Ins) concentrations was measured on the 
ProteinSimple Wes automated Western capillary system (see Figs. 3.2, 3.3) and 
data are shown as mean ± SEM (N = 3) (C-D). Images of myotubes differentiated 
in various conditions were taken using the Leica MD IL LED inverted microscope 
at 10X magnification and an example of myotubes in 5.5 mM and 25 mM glucose 
is shown (E). *p < 0.05 vs 5.5 mM glucose (A). Letters above bars denote p < 0.05 
(B). ***p < 0.001 for the biggest difference between two groups (B). *p < 0.05, 
**p < 0.01, ***p < 0.001 vs 5.5 mM glucose + 0 nM insulin control (C). # p < 
0.05 vs 5.5 mM glucose + 50 nM insulin (C). Letters above bars denote where p < 
0.05 between time-points (D).  
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Figure 3.6: Antibody validation for Western analysis of GLUT4 and α-actinin 1. 
Various total protein concentrations of differentiated LHCN-M2 whole cell lysate 
were analysed with GLUT4 and α-actinin 1 antibodies and run in the same capillary 
on the ProteinSimple Wes automated Western system to establish standard curves, 
with electropherogram view (A) and gel-style lane view (B); α-actinin 1 was 
detected in high dynamic range mode while GLUT4 (boxed) was detected after a 
512 s exposure. The peak areas taken from the pherograms were used to establish 
a standard curve for each antibody when duplexed (C). With relatively small peaks 
for GLUT4 and some non-target/non-specific noise, the specificity of the peak at 
~47 kDa was supported by running the LHCN-M2 lysate alongside a human 
skeletal muscle whole cell lysate (HuSkM WCL) as a positive control and HepG2, 
Caco-2/TC7 and HUVEC total cell lysate negative controls (D). 
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Figure 3.7: Antibody validation for Western analysis of GLUT1 and α-actinin. 
Various total protein concentrations of differentiated LHCN-M2 whole cell lysate 
were analysed with GLUT1 and α-actinin antibodies when run in the same capillary 
on the ProteinSimple Wes automated Western system to establish standard curves, 
with electropherogram view (A) and gel-style lane view (B) for detection after a 16 
s exposure. The peak areas taken from the pherogram were used to establish a 
standard curve for each antibody when duplexed (C). 
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Figure 3.8: Glucose and insulin affect (deoxy-)glucose uptake and metabolism, 
insulin sensitivty and GLUT expression in LHCN-M2 myotubes. Acute uptake 
of 2-[1-14C(U)]-deoxy-D-glucose (A-B) and longer-term D-[14C(U)]-glucose 
uptake (or retention of downstream 14C metabolites) (C-D) in response to insulin 
in myotubes differentiated for 96 h in 5.5 mM or 25 mM glucose was measured. 
Cells were starved of glucose and serum for 4 h then incubated with various 
concentrations of insulin and 0.15 µCi/ml 2-[14C(U)]-deoxy-D-glucose in 0.55 mM 
2-deoxy-D-glucose for 30 min (A-B) or 0.2 µCi/ml D-[14C(U)]glucose in 0.55 mM 
D-glucose for 4 h (C-D), then washed, lysed and measured by liquid scintillation 
counting and corrected for total protein. In order to compare responses to insulin 
the data in A and C were normalised to the 0 nM insulin controls for both 5.5 and 
25 mM glucose (B and D). Glucose (metabolised) in cells after 4 h was measured 
in the same way but in myotubes differentiated in 5.5 or 25 mM glucose with 10 or 
50 nM insulin (E) and normalised to each 0 nM insulin control (F). Total GLUT4 
(G) and GLUT1 (H) protein levels in whole cell lysates of myotubes differentiated 
in 5.5 mM glucose and 10 nM insulin or 25 mM glucose and 50 nM insulin were 
measured on the ProteinSimple Wes automated Western capillary system and 
corrected for α-actinin (see Figs. 3.6 and 3.7 respectively for antibody validation 
and linear range of detection). Lysates were extracted at time-points during 
differentiation and then for GLUT4 analysis loaded at 0.5 mg/ml and detected in 
high dynamic range mode for α-actinin 1 and after a 512 s exposure for GLUT 4 
(G) and for GLUT1 analysis 0.1 mg/ml was loaded and both α-actinin and GLUT1 
detected after a 16 s exposure. All data are shown as mean ± SEM (n/N = 12/4 (A-
B); 16/4 (C-D); 9/3 (E-F); 3/3 (G-H)). *p < 0.05, **p < 0.01, ***p < 0.001 for 
differences between differentiation conditions at each incubation concentration or 
time-point. 
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3.4.2  (Poly)phenol metabolites increase glucose uptake and metabolism 
3.4.2.1 Effects of metabolite profiles 
2-[1-14C(U)]-DG uptake in LHCN-M2 myotubes was stimulated by a range of 
(poly)phenol metabolites, including the ferulic acid conjugates, resveratrol conjugates 
and berry phenolic sulfates. The ferulic acid derived combination increased uptake, 
independent of insulin, in the high GI myotubes by 38% (p < 0.05) to match basal uptake 
in the normal, but had no effect on the latter. Insulin-stimulated uptake was slightly 
inhibited when the metabolites were also present (NS, FA vs FA + insulin) (Fig. 3.9A) 
(p < 0.05 vs Ins). This metabolite profile lowered the 14C taken into/retained in the cells 
after a 4 h D-[14C(U)]-Glc incubation, again only in the high GI myotubes and 
independent of insulin (down 12%, p < 0.05 vs control) (Fig. 3.10A). 
The flavonols had no effect on 2-[1-14C(U)]-DG uptake, although uptake in the high GI 
myotubes was no longer significantly different to that in the normal control (Fig. 3.9B). 
In the high GI myotubes the flavonols completely blunted the longer term effect of 
insulin (Fig. 3.10B), but otherwise again had no effects on basal uptake. 
The combination of the resveratrol glucuronide conjugates and sulfate increased 2-[1-
14C(U)]-DG uptake in both normal and high GI myotubes, by almost 50% in the former 
(p < 0.05) and restored uptake in the latter to a similar level in the normal control (NS) 
(Fig. 3.9C). As with the ferulic acid derivatives, uptake was increased no further than 
that with insulin alone, nor was it increased further when incubated with both (Figs. 3.9A, 
C). The resveratrol metabolites lowered basal 14C uptake/retention in the cells after 4 h 
in both normal and high GI, by as much as 25% in the latter (p < 0.001), as well as 
blunting the insulin effect in these cells too (Fig. 3.10C). 
The phenolic sulfates increased basal 2-[1-14C(U)]-DG uptake in the same manner in 
both normal and high GI myotubes, up by 60% in normal (p < 0.05) and nearly 50% in 
high (p < 0.01), and in the latter increased it further when incubated with insulin too, by 
65% (p < 0.001) (Fig. 3.9D). They had no effects on the 4 h D-[14C(U)]-Glc uptake 
however (Fig. 3.10D).  
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Figure 3.9: (Poly)phenol metabolite profiles stimulate 2-[1-14C(U)]-deoxy-D-glucose 
uptake in LHCN-M2 myotubes. Myotubes, differentiated for 96 h in 5.5 mM 
glucose and 10 nM insulin (‘Normal’) or in 25 mM glucose and 50 nM insulin 
(‘High Glc/Ins), were starved of glucose and serum in the presence of a selected 
combination of (poly)phenol metabolites (or DMSO control) for 4 h then incubated 
with a DMSO control, 100 nM insulin, the same metabolites or both metabolites 
and insulin, and 0.15 µCi/ml 2-[14C(U)]-deoxy-D-glucose in 0.55 mM 2-deoxy-D-
glucose for 30 min, then washed, lysed and measured by liquid scintillation 
counting and corrected for total protein. In order to compare responses to the 
various treatments and differentiation conditions the data were normalised to the 
DMSO controls for the Normal cells and shown as mean ± SEM (n/N = 12/4). 
Ferulic acid (FA) derivatives – FA4S, DHFA-4S and DHFA, all at 2 µM (A); 
flavonol conjugates – Q3S, Q3G and K3G, all at 2 µM (B); resveratrol (Res) 
conjugates – R4G, R3S and R3G, all at 2 µM (C); berry phenolic sulfates (Sulf) – 
CS, MCS, PS, MGS, VAS and IVAS, all at 5 µM (D). 2-DG – 2-deoxy-D-glucose; 
Ins - insulin. Letters above bars indicate p < 0.05 between groups.  
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Figure 3.10: (Poly)phenol metabolite profiles stimulate glucose metabolism (less 
intracellular 14C after 4 h) in LHCN-M2 myotubes. Myotubes, differentiated for 
96 h in 5.5 mM glucose and 10 nM insulin (‘Normal’) or in 25 mM glucose and 50 
nM insulin (‘High Glc/Ins), were starved of glucose and serum in the presence of 
a selected combination of (poly)phenol metabolites (or DMSO control) for 4 h then 
incubated with a DMSO control, 25 nM insulin, the same metabolites or both 
metabolites and insulin, and 0.2 µCi/ml D-[14C(U)]glucose in 0.55 mM D-glucose 
for 4 h, then washed, lysed and measured by liquid scintillation counting and 
corrected for total protein. In order to compare responses to the various treatments 
and differentiation conditions the data were normalised to the DMSO controls for 
the Normal cells and shown as mean ± SEM (n/N = 12/4). Ferulic acid (FA) 
derivatives – FA4S, DHFA-4S and DHFA, all at 2 µM (A); flavonol conjugates – 
Q3S, Q3G and K3G, all at 2 µM (B); resveratrol (Res) conjugates – R4G, R3S and 
R3G, all at 2 µM (C); berry phenolic sulfates (Sulf) – CS, MCS, PS, MGS, VAS 
and IVAS, all at 5 µM (D). Glc – glucose; Ins - insulin. Letters above bars indicate 
p < 0.05 between groups.  
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3.4.2.2 Individual metabolites 
Individual metabolites were tested on high GI myotubes, where the greatest or most 
promising effects were seen, and with or without insulin according to whether previous 
effects were deemed insulin-dependent or not. The increases in 2-[1-14C(U)]-DG uptake 
were primarily due to sulfated conjugates. FA4S and DHFA-4S increased uptake by 
around 15% (p < 0.05) (Fig. 3.11A) and R3S by 24% (p < 0.001) (Fig. 3.11C), but IVAS 
was most effective, with an increase of 41% (p < 0.001). This was the only phenolic 
sulfate in the berry profile to have an effect (Fig. 3.11D) and the effect was on top of an 
insulin-stimulated increase. The only glucuronide conjugate to exert an effect was R4G, 
with a 23% increase (p < 0.01). Despite having no significant effects on 2-[1-14C(U)]-
DG uptake when in combination, the flavonols were tested individually because the 
combined data looked as though there may be potential for one or two of the individual 
compounds to increase uptake, but this was not the case. 
For the 4 h D-[14C(U)]-Glc uptake the effects of the ferulic acid derived metabolite 
profile were exclusive to the high GI myotubes (Fig. 3.10A) and the effects of the 
resveratrol conjugates were most promising also on these cells (Fig. 3.10C), so these 
individual metabolites were only tested on high GI. Resveratrol conjugates were tested 
with and without insulin because effects were seen for both when the conjugates were 
combined (Fig. 3.10C). The insulin-blunting effect of the flavonol profile was explored 
for the individual compounds in normal and high GI myotubes because, although the 
insulin-blunting was only significant in the high, again the data looked as though there 
may have been differences between the two with individual conjugates. Originally the 
phenolic sulfates had shown no effect on 4 h D-[14C(U)]-Glc uptake, but following the 
promising effects of IVAS alone on the 2-[1-14C(U)]-DG uptake, this was tested in 
normal and high GI myotubes with and without insulin. 
DHFA-4S and R4G were responsible for decreasing 14C uptake/retention in the cells after 
4 h by 27% (p < 0.001) and 11% (p < 0.05) respectively, and both independently of 
insulin (Figs. 3.11E, G). Despite having no effects on 2-[1-14C(U)]-DG transport (Fig. 
3.11B), Q3G lowered the 14C after 4 h incubation with D-[14C(U)]-Glc in normal 
myotubes by 22% (p < 0.01), and K3G did so in both normal and high GI, by 19% (p < 
0.01) and 25% (p < 0.05) respectively (Fig. 3.11F). With the 2-[1-14C(U)]-DG uptake 
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result for IVAS, it also lowered basal intracellular 14C after 4 h by around 17% (p < 0.05) 
in both normal and high GI myotubes, and mildly inhibited the effect of insulin but only 
in the normal myotubes (p = 0.08 insulin vs IVAS + insulin; NS vs Control) (Fig. 3.11H). 
3.4.3 Establishing a mechanism of action for isovanillic acid 3-O-sulfate 
3.4.3.1 IVAS dose-dependently increases 2-deoxy-D-glucose uptake 
For its superior capacity to increase 2-[1-14C(U)]-DG uptake in myotubes, notably in 
high GI (Fig. 3.9D), and synergistically with insulin (Fig. 3.11D), the effects of IVAS 
were probed further to establish a mechanism of action. IVAS dose-dependently 
increased 2-[1-14C(U)]-DG uptake in the low micromolar range; with 2.5 µM the 
transport was increased by 15% in normal (p < 0.01) and by 29% in high GI myotubes 
(p < 0.001) (Figs. 3.12A, B). Uptake plateaued with higher concentrations, likely that 
the cells were taking up 2-[1-14C(U)]-DG at maximal rate; insulin had the same effect 
(Figs. 3.4A, 4A, B). Whilst actual uptake was higher in the normal myotubes, the high 
GI myotubes were more responsive to the IVAS than the normal (p = 0.05 at 10 µM and 
p < 0.05 at 30 µM) (Fig. 3.12B), again in the same manner as with insulin (Fig. 4B) and 
thus suggestive of a similar mechanism of action. 2-[1-14C(U)]-DG uptake was increased 
dose-dependently synergistically when myotubes were treated with both insulin and 
isovanillic acid sulfate (Fig. 3.11D). The increase in 2-[1-14C(U)]-DG uptake was not 
reliant on the sulfate group of the metabolite because isovanillic acid increased it to the 
same extent in normal and high GI myotubes (both NS vs IVA) (Fig. 3.12C). 
3.4.3.2 IVAS Increases GLUT Expression and Activates Insulin Signalling 
To test the insulinomimetic hypothesis, myotubes were incubated with insulin and IVAS 
in the presence of wortmannin, PI3K inhibitor, and indinavir, GLUT4 inhibitor. Both 
prevented insulin- and IVAS-stimulated 2-[1-14C(U)]-DG uptake (both p < 0.001 vs 
insulin, both p < 0.01 vs IVAS), but neither had an effect on basal uptake (Fig. 3.12D). 
Furthermore, the acute effect (30 min incubation only) was tested and IVAS still 
increased 2-[1-14C(U)]-DG uptake, though to a lesser extent than with the chronic effect 
(4.5 h total incubation) (19% vs 41%, p < 0.05) (Fig. 3.12E). This suggested both acute 
and chronic effects were in play and protein analyses revealed this to be true. 
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The degree of differentiation was unaffected by the 4 h treatment with IVAS (Fig. 
3.15A), but GLUT4 expression was increased in both normal and high GI myotubes by 
a mean of 57% (p < 0.001) (Fig. 3.15B) and GLUT1 was increased by 23% in high GI 
(p < 0.05), to the same level as in the normal; in normal it was unchanged (Fig. 3.15C). 
PI3K was upregulated in both myotube models, but more so in the high (38% in normal, 
p < 0.05; 64% in high GI, p < 0.001) (Fig. 3.15D). It is also worth noting that PI3K was 
16% higher in the high GI control than in the normal (p < 0.05) and 37% higher when 
comparing the two with IVAS treatment (p < 0.01). Incubation with IVAS for 15 min 
increased Akt phosphorylation by 54% (p < 0.05) in normal and high GI myotubes (Fig. 
3.15E). As expected, Akt was phosphorylated with insulin and inhibited by wortmannin, 
and was synergistically activated more so with both insulin and IVAS (Fig. 3.15E).  
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Figure 3.11: Individual (poly)phenol metabolites also stimulate 2-[1-14C(U)]-deoxy-
D-glucose uptake and glucose metabolism. Myotubes, all differentiated for 96 h 
in 25 mM glucose and 50 nM insulin, were starved of glucose and serum in the 
presence of a metabolite or DMSO control for 4 h then incubated with the same 
metabolite (plus 100 nM insulin (B, D)) and 0.15 µCi/ml 2-[14C(U)]-deoxy-D-
glucose in 0.55 mM 2-deoxy-D-glucose for 30 min, then washed, lysed, measured 
by liquid scintillation counting, corrected for total protein and normalised to the 
control (A-D). Myotubes, differentiated for 96 h in 5.5 mM glucose and 10 nM 
insulin or in 25 mM glucose and 50 nM insulin, were starved of glucose and serum 
in the presence of a metabolite or DMSO control for 4 h then incubated with the 
same metabolite ± 25 nM insulin and 0.2 µCi/ml D-[14C(U)]glucose in 0.55 mM 
D-glucose for 4 h, then washed, lysed, measured by liquid scintillation counting, 
corrected for total protein and normalised to the controls (E-H). All data are shown 
as mean ± SEM (n/N = 12/4). Ctrl – control; 2-DG – 2-deoxy-D-glucose; Glc – 
glucose; Norm. – normalised; Ins - insulin. *p < 0.05, **p < 0.01, ***p <0.001 vs 
the controls accordingly. Letters above bars (H) indicate p < 0.05 between groups.  
 
 
- 118 - 
 
 
 
- 119 - 
Figure 3.12: IVAS increases 2-[1-14C(U)]-deoxy-D-glucose uptake in a dose-
dependent manner via the PI3K-dependent pathway. Myotubes, differentiated 
for 96 h in 5.5 mM glucose and 10 nM insulin or in 25 mM glucose and 50 nM 
insulin, were starved of glucose and serum in the presence of various 
concentrations of IVAS or DMSO control for 4 h then incubated with the same plus 
0.15 µCi/ml 2-[14C(U)]-deoxy-D-glucose in 0.55 mM 2-deoxy-D-glucose for 30 
min, then washed, lysed, measured by liquid scintillation counting and corrected 
for total protein (A-B). In order to compare responses to the IVAS, the data shown 
in A were normalised to the controls (B). The same was done with 30 µM IVAS or 
30 µM isovanillic acid (IVA) (C) and with 100 nM insulin (during the 30 min 
incubation), 30 µM IVAS (during the 4 h starvation and 30 min incubation) or 
DMSO ± 5 µM wortmannin (inhibitor of PI3K) or 20 µM indinavir (inhibitor of 
GLUT4) (or DMSO controls) (D). Uptake was also measured in the same way but 
in myotubes treated acutely with IVAS for 30 min (starvation followed by 30 min 
incubation with 2-[1-14C(U)]-deoxy-D-glucose), and with inhibitors added again, 
or DMSO control (E). All data are shown as mean ± SEM (n/N = 12/4). Ctrl(s) – 
control(s); 2-DG – 2-deoxy-D-glucose; Ins – insulin; Norm. – normalised; Wort – 
5 µM wortmannin; Ind – 20 µM indinavir. *p < 0.05, **p < 0.01, ***p < 0.001 vs 
controls accordingly. ## p < 0.01 vs 5.5+10 with 0 nM insulin + 30 µM IVA. † p 
< 0.05, †† p < 0.001 vs 25+10 with 0 nM insulin accordingly. NS not significantly 
different to the control.  
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Figure 3.13: Antibody validation for Western analysis of regulatory unit p85α of 
PI3K and troponin T. Various total protein concentrations of differentiated 
LHCN-M2 whole cell lysate were analysed with PI3K p85α and troponin T 
antibodies and run in the same capillary on the ProteinSimple Wes automated 
Western system to establish standard curves, with electropherogram view (A) and 
gel-style lane view (B) for detection after a 16 s exposure. The peak areas taken 
from the pherogram were used to establish a standard curve for each antibody when 
duplexed (C). Note, troponin T was chosen as a loading control for PI3K p85α 
because the MW of the latter is too close to that of α-actinin. 
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Figure 3.14: Antibody validation for Western analysis of total and phospho- Akt 
with α-actinin. Various total protein concentrations of differentiated LHCN-M2 
whole cell lysate analysed with Akt or phospho-Akt (P-Akt) and α-actinin 
antibodies when run in the same capillary to establish standard curves, with 
electropherogram view (A-B) and gel-style lane view (C); α-actinin was detected 
in high dynamic range mode while Akt and P-Akt (boxed) were detected after a 
512 s exposure. The peak areas taken from the pherograms were used to establish 
a standard curve for each antibody when duplexed. Note, the α-actinin curve 
consists of mean data of each of the curves run with Akt and P-Akt) (D). 
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Figure 3.15: IVAS upregulates GLUTs and PI3K, and activates Akt of the insulin 
pathway. Protein analyses were performed on the ProteinSimple Wes automated 
Western capillary system using total cell lysates of myotubes differentiated in 5.5 
mM glucose and 10 nM insulin or 25 mM glucose and 50 nM insulin and then 
treated with 30 µM IVAS or DMSO control (Ctrl) for 4 h while starved of glucose 
and serum. Lysates were loaded onto the Wes system at 0.4 mg/ml, probed with 
troponin T and α-actinin 1 antibodies (see Figs. 3.2, 3.3) and chemiluminescence 
detected after a 16 s exposure (A); 0.5 mg/ml, probed with GLUT4 and α-actinin 1 
antibodies (see Fig. 3.6) and detected in high dynamic range mode for α-actinin 1 
and after a 512 s exposure for GLUT4 (B); 0.1 mg/ml, probed with GLUT1 and α-
actinin antibodies (see Fig. 3.7) and detected after a 16 s exposure (C); 0.4 mg/ml, 
probed with PI3K p85α and troponin T antibodies (see Fig. 3.13) and detected after 
a 16 s exposure (D). After the 4 h starvation/incubation with IVAS or DMSO, 
myotubes were incubated with 0.55 mM glucose and 30 µM IVAS, 100 nM insulin 
(Ins, positive control), IVAS and insulin combined, insulin and 5 µM wortmannin 
(Wort) (as a negative control), or DMSO controls for 15 min then washed and 
lysed. Lysates were loaded onto the Wes system at 0.1 mg/ml, probed with Akt or 
phospho-Akt (Ser473) (P-Akt) and α-actinin antibodies (see Fig. 3.14) and detected 
in high dynamic range mode for α-actinin and after a 512 s exposure for Akt/P-Akt 
(E). All data are shown as mean ratios of the target protein/loading control (for 
PI3K the loading control was troponin T and this was corrected for the troponin 
T/α-actinin data (D)) ± SEM (N = 3). Letters above bars denote where p < 0.05 
between treatments.  
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3.5 Discussion 
Hyperglycaemia and insulin resistance are biomarkers of type 2 diabetes and overcoming 
these can help maintain healthy glucose homeostasis (Kahn, Rosen et al. 1992, Saltiel 
and Kahn 2001, Alvim, Cheuhen et al. 2015, Deshmukh 2016). With the skeletal muscle 
accounting for up to 75% of postprandial glucose disposal (Saltiel and Kahn 2001), 
improving insulin-stimulated glucose uptake in muscle cells is a promising therapy for 
diabetics. Epidemiological, animal, human intervention and in vitro cell studies have 
demonstrated that (poly)phenols can improve glucose transport into insulin-responsive 
muscle, but it is clear that there are a lack of studies investigating the effects of relevant 
conjugates that circulate in plasma in vivo, notably those metabolised by the gut 
microbiome. Furthermore, the majority of in vitro studies investigating glucose uptake 
and metabolism mechanisms in skeletal muscle use the murine C2C12 or rat L6 
immortalised cells and not a human muscle model. It was demonstrated here for the first 
time that (poly)phenol metabolites affect glucose uptake and metabolism in immortalised 
human skeletal muscle cells, with different effects observed in myotubes differentiated 
in a normal or high glucose/insulin environment. In particular, isovanillic acid 3-O-
sulfate, a catabolite of the gut microflora following the ingestion of berries (Pimpao, 
Ventura et al. 2015), has promising effects in restoring glucose transport in high GI 
myotubes through an acute activation of the insulin signalling pathway and a chronic 
upregulation of GLUTs 1 and 4 and of PI3K. 
3.5.1 Skeletal muscle cell characterisation and model setup 
LHCN-M2 myoblasts were differentiated to myotubes and consequently expression of 
troponin T increased as expected (Gardner, Anguiano et al. 2012). Total α-actinin and α-
actinin 1 protein, recognised by the rabbit and mouse antibodies respectively, was 
unchanged during differentiation despite RNA-seq data showing a decrease in RNA from 
day 0 to 4 (Table 3.2). The myoblasts are in the growth phase on day 0 and thus require 
actinin synthesis, the day 4 myotubes are already established and the need for actinin 
synthesis has diminished, albeit the actinin protein remains. Protein expression of 
different actinin isoforms were previously reported to remain stable during 
differentiation (Goffart, Franko et al. 2006). Recognised traits of mature muscle, in 
addition to increased troponin, include insulin sensitivity (Iovino, Burkart et al. 2016) 
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and a greater aerobic metabolism than in other tissues, such as liver (Rolfe, Newman et 
al. 1999, Berg, Tymoczko et al. 2002). Here in the LHCN-M2 muscle, mitochondrial 
respiration was greater than in hepatocytes as expected, especially with HepG2 being a 
primarily glycolytic cell (DeBerardinis, Lum et al. 2008). The differentiated myotubes 
responded to insulin in a dose-dependent manner acutely, increasing 2-[1-14C(U)]-
deoxy-D-glucose (2-DG) uptake beyond basal, and chronically, increasing intracellular 
14C after 4 h with D-[14C(U)]-glucose, stored predominantly as glycogen (Saltiel and 
Kahn 2001, Yeaman, Armstrong et al. 2001); the LHCN-M2 myoblasts express glycogen 
synthase (GYS1) and this is increased > 3-fold in the myotubes (Table 3.2).  
Further support for the change in phenotype with differentiation was demonstrated by 
the lack of insulin-stimulated 2-DG transport in myoblasts; the response was limited to 
the longer term in the precursor cells. The insulin receptor, and its downstream proteins, 
is expressed (Table 3.2) and is active in myoblasts (Youngren, Goldfine et al. 1999), 
however GLUT4 is very low in LHCN-M2 myoblasts and increases with differentiation 
while GLUT1 decreases, shown here in Fig. 3.8 and Table 3.2, and previously (Al-
Khalili, Chibalin et al. 2003). This leads to the insulin-stimulated increase seen in 2-DG 
uptake. GLUT1 is ubiquitously expressed (Mueckler and Thorens 2013) and is the 
primary glucose transporter in these cells, even after differentiation, and is generally 
increased in cultured cells compared to those in vivo (Al-Khalili, Chibalin et al. 2003). It 
is known primarily as the basal glucose transporter, though in rat it can also be stimulated 
by insulin (Klip, Volchuk et al. 1996, Rett, Wicklmayr et al. 1996). In LHCN-M2 
undifferentiated myoblasts the cells responded to insulin in the longer term by increasing 
storage of glucose transported in through the basal GLUT1, but only when GLUT4 is 
upregulated was there an acute insulin-stimulated increase in 2-DG uptake. 
High glucose heightened proton leak across the IMM and cellular ROS levels, as was 
seen in HepG2 cells (Chapter 2). ROS are generated by insulin signalling and this is 
enhanced by high glucose (Goldstein, Mahadev et al. 2005). Increasing insulin induced 
oxidative stress in the LHCN-M2 myotubes, similarly to a recent study on lymphatic 
muscle (Lee, Fluckey et al. 2017) and others (Aggeli, Theofilatos et al. 2011, Barazzoni, 
Zanetti et al. 2012), although 10 nM insulin was protective, suggesting a hormetic 
function. Insulin has been shown to protect against oxidative stress in neuronal cells 
(Ramalingam and Kim 2014) and is upstream of a nitric oxide-induced antioxidant 
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defence system (Yu, Gao et al. 2011). Increasing the concentration of insulin in the 
normal glucose medium increased the degree of myotube differentiation after 96 h, in 
line with insulin being a promoter of differentiation (Rochat, Fernandez et al. 2004). In 
high glucose, insulin had the opposite effect, notably with 50 nM, due to the increased 
oxidative stress. In the absence of insulin, high glucose increased differentiation, with 
higher troponin T at 96 h, likely through activation of the MLX (Max-like protein X) 
transcription factor, which promotes myogenesis (Hunt, Xu et al. 2015). Insulin 
concentrations of up to 1.7 µM were tested because this has been used in differentiation 
medium previously (Tzatsos and Kandror 2006). There were no significant differences 
between myotubes differentiated in 10, 50, 500 or 1700 nM and thus this demonstrates 
that such insulin concentrations in culture media are unnecessarily high and increasing 
insulin further is more likely to induce other, undesirable changes in signalling and 
metabolism, even death (Sampson, Bucris et al. 2010). Differentiation media with 5.5 
mM glucose and 10 nM insulin or 25 mM glucose with 50 nM insulin resulted in the 
same rate of differentiation over 96 h and, coupled with the heightened stress in the latter 
versus the former, this was the model selected for comparing a normal to a high 
glucose/insulin phenotype. 
Myotubes differentiated in normal glucose had greater (deoxy-)glucose uptake, but 
myotubes in high glucose were more sensitive to insulin stimulation. High glucose 
lowered GLUT1 content, accounting for the lower basal uptake and subsequent storage. 
Insulin was shown to upregulate GLUT1 previously in rat cardiac muscle (Laybutt, 
Thompson et al. 1997) and this was evident in the first 48 h in this study, but Laybutt et 
al. also showed that when high insulin was accompanied by high glucose this effect was 
blocked, and this was seen here by day 4. GLUT4 expression was not affected by glucose 
or insulin, consistent too with the rat cardiac muscle (Laybutt, Thompson et al. 1997) 
and with L6 myotubes (Huang, Somwar et al. 2002). However, it has been shown 
elsewhere that high glucose and insulin can increase basal GLUT4 activity, despite 
decreasing translocation and without affecting expression (Huang, Somwar et al. 2002). 
In adipocytes insulin increased GLUT4 expression (Valverde, Navarro et al. 1999) and 
Vmax of glucose transport (Kobayashi and Olefsky 1978). Moreover, ROS was elevated 
in the high glucose and the high GI myotubes in the present study, and is known to 
enhance insulin sensitivity (Loh, Deng et al. 2009). These studies combined explain the 
increased insulin sensitivity with high glucose and/or high insulin that was seen here. 
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Despite enhanced sensitivity, the amount of 14C stored in the cells after a 4 h incubation 
with D-[14C(U)]-glucose was lower with increased insulin, and for increased glucose, in 
the differentiation medium. Sensitivity was lost in the high glucose myotubes when 
differentiated with the lower insulin. Insulin, at the lower concentrations, will increase 
metabolism (Nisr and Affourtit 2014), resulting in less glycogen storage and, in the 
LHCN-M2 cells, more glucose was metabolised to lactate or CO2 and the 
14C expelled 
into the medium. In muscle tissue in vivo, insulin-dependent production of nitric oxide 
improves the action of insulin and glucose homeostasis via recruitment of capillaries and 
increased blood flow (Grassi, Desideri et al. 2015). While not relative to the in vitro 
model due to the lack of a capillary network, the outcome with increased insulin was the 
same, suggesting the system was a representative model. The increased insulin sensitivity 
in high GI myotubes was confirmed by the increased PI3K (p85α) protein expression and 
enhanced p-Akt/Akt. 
3.5.2 Effects of (poly)phenol metabolites on glucose uptake and metabolism 
A profile of ferulic acid derivatives, found in circulation after the consumption of coffee 
or cereals for example (Guy, Renouf et al. 2009, Fardet 2010) (Table 3.1), restored basal 
2-DG transport and increased glucose metabolism in the high GI myotubes, but blunted 
the acute effect of insulin and did not affect metabolism in the normal myotubes. The 
sulfated conjugates, FA4S and DHFA-4S, were responsible for the stimulation of glucose 
transport and the latter alone for the increased metabolism. The thwarted acute insulin 
stimulation suggests a competitive mechanism, possibly at the insulin receptor, and the 
effects in high GI are independent of insulin. Unconjugated ferulic acid has been shown 
to increase (deoxy-) glucose uptake into muscle previously. Ferulic acid dose-
dependently increased uptake in L6 myotubes, doing so synergistically with oral 
hypoglycaemic drugs, and increased expression of GLUT4 and PI3K (Prabhakar and 
Doble 2009). Ferulic acid also increased uptake in primary porcine myotubes and 
primary human myotubes (Bhattacharya, Christensen et al. 2013, Ho, Kase et al. 2017). 
A PI3K-dependent mechanism suggests ferulic acid operates as an insulinomimetic and 
the data from the present study demonstrate the same for its sulfated conjugates. Gogoi 
et al. recently found that ferulic acid recovered the saturated fatty acid-impaired 
expression of insulin receptor in L6 myotubes (Gogoi, Chatterjee et al. 2014), alluding 
to an additional chronic mechanism. 
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There were no effects on 2-DG uptake in myotubes treated with the flavonols when tested 
in combination or individually. The former lowered insulin-stimulated glycogen storage, 
while increasing glucose metabolism, with the glucuronides of quercetin and kaempferol 
eliciting this effect. The aglycone quercetin and kaempferol increased 2-DG uptake in 
L6 myotubes, but only with a 30 µM dose (Kawabata, Sawada et al. 2011). An 18 h 
treatment with 50 or 100 µM quercetin increased phosphorylation of acetyl-coA 
carboxylase, stimulating AMPK and increasing glucose uptake independent of insulin in 
C2C12 and L6 muscle cells (Eid, Martineau et al. 2010, Eid, Nachar et al. 2015). AMPK 
activation also increases carbon metabolism via fatty acid oxidation and mitochondria 
(Cederroth, Vinciguerra et al. 2008), and this is indicative of the conjugates here. It is 
possible that the conjugates had no effect on transport because the doses tested were 
much lower, and closer to a physiological relevance, than in these previous studies. With 
Q3S specifically the LHCN-M2 cells lack the OATs required for cellular uptake of 
sulfated compounds (Table 3.2); glucuronides can enter passively (Wong, Akiyama et 
al. 2012). Q3G was shown to activate AMPK in a recent study in which quercetin 
decreased insulin-stimulated glucose uptake in normal C2C12 cells, but under 
inflammatory conditions quercetin and Q3G (both at 10 µM) improved it; these opposing 
effects were regulated by AMPK (Liu, Mei et al. 2016). Again, this was still at 
concentrations higher than those tested in the present study. Various other studies report 
the effects of quercetin and/or kaempferol on glucose uptake. Primary human myotubes 
treated with 0.1-10 µM quercetin or kaempferol for 2 days showed increased glucose 
uptake over 4 h (Ho, Kase et al. 2017) and kaempferol was shown to reverse the high fat 
diet-induced decline in GLUT4 and AMPK expression in diabetic mice (Alkhalidy, 
Moore et al. 2015). A plant conjugate, kaempferol 3-neohesperidoside, displayed 
insulinomimetic properties in rat muscle (Zanatta, Rosso et al. 2008), though this is 
unlikely to be found in plasma following consumption. Based on the literature, the effects 
of Q3G and K3G seen in the present study are most likely attributable to increased 
metabolism via AMPK activation, but no effects were seen on transport either due to the 
use of lower doses than used in previous studies in which an effect was seen, and/or 
because Q3S specifically did not enter the cells in order to be deconjugated to active 
quercetin. 
The resveratrol conjugates increased basal uptake and metabolism in both normal and 
high GI myotubes, restoring the lowered 2-DG transport and negating the longer term 
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effect of insulin in the latter. The increased transport was attributable to R4G and R3S, 
but only R4G was shown to increase metabolism, suggesting that more than one 
mechanism may be in play. Resveratrol aglycone has been shown previously to increase 
glucose uptake in muscle, with papers mostly citing an effect on the AMPK pathways. 
The studies by Breen et al. and by Park et al. showed that elevated uptake in myotubes, 
L6 and C2C12 respectively, was dependent on GLUT4 translocation through activation 
by sirtuins and AMPK (Park, Kim et al. 2007, Breen, Sanli et al. 2008), and in the latter 
it was shown that resveratrol potentiated the effect of insulin on uptake via AMPK 
activation, leading to PI3K/Akt pathway activation (Park, Kim et al. 2007). Other studies 
suggest both insulin-dependent and -independent pathways are involved (Deng, Hsieh et 
al. 2008, Frojdo, Durand et al. 2011, Minakawa, Kawano et al. 2011). Resveratrol 
enhances mitochondrial function, again through SIRT1 and AMPK activation (Price, 
Gomes et al. 2012), and, assuming R4G has the same effect, this will have contributed 
to the increased glucose metabolism. Furthermore, with the documented activity of 
resveratrol dominated by its anticancer properties, it is interesting that in the recent 
review by León et al. the authors link, at least in part, this asset to its effects on glucose 
uptake and metabolism (Leon, Uribe et al. 2017). Resveratrol is rapidly metabolised and 
circulates in plasma almost entirely in a conjugated form (Boocock, Faust et al. 2007) 
so, unless taken up and deconjugated in the muscle, it is more pertinent to test the effects 
on glucose uptake and metabolism using the circulating metabolites; this is the first study 
to do so. 
The phenolic sulfates, predominantly colonic catabolites in circulation after berry 
consumption (Pimpao, Ventura et al. 2015), increased basal 2-DG uptake in normal and 
high GI myotubes and even potentiated the effect of insulin in the latter, the only 
combination of metabolites in this study to do so. When in combination, the metabolites 
had no effects on metabolism however. The increased transport was solely due to IVAS 
and thus this was tested alone for effects on metabolism and, without the other phenolic 
sulfates present, it increased basal metabolism in normal and high GI. Only several 
papers have been published on the biological activity of IVAS. It has been identified as 
a plasma metabolite following consumption of berries or cyanidin 3-O-glucoside (de 
Ferrars, Czank et al. 2014, Pimpao, Ventura et al. 2015), as a phase II conjugate of 
protocatechuic acid (Czank, Cassidy et al. 2013), but in these studies was 
undistinguishable from VAS. A recent study demonstrated that a mixture of anthocyanin 
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metabolites containing IVAS ameliorated the TNF-α-stimulated secretion of VCAM-1 
and IL-6 in human endothelial cells (Warner, Smith et al. 2017), suggesting that such 
metabolites may have anti-inflammatory and cardiovascular benefits, otherwise this is 
the first study to investigate the effects of these metabolites on glucose uptake and the 
first to investigate the biological activity of IVAS individually. Several studies have 
demonstrated an increase in muscular glucose uptake when cells were incubated with 
extracts or mixtures that may have included IVAS; fermented blueberry juice for 
example, or phenolic compounds related to IVAS, such as its PCA precursor or upstream 
anthocyanins (Table 3.1). Fermented blueberry juice increased glucose uptake in C2C12 
myotubes with and without insulin via AMPK activation (Vuong, Martineau et al. 2007, 
Nachar, Eid et al. 2017) and elderberry metabolites, including PCA, dose-dependently 
increased glucose uptake in primary human muscle cells (Ho, Kase et al. 2017). A recent 
study showed that PCA mimics insulin by activating the insulin receptor to increase 
glucose uptake in human adipocytes (Scazzocchio, Vari et al. 2015). It would seem PCA 
and its metabolite(s) may have an effect on both pathways that stimulate GLUT4 
translocation, also shown by an Artemisia princeps extract on L6 myotubes (Yamamoto, 
Ueda et al. 2010). Here, the insulin-dependent mechanism was dominant, with no 
significant increase in metabolism when both IVAS and insulin were present. 
IVAS-stimulated 2-DG uptake was dose-dependent and, much like insulin, had a greater 
effect in the high GI myotubes. Inhibition of IVAS-stimulated uptake by wortmannin 
and indinavir confirmed the mechanism was dependent on PI3K signalling and GLUT4 
translocation. Furthermore, the effect was time-dependent, eluding to acute and chronic 
mechanisms. IVAS upregulated GLUT1, GLUT4 and PI3K p85α, as well as activating 
Akt in the short term. With a LogP of -0.73, IVAS would not enter the myotubes without 
facilitated transport. IVA, without sulfate conjugation, has a LogP of 1.81 
(Agronomique. 2014) and thus would enter by passive diffusion. IVAS would not have 
entered the cells because the LHCN-M2 lack the appropriate transporters (Table 3.2) to 
facilitate the uptake of sulfated conjugates. It is therefore likely that IVAS, the effects of 
which were not dependent on the presence of the sulfate, acts as a substrate of the insulin 
receptor, initiating its autophosphorylation and downstream signalling events, including 
Akt phosphorylation and GLUT4 translocation and, in the longer term, upregulation of 
the GLUTs and insulin pathway itself. The activation of insulin signalling also led to 
glycogen storage being undeterred in the high GI myotubes, although the lower 14C in 
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the normal myotubes after 4 h incubation with both insulin and IVAS indicates there 
could be a secondary mechanism involved, such as activation of AMPK; inhibition of 
insulin is less likely due to the synergistic effects on transport and Akt phosphorylation. 
Insulin, and maybe IVAS, could also have increased metabolism via the mitochondria 
(Nisr and Affourtit 2014), which would have been more effective in the normal myotubes 
lacking dysfunctional mitochondria (see 3.5A, B and Chapter 2). This was outweighed 
in the high GI by the increased storage via elevated PI3K expression, which was notably 
even more so when treated with IVAS. 
In summary, the present study has demonstrated that an immortalised human skeletal 
muscle cell line, LHCN-M2, can be used as a model system to investigate effects on 
glucose uptake and metabolism in muscle. Differentiating these cells in various glucose 
and insulin concentrations highlighted that the LHCN-M2 myotubes had a phenotype 
typical of muscle seen in previous studies. Myotubes differentiated in 5.5 mM glucose 
with 10 nM insulin or in 25 mM glucose with 50 nM insulin differentiated at the same 
rate and this setup was used to draw comparisons between normal and high GI conditions 
when investigating the effects of (poly)phenol metabolites on glucose uptake and 
metabolism. Uptake was stimulated, notably in high GI myotubes, by sulfated conjugates 
derived from ferulic acid, resveratrol and cyanidin 3-O-glucoside. The only glucuronide 
to stimulate uptake was R4G, which also increased glucose metabolism, along with 
DHFA-4S, IVAS and the flavonol glucuronides. IVAS increased uptake and metabolism 
by upregulating GLUTs and PI3K and acutely activating the insulin pathway. (See Fig 
3.16.) 
This is the first time (poly)phenol metabolites have been investigated for effects on 
glucose uptake and metabolism in immortalised human myotubes, with comparisons 
drawn between normal and high glucose/insulin environments. It is also the first time 
that such compounds, notably colonic catabolites DHFA-4S and IVAS, have been 
reported to have beneficial effects on glucose transport into muscle and longer term 
metabolism. This highlights the importance of gut microbiome metabolites. In particular 
this is the first report of any biological activity for IVAS alone and should now be 
investigated further in animal and human intervention studies for its hypoglycaemic 
properties. Studies on foods from which IVAS is metabolised have already shown 
promise in vivo. Supplementation with blueberry bioactives for 6 weeks improved insulin 
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sensitivity in obese, insulin-resistant participants (Stull, Cash et al. 2010) and when bread 
was consumed with berries less insulin was needed to control the post-prandial glucose 
(Torronen, Kolehmainen et al. 2013). After following a (poly)phenol-rich diet insulin 
sensitivity was improved (Bozzetto, Annuzzi et al. 2015) and based on the foods 
consumed this could have been due in part to any of the metabolites presented in this 
study. It has been shown that berries and their anthocyanins also have effects on lowering 
post-prandial blood glucose by inhibiting carbohydrate digestion and glucose absorption 
in the gut (Castro-Acosta, Lenihan-Geels et al. 2016), suggesting pleiotropic effects on 
systemic glucose metabolism. 
 
Table 3.2: Changes in the RNA* of selected genes during differentiation (from Day 0 to 
Day 4) support the changes in protein expression seen in the present study. 
Gene # Protein 
FPKM 1 
Ratio to 
Actinin 
Differentiation 
fold-change 
Day 0 Day 4 Day 0 Day 4 FPKM Ratio 
181856 GLUT4 0.05 7.29 0.0003 0.11 146 323 
117394 GLUT1 126 58.8 0.83 0.86 0.46 1.03 
118194 Troponin T2 (cardiac) 74.5 1103 0.49 16.1 14.8 32.8 
72110 α-Actinin 1 152 68.8 1.00 1.00 0.45 1.00 
145675 PI3K α 7.85 9.93 0.05 0.14 1.26 2.80 
105221 Akt2 45.1 33.3 0.30 0.48 0.74 1.63 
171105 INSR 3.54 5.64 0.02 0.08 1.59 3.53 
169047 IRS1 13.7 11.8 0.09 0.17 0.86 1.91 
104812 GYS1 38.29 130.6 0.25 1.90 3.41 7.56 
197901 OAT1 (SLC22A6) 0 0 - - - - 
137204 OAT2 (SLC22A7) 0 0 - - - - 
149452 OAT3 (SLC22A8) 0 0 - - - - 
168065 OAT4 (SLC22A11) 0 0 - - - - 
*Using total RNA-seq gene quantification data in files ENCFF581EE and ENCFF580JSN (LHCN-M2 
myoblasts and myotubes respectively) taken from the ENCODE database (2012) 
1 Fragments Per Kilobase of transcript per Million mapped reads 
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Figure 3.16: The mechanisms of action by which IVAS and other conjugates 
increase glucose uptake and metabolism in human skeletal muscle. Numbered 
green arrows are confirmed mechanisms for IVAS: 1) PI3K (p85α) is upregulated; 
2) Akt phosphorylation is acutely increased; 3) total GLUT4 is upregulated; 4) 
GLUT4-mediated glucose uptake is increased; 5) glucose metabolism is increased, 
likely via an AMPK-dependent mechanism; 6) GLUT1 is also upregulated and this 
increases basal glucose uptake. Dashed arrows are proposed sites of action for other 
metabolites. Plasma membrane proteins: blue – GLUT4 (also shown stored in 
cytosolic vesicle); green – insulin receptor; orange – GLUT1. Ins – insulin; P – 
phosphate; Ac – acetylation; hexagons – glucose.  
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Chapter 4  
Conclusions and Future Perspectives. 
4.1 Summary, conclusions and impact of this research 
4.1.1 Overview of the literature 
The incidence of diabetes is growing at an alarming rate and being overweight or obese 
are the biggest risk factors for type 2, which accounts for at least 90% of cases (WHO 
2016). An improved diet and increased physical activity can help lower risk (Chatterjee, 
Khunti et al. 2017). In addition to reducing carbohydrate and lipid consumption, and 
increasing dietary fibre, there is a substantial amount of evidence from epidemiological 
studies to suggest that a diet rich in (poly)phenols may prevent the development of 
metabolic diseases, and could help diabetics with the management of glucose 
homeostasis (Kim, Keogh et al. 2016). For example, the Nurses Health Study I and II, 
which investigated the urinary excretion of (poly)phenol metabolites in 1111 type 2 
diabetes case-control pairs, found that (poly)phenols, including quercetin and caffeic 
acid, were associated with a ~45% lower type 2 diabetes risk during the first 4.6 years 
since urine collection (p < 0.05) (Sun, Wedick et al. 2015). Furthermore, two studies 
showed lower risk of type 2 diabetes associated with the consumption of apples and/or 
berries; in the Women’s Health Study of 38,018 American women, the consumption of 
at least one apple per day showed a 28% lower risk compared with no apples (p = 0.006) 
(Song, Manson et al. 2005) and in a Finnish study of 10,054 men and women, in which 
there were 526 cases of type 2 diabetes, apples were associated with a 27% lower risk (p 
= 0.003) and berries a 26% lower risk (p = 0.03) (Knekt, Kumpulainen et al. 2002). In 
the latter study, a trend toward a lower risk of type 2 diabetes was associated specifically 
with higher quercetin intake (p = 0.07) (Knekt, Kumpulainen et al. 2002). 
Type 2 diabetes is manifested by chronic hyperglycaemia and insulin resistance and is 
associated with excessive calorie intake (Taylor 2013, Krentz and Hompesch 2016, 
Zaccardi, Webb et al. 2016). This disrupts cellular and glucose metabolism and causes 
oxidative stress, in part via a reductive stress (Yan 2014). Lipid accumulation in the liver 
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and adipose not only precedes obesity, but can disrupt insulin signalling and induce 
systemic inflammation (Samuel, Petersen et al. 2010, Kwon and Pessin 2013). Insulin-
secreting pancreatic β-cells become dysfunctional and insulin resistance in the peripheral 
tissues lowers postprandial glucose uptake and causes uncontrolled hepatic glucose 
metabolism and efflux. Chronic hyperglycaemia and dyslipidaemia ensues, which in turn 
propagate the oxidative stress and inflammation (Tangvarasittichai 2015) and cause 
associated complications such as CVDs, nephropathy, retinopathy, peripheral 
neuropathy and even neurodegenerative diseases such as Alzheimer’s (Xia, Wang et al. 
2007, Shenouda, Widlansky et al. 2011, Guo, Sun et al. 2013, Gurel, Sieg et al. 2013). 
Oxidative stress is closely associated with hyperglycaemia and insulin resistance and 
causes dysfunctional mitochondria, as a primary source and target of ROS (Montgomery 
and Turner 2015). An increased intracellular pool of NADH, induced by excessive intake 
and metabolism of glucose and fatty acids, puts pressure on ETS complex I, increasing 
electron leakage and superoxide production and an imbalanced redox status (Brand 
2010). ROS affect signalling and disrupt proteins, membranes and genetic expression in, 
and linked to, the mitochondria and this exacerbates the oxidative stress (Sivitz and 
Yorek 2010). The cell tries to protect itself from oxidative stress by lowering flux into 
mitochondria, but this increases free fatty acids, inhibiting GLUT4 translocation, and 
cellular dependence on glycolysis (Rudich, Tirosh et al. 1998, Ceriello and Motz 2004). 
Pathways branching off from glycolysis are induced to mediate the accumulation of G3P 
from excessive glycolysis, which worsens the situation by further augmenting NADH 
and ROS, and are regarded particularly important in the pathophysiology of various 
diabetic complications (Yan 2014). A principal mechanism in insulin resistance is 
increased phosphorylation of the IRS proteins, preventing their interaction with the 
insulin receptor. This may be caused by ROS, stress, inflammation and DAG 
accumulation (Itani, Ruderman et al. 2002, Kim, Wei et al. 2008, Boucher, Kleinridders 
et al. 2014). Insulin likewise regulates mitochondrial function, through the FOXO-SIRT 
axis, and ROS acts as a secondary messenger in the insulin signalling network under 
normal conditions, so the interplay between mitochondria and insulin signalling make it 
difficult to pinpoint the cause-effect relationship in the development of insulin resistance 
(Canto, Gerhart-Hines et al. 2009, Montgomery and Turner 2015).  
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A common factor in the onset of diabetes is hyperglycaemia and there is evidence from 
epidemiological, animal, human and in vitro studies eluding to various roles that dietary 
(poly)phenols may play in regulating glucose homeostasis, as well as attenuating 
oxidative stress and insulin resistance (Hanhineva, Torronen et al. 2010, Babu, Liu et al. 
2013, Kim, Keogh et al. 2016). The potential benefits of (poly)phenols proposed by 
researchers may be difficult to accomplish in vivo due to the vast and varying 
combinations of compounds ingested on a daily basis and highly complex 
biotransformation of the aglycones and plant metabolites that are found in food. 
(Poly)phenols are metabolised in the small intestine and by the colonic microbiome 
before absorption, and in the liver and kidneys before excretion, and this often results in 
low bioavailability. Moreover, the intricate, and often pleiotropic, effects at the 
molecular and cellular levels remain to be fully understood (Del Rio, Rodriguez-Mateos 
et al. 2013, Williamson and Clifford 2017). Limitations in the literature generally include 
the testing of supra-physiological doses of (poly)phenols in vitro and a lack of regard for 
the metabolites that would be found in circulation in vivo. 
From the range of (poly)phenols that may be ingested, or arise from metabolism, 
compounds were selected to focus on in this project based on their regular appearance in 
the diet and existing knowledge of the potential antidiabetic effects. The flavonols 
quercetin and kaempferol, found in onions, capers, endive, apples and berries, are rapidly 
metabolised in the small intestine and enter the blood mostly conjugated to a sulfate or 
glucuronide (Del Rio, Rodriguez-Mateos et al. 2013, Rothwell, Perez-Jimenez et al. 
2013, Kerimi, Jailani et al. 2015, Williamson and Clifford 2017). Ferulic acid is a 
hydroxycinnamic acid found in cereals and is a derivative of the coffee chlorogenic acids. 
Some ferulic acid is absorbed and sulfated in the small intestine, but most passes to the 
colon where it is metabolised by the microbiome to dihydroferulic acid and others before 
absorption (Zhao and Moghadasian 2008, Stalmach, Mullen et al. 2009, Mateo Anson, 
Aura et al. 2011, Williamson and Clifford 2017). The stilbene resveratrol is found in 
grape seed and, like the flavonols, is rapidly metabolised to sulfate and glucuronide 
conjugates in the small intestine. It has been shown that bioavailability is particularly 
low, but the compound has shown promise as a pharmaceutical (Boocock, Faust et al. 
2007, Brown, Patel et al. 2010, Del Rio, Rodriguez-Mateos et al. 2013). Consumption of 
berries gives rise to metabolites of anthocyanins and gallic acid, predominantly as 
phenolic sulfates from the colon after bacterial biotransformation (Williamson and 
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Clifford 2010, Pimpao, Ventura et al. 2015). Pharmacokinetic data has revealed that the 
bioavailability of the various (poly)phenol metabolites can vary depending on the 
compound in question, its source and the quantity ingested/administered, but generally 
metabolites, and some aglycones in smaller amounts, were found in the plasma in the 
nanomolar to low micromolar range. 
4.1.2 Quercetin protects mitochondria from high glucose-induced stress 
Quercetin sulfates and glucuronides are deconjugated in peripheral tissues (Kawai, 
Nishikawa et al. 2008, Hashimoto, Blumberg et al. 2016) and, in this regard, the aglycone 
has been shown to interact with various cellular targets, in particular accumulating in 
mitochondria and eliciting pleiotropic effects on mitochondrial function, including those 
in the context of diabetes (Fiorani, Guidarelli et al. 2010, de Oliveira, Nabavi et al. 2016, 
Haddad and Eid 2016). Quercetin was shown previously to affect mitochondrial 
biogenesis, metabolic flux and the ETS, however the evidence is scarce and conflicting, 
with mechanistic studies limited to an acute setup on isolated mitochondria. The aims of 
the first half of this project were to evaluate the effects of a chronic exposure to high 
glucose on mitochondrial function and explore the effects and mechanisms of quercetin 
in its potential protective role. 
In Chapter 2 the mechanisms of action of quercetin on mitochondria were investigated 
in light of its ability to prevent oxidative stress. HepG2 cells were grown chronically in 
normal or high glucose and treated with quercetin for a prolonged period before 
mitochondria were isolated or cells collected to assay various aspects of mitochondrial 
function. Complex I activity was decreased in cells exposed to high glucose as a result 
of elevated NADH and ROS, however quercetin dose-dependently recovered this after 
24 h. It was proposed, based on previous mechanistic work, that quercetin transiently 
inhibits complex I, and the associated superoxide generation, at the CoQ10-binding site 
and transfers electrons from NADH to complex III. The pressure on complex I was 
relieved and the proton gradient restored, attenuating the high glucose-induced IMM 
proton leak and enhancing the mitochondrial respiration efficiency. Cellular 
NAD+/NADH was increased within 2 h of quercetin treatment and induction of PGC-1α 
transcription followed, further increasing mitochondrial function and shifting metabolic 
output to mitochondrial respiration. The overall chronic result was lowered oxidative 
stress and enhanced mitochondrial integrity, with increased respiration, complex I 
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activity and improved cell viability. Furthermore, non-ETS oxygen consumption, 
together with the increased mitochondrial output, indicated the cells relied less on 
glycolysis for ATP synthesis and therefore the alternative glycolytic pathways were also 
likely mitigated. 
The potential of quercetin to bind to PPARα and affect recruitment of its coactivator 
(PGC1-α) was tested in our lab by Dr Asimina Kerimi. A time-resolved fluorescence 
energy transfer (TR-FRET) assay was set up, able to detect binding interactions with 
high sensitivity and small variability, as shown by the control agonist GW7647 (Fig. 
4.1A) and antagonist GW9662 (Fig, 4.1B) of PPARα. The LanthaScreen TR-FRET assay 
(#PV4684, Invitrogen, Thermo Fisher Scientific, UK) was used according to the 
supplier’s guidelines. Briefly, PPARα ligand binding domain tagged with glutathione-S-
transferase was added to either GW7647 (PPARα agonist) or GW9662 (antagonist), or 
quercetin, Q3S or Q3G, followed by the addition of pre-mixed fluorescein-PGC1-α 
coactivator peptide (in 50 mM HEPES, pH 7.5) and LanthaScreen terbium-labelled anti-
GST antibody (in 137 mM NaCl, 2.7 mM KCl, 10 mM HEPES, pH 7.5). Following 
optimization by comparison of achieved Z´ values, calculated by using the “maximum 
agonist/antagonist” and “no agonist/antagonist” control data (Zhang, Chung et al. 1999), 
incubation in the agonist mode assays was set at 3 h and at 2 h for the antagonist mode 
(room temperature). The TR-FRET ratio was calculated by dividing Em at 520 nm by Em 
at 495 nm, measured on a PheraSTAR FS microplate reader with a LanthaScreen filter 
module. The EC50 and IC50 values were calculated by GraphPad Prism 6 after fitting the 
data on an equation for a sigmoidal dose response. 
Quercetin was found to exert only minimal effects in the agonist mode, at ≥ 10 µM (p < 
0.01) (Fig. 4.1C), while it had no effect as an antagonist (Fig. 4.1D). An EC50 was not 
calculated for quercetin because a plateau was not reached for the concentration range 
tested. Conjugates Q3S and Q3G were weaker agonists than quercetin aglycone; an 
increase in fluorescence emission was measured only at ≥ 100 µM (p < 0.01) (Fig. 4.1C). 
Direct effects of quercetin on PGC-1α activity were therefore minimal as quercetin was 
found to only weakly enhance PGC-1α binding to PPARα in vitro at concentrations ≥ 10 
μM, although this could still occur in the cellular environment due to the rapid quercetin 
influx (Fiorani, Guidarelli et al. 2010). It can be concluded from this that the effects of 
quercetin on PGC-1α are most likely via indirect mechanisms as a result of the effects 
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seen on complex I, respiration and NAD+/NADH. However, the involvement of other 
transcriptional factors in the regulation of PGC-1α by quercetin cannot be excluded. 
 
Figure 4.1: Quercetin has a minimal effect on PGC-1α recruitment to PPARα in 
vitro. A LanthaScreen TR-FRET assay was used to assess the potential of quercetin 
to bind to PPARα and affect recruitment of its coactivator (PGC1-α). PPARα ligand 
binding domain tagged with glutathione-S-transferase was added to either GW7647 
(PPARα agonist) (A) or GW9662 (antagonist) (B), or quercetin (Q), Q3S or Q3G 
(C-D), followed by the addition of pre-mixed fluorescein-PGC1-α coactivator 
peptide and LanthaScreen terbium-labelled anti-GST antibody. Following 
optimization, agonist mode assays (A, C) were incubated for 3 h and antagonist 
mode assays (B, D) for 2 h. TR-FRET ratio was calculated by dividing Em at 520 
nm by Em at 495 nm, measured on a PheraStar FS microplate reader with a 
LanthaScreen filter module and EC50 and IC50 values were calculated. Data are 
mean values ± SD (n = 18). Letters indicate significant differences between tested 
concentrations (p < 0.01). 
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This is the first study to bring these biomarkers together in this way, in particular the 
complex I activity assay with intact cell respirometry and redox flux in the way of 
NAD+/NADH, to observe an overall lasting effect of quercetin on mitochondrial 
function. Furthermore, it is the first investigation into the effects of quercetin on 
mitochondria in cells in a high glucose environment. A novel mechanism of action for 
intracellular quercetin has been proposed. Future studies can utilise this experimental 
setup to elucidate further details of the mechanisms, and to investigate other promising 
compounds. If these effects are inferred to hepatocytes in vivo then preventing hepatic 
mitochondrial dysfunction would help alleviate insulin resistance and restore normal 
glucose and lipid metabolism. Concentrations of quercetin used to probe mechanisms 
here were higher than that generally found in vivo, although one report claims to have 
seen a plasma Cmax of 7.6 µM for total quercetin and its metabolites (Graefe, Wittig et 
al. 2001). However, the effects were dose-dependent and quercetin accumulates in 
peripheral tissues, in mitochondria specifically. This implies that continued ingestion of 
quercetin-rich foods or supplements over a prolonged period, say a lifetime, could elicit 
the chronic mechanisms evidenced here and this may account for the benefits seen in 
epidemiological and animal studies (Kobori, Masumoto et al. 2009, Jacques, Cassidy et 
al. 2013). 
The HepG2 model was chosen as a well-established and well-characterised cell line; 
there are close to 24,000 articles on HepG2 when searching on PubMed. The 
immortalised carcinoma-derived cell line is thought to retain some hepatic functions and 
is thus considered an adequate model for some areas of research, though a study that used 
microarray technology to compare the gene profiles of HepG2 and primary cells found 
~2600 genes significantly downregulated and ~3600 upregulated in the former 
(Costantini, Di Bernardo et al. 2013). Among these changes were genes relating to their 
glycolytic character, and as such metabolic effects seen in vitro may not be translated to 
liver tissues in vivo. It may be that the effects of quercetin on mitochondria are heightened 
in vivo, because in the glycolytic HepG2 cells the changes in mitochondrial respiration 
may have been comparatively smaller. Growing the cells in galactose proved to increase 
complex I activity (Fig. 2.7D) and this could be used to prime the cells for quercetin-
induced mitochondrial effects, by forcing them to rely more on OXPHOS and less on 
glycolysis as demonstrated previously, though this was not the case for all xenobiotics 
(Marroquin, Hynes et al. 2007). Furthermore, culturing conditions can cause significant 
 
 
- 141 - 
variation between experiments and between labs; even ex vivo tissue differs to in vivo 
(Kerimi and Williamson 2017), so consistent models to study (poly)phenols in vitro, ex 
vivo and in vivo, regardless of the context or cellular challenges imposed, should be 
universally employed. 
Another key difference between HepG2 and primary hepatocytes/liver tissue is the 
down-regulation of the OATs, upon which sulfated flavonols rely for intracellular 
transport (Wong, Akiyama et al. 2012, Kerimi and Williamson 2017). Quercetin 
aglycone enters the cells rapidly by passive diffusion and was one reason why the 
aglycone was chosen for this study on mitochondria in HepG2. This was a reasonable 
model, since previous studies have shown quercetin 3′-O-sulfate is deconjugated to the 
more active form anyway, at least in macrophages (Kawai, Nishikawa et al. 2008), but it 
would be interesting compare how the effects of quercetin conjugates compare using 
OAT-transfected cells. Many cancer cells also have upregulated efflux transporters, so 
conjugated flavonoids and chemotherapeutic drugs may be rapidly transported out of the 
HepG2 cells (Kerimi and Williamson 2017), although it has been shown that quercetin 
and its metabolites were retained for at least 4 h (Hashimoto, Blumberg et al. 2016). 
The protective effects of quercetin on high glucose-induced mitochondrial dysfunction 
holds promise for its future use as a nutraceutical or therapeutic against metabolic 
diseases. The so-called reductive stress may be a small aspect in the overall aetiology of 
type 2 diabetes, but if prolonged exposure to quercetin shifts the redox balance in 
hepatocytes to lower oxidative stress and subsequent mitochondrial dysfunction, this will 
help restore hepatic glucose homeostasis and prevent insulin resistance. Research into 
enhancing the bioavailability of quercetin, with nano-technology delivery systems for 
example, is useful. Nano-capsuled quercetin and high-dose free quercetin had anti-
oxidative effects in rats subjected to ethanol-induced gastric inflammation, also restoring 
mitochondrial morphology and complex I and II functions (Chakraborty, Stalin et al. 
2012). Further studies are understandably required, to ensure such administration would 
not result in side effects in humans; quercetin is hormetic and would be toxic at high 
doses. 
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4.1.3 (Poly)phenol metabolites increase glucose uptake in skeletal muscle 
Some (poly)phenols were previously investigated in vitro for their potential in 
stimulating glucose uptake into skeletal muscle, in light of their capacity in regulating 
postprandial glycaemia in vivo (Kim, Keogh et al. 2016). Ferulic acid increases glucose 
uptake in L6 and primary porcine and human myotubes (Prabhakar and Doble 2009, 
Bhattacharya, Christensen et al. 2013, Ho, Kase et al. 2017) and it has been suggested 
that this is via an insulin-dependent mechanism (Prabhakar and Doble 2009, Gogoi, 
Chatterjee et al. 2014). Quercetin and kaempferol have been shown to increase uptake in 
L6 myotubes (Kawabata, Sawada et al. 2011) and for the former an AMPK-mediated 
increase in glucose metabolism was demonstrated (Cederroth, Vinciguerra et al. 2008, 
Eid, Martineau et al. 2010, Eid, Nachar et al. 2015). Quercetin 3-O-glucuronide is the 
only flavonol conjugate to have been explored on muscular glucose transport and, as with 
its aglycone, increased uptake in C2C12 myotubes under inflammatory conditions (Liu, 
Mei et al. 2016). For resveratrol, both insulin- and AMPK-stimulated glucose uptake has 
been reported (Deng, Hsieh et al. 2008, Frojdo, Durand et al. 2011, Minakawa, Kawano 
et al. 2011), accompanied with increases in metabolism through the SIRT1-AMPK 
pathway and enhanced mitochondrial function (Price, Gomes et al. 2012). To date, no 
studies have explored potential effects of berry-associated phenolic sulfate metabolites 
downstream of cyanidin 3-O-glucoside, via protocatechuic acid, and gallic acid. Berry 
extracts that may have included such metabolites have shown promising effects (Vuong, 
Martineau et al. 2007, Ho, Kase et al. 2017, Nachar, Eid et al. 2017) and, as with 
resveratrol, both insulin-dependent and -independent pathways may be in play 
(Yamamoto, Ueda et al. 2010). 
However, the single study on Q3G aside, all of these studies were done with the parent 
aglycone compounds, or extracts or plant metabolites, and not on the bioavailable 
metabolites that would be found in circulation in vivo. Moreover, the majority of 
compounds had been tested only at supra-high concentrations and primarily in rodent 
myotube models. The key aims to this part of the project included establishing an 
appropriate model using an immortalised human skeletal muscle cell line, LHCN-M2, to 
investigate the potential effects of (poly)phenol metabolites, at concentrations closer to 
the physiologically achievable range (see Table 1.1 and Table 3.1), on glucose uptake 
and metabolism and elucidating the mechanism of action by which such effects may have 
occurred. 
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In Chapter 3 it was demonstrated that LHCN-M2 can be used as a model system in the 
context of investigating glucose uptake and metabolism in human skeletal muscle. 
Differentiating these cells to myotubes in high glucose led to elevated ROS and 
mitochondrial dysfunction, and increasing the chronic insulin led to increased 
differentiation of the normal myotubes, but impeded it in the high. Basal 2-deoxy-D-
glucose and glucose uptake was higher in normal glucose but myotubes in high glucose 
were more sensitive to insulin. Myotubes differentiated in 5.5 mM glucose with 10 nM 
insulin or in 25 mM glucose with 50 nM insulin were differentiated by the same 
proportion after 96 h and this end model was used for comparisons of normal and high 
glycaemia/insulinaemia when investigating the effects of (poly)phenol metabolites. 
FA4S and DHFA-4S caused the increase in basal uptake seen with a combination of 
ferulic acid derivatives in high GI myotubes and the latter increased glucose metabolism 
too. The flavonol conjugates had no effect on uptake but increased metabolism to 
supersede the insulin-stimulated glycogen storage. R4G and R3S increased glucose 
uptake in normal and high GI myotubes, and R4G increased metabolism in both. A berry 
metabolite profile consisting of phenolic sulfates was found to increase acute glucose 
transport synergistically with insulin, but had no effect on metabolism. When the 
compounds were tested alone only IVAS had an effect and this increased metabolism 
too, negating the longer-term effect of insulin in normal myotubes. IVAS increased 
uptake in a dose-dependent manner and this was inhibited by the addition of wortmannin 
and indinavir, indicating a PI3K- and GLUT4-dependent mechanism. Uptake and 
metabolism were increased by IVAS through upregulation of GLUTs 1 and 4 and PI3K, 
as well as acute activation of the insulin pathway, shown by increased Akt 
phosphorylation, and it was proposed that this was via stimulation at the insulin 
signalling receptor (see Fig. 4.2). This is the first time (poly)phenol metabolites have 
been reported to increase glucose uptake and metabolism in an immortalised human 
skeletal muscle model, with comparisons between normal and high GI conditions, and it 
is the first study to report biological activity specifically for IVAS. 
It should be acknowledged that there are certain limitations to the cell model utilised in 
the present study, as there are with any model; especially with the low expression of 
GLUT4 in cultured cells and that the high GI myotubes were not insulin-resistant per se. 
GLUT1 expression outweighed that of GLUT4 and it was shown previously that GLUT1 
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may be upregulated by insulin in rat (Laybutt, Thompson et al. 1997), but the indinavir 
inhibition of insulin- and IVAS-stimulated uptake suggests translocation was by GLUT4 
specifically. Indinavir is specifically a GLUT4 inhibitor at 20 µM (Rudich, Konrad et al. 
2003) and it has been shown that GLUT1 translocation is not stimulated by the insulin 
pathway (Al-Khalili, Chibalin et al. 2003). The normal/high GI LHCN-M2 model suited 
its purpose in this study, as a useful tool to investigate glucose transport into muscle, for 
which other cultured human myotubes have been affirmed in this context (Al-Khalili, 
Chibalin et al. 2003), especially when investigating a compound that turns out to be 
insulinomimetic. Primary cell models have been used in uptake studies but this also 
carries drawbacks, namely availability and variability. Moreover, it was demonstrated 
recently that hyperglycaemia and hyperinsulinaemia are necessary to promote insulin 
resistance in lymphatic muscle, with reduced glucose uptake and mitochondrial 
dysfunction (Lee, Fluckey et al. 2017), so not dissimilar to the normal and high GI-
differentiated cells used here. There is limited literature specifically on the LHCN-M2 
cell line, so further characterisation may be necessary for its use as a model in other 
investigations. 
Not only is the model suitable to study other compounds for effects on glucose uptake 
and metabolism in the context of diabetes, but so too are the biomarkers established with 
it. The use of the radiolabelled uptake assays with 2-[1-14C(U)]-deoxy-D-glucose and D-
[14C(U)]-glucose is not a new technique (Kerimi, Jailani et al. 2015), but the benefit of 
distinguishing between effects on glucose transport and further metabolism, over a longer 
period than previously, in this system was highlighted. Emerging technologies such as 
high-performance anion-exchange chromatography can be used for carbohydrate 
analyses for the same purpose and it would be worthwhile comparing the two techniques 
for uptake and metabolism assays; downstream carbon metabolites of glucose can be 
measured and greater detail of effects on glycolysis, the TCA cycle, lactate production 
etc. may be revealed. This system has been used primarily for food analyses and recently 
for carbohydrate digestion assays (Rohrer, Basumallick et al. 2013, Pyner, Nyambe-
Silavwe et al. 2017). Uptake assays coupled with precise protein expression 
measurements revealed details of the mechanisms involved. In particular, the use of an 
automated Western capillary system in this project has demonstrated that one should 
consider replacing traditional Western blotting and other immunoassays with this 
modern, quantitative and (most importantly) scientifically robust technique. The 
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ProteinSimple system used here is able to quantify proteins, and their post-translational 
modifications and phosphorylation events, accurately from ultralow sample input with 
high reproducibility and allows for multiplexing in the same capillary (Chen, Wakefield 
et al. 2015). The combination of both GLUTs 1 and 4, and insulin pathway analyses on 
the automated Western capillary system in the present study is the first of its kind in the 
context of glucose uptake in muscle and can be used for similar future studies. 
4.1.4 Impact and implications of this research 
The results from this project enhance our understanding of how the antidiabetic effects 
of dietary (poly)phenols are induced. Quercetin prevents oxidative stress and 
mitochondrial dysfunction, which improves hepatic glucose and lipid metabolism and 
prevents pancreatic β-cell damage in vivo, attenuating insulin resistance and enhancing 
insulin synthesis and secretion respectively. While quercetin is rapidly conjugated and 
absorbed in the small intestine, it has been shown that the aglycone accumulates in 
peripheral tissues and in particular in mitochondria. Quercetin has relatively low 
bioavailability but, with its reported high biological activity, habitual consumption may 
reduce the risk of chronic diseases such as type 2 diabetes and this has been demonstrated 
by several human intervention studies (Williamson 2017). Pure quercetin supplements 
are commercially available, but these are in aglycone form and less bioavailable than the 
quercetin in food (Shi and Williamson 2015). 
The circulating metabolite profiles from commonly consumed (poly)phenol-rich foods 
(or resveratrol in tablet form) demonstrate promising effects on glucose uptake and 
metabolism in skeletal muscle, notably in a high glucose/insulin environment. Together 
with the inhibitory effects seen previously on carbohydrate digestion and absorption in 
the gut by food extracts and aglycones, this provides an insight into how (poly)phenols 
may regulate postprandial glycaemia and help to maintain healthy glucose homeostasis 
in vivo. Preventing or attenuating chronic hyperglycaemia would prevent systemic 
insulin resistance, oxidative stress and inflammation, especially if the effects are also 
seen in the insulin-stimulated adipocytes too. 
Insulin and anti-hypoglycaemic drugs are currently prescribed to insulin-resistant and 
diabetic individuals to lower glycaemia and improve insulin sensitivity. There are several 
different classes, which are selected based on the individual’s circumstances, and these 
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were reviewed recently (Chaudhury, Duvoor et al. 2017). Biguanides such as metformin 
enhance AMPK signalling pathways to lower hepatic glucose output, by preventing 
insulin resistance and gluconeogenesis. Thiazolidinediones (TZDs) reduce insulin 
resistance in muscle and adipose by activating PPAR-γ, which in muscle also lowers 
lipid uptake and storage and in adipose in particular this lowers inflammation. 
Sulfonylureas stimulate insulin release by pancreatic β-cells, and α-glucosidase 
inhibitors such as acarbose regulate glucose digestion in the gut (Chaudhury, Duvoor et 
al. 2017). The mechanisms of the compounds studied in the present study can be likened 
to those for prescribed therapeutics. Quercetin in particular, but the flavonol 
glucuronides, R4G and DHFA-4S too, all upregulated glucose metabolism as with 
metformin and the metabolites lowered carbon storage as with TZDs. The prevention of 
oxidative stress by quercetin in the pancreas would rescue insulin secretion, in similar 
fashion to sulfonylureas, though via a different mechanism. Furthermore, the sulfated 
conjugates and R4G that displayed insulinomimetic properties could lower the 
dependence on insulin injections. 
Following successful clinical trials, (poly)phenols could be administered to replace, or 
work synergistically, with insulin and the other current therapeutics and at least until then 
the evidence is substantial enough for doctors to recommend a (poly)phenol-rich diet, 
although this is heavily dependent on patient cooperation. As bioavailability is improved 
with better supplementation and nanotechnology, administration of (poly)phenols may 
soon become a reality in the management of diabetes. There have already been clinical 
trials for resveratrol in cancer patients, where pharmacokinetics, efficacy and side effects 
were monitored (Brown, Patel et al. 2010). The same would need to be done with 
quercetin and others, as they often have multiple and hormetic roles, for example the 
dose-dependent effects of quercetin on mitochondria and its dual role in AMPK 
activation (de Oliveira, Nabavi et al. 2016, Liu, Mei et al. 2016). In the not-so-distant 
future, doctors and scientists envisage the possibility of personalised nutrition, based on 
individual genomics, metabolomics and gut microbiome fingerprints, becoming a reality 
and prescribed (poly)phenol intake could feature. The potential for this was eluded to in 
a review on nutritional genomics and (poly)phenols (Barnes 2008). The mechanisms 
highlighted in the present study hold promise for the beneficial roles of (poly)phenols 
against chronic diseases beyond diabetes too, such as CVDs, cancers and 
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neurodegeneration, the pathophysiology of which involve oxidative stress and glucose 
metabolism (Del Rio, Rodriguez-Mateos et al. 2013). 
The present study will impact the field of (poly)phenols and health research, in providing 
new details of mechanisms of action and highlighting the importance of studying relevant 
metabolites, in addition to improved models and biomarkers. The study is part of the 
wider POLYTRUE? project (European Research Council Advanced Grant 322467), 
which set out to explore the true chronic effects and mechanisms of action of dietary 
(poly)phenols, with the hypothesis that the exposure of chronic, low levels of 
metabolites, relevant to in vivo nutrition, in an in vitro system will have significant and 
different effects to acute, high concentrations. 
This study ties in with several of the objectives for POLYTRUE?, in that the chronic 
effects, such as longer-lasting changes to gene expression and metabolism, of metabolite 
mixtures were investigated in the presence and absence of chronic stress, which was high 
glucose and/or insulin in this instance. Metabolites were selected based on previous 
human intervention studies conducted, and some of them subsequently synthesised, as 
part of the POLYTRUE? project. New theories for the mechanisms of action of 
(poly)phenols on human health have been suggested; dietary quercetin prevents against 
high glucose-induced hepatic mitochondrial dysfunction through pleiotropic 
mechanisms resulting in improved redox status and enhanced mitochondrial respiration 
and gut microbiome catabolites, such as isovanillic acid 3-O-sulfate, restore glucose 
uptake and metabolism, via insulin-dependent pathways, in skeletal muscle cells. 
Furthermore, novel in vitro cell systems and approaches were established and utilised for 
the study of such chronic effects. The immortalised human skeletal muscle cell model 
established here may be further used to investigate glucose uptake and metabolism in the 
diabetes context, and in particular the beneficial role (poly)phenol metabolites. 
Biomarkers for muscle and glucose metabolism were used in a novel way for Western 
protein analyses and previously unused combinations of systems and biomarkers, such 
as the chronic effects of glucose and quercetin in cells assayed for complex I activity, 
respiration and metabolite flux to ascertain an overall picture of mitochondrial function. 
The future direction of the project involves furthering the novel cell systems used here 
by expressing appropriate transporters (see 4.2) and establishing multi-cell models and 
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expressing appropriate transporters. This will enable an investigation into the effects of 
inter-cell interactions and the metabolic function of hepatocytes and/or myocytes in the 
presence of endothelial and colon cells when the system is exposed to chronic 
(poly)phenol treatments, to mimic the complexity of whole-body metabolism and 
physiology in vivo. 
4.2 Future Perspectives 
For the work on quercetin and mitochondria, a next step could be to analyse the effects 
in the muscle model to see if they are consistent or cell/tissue-specific. Mitochondrial 
assays were already tested on the LHCN-M2 myotubes and so this would be 
straightforward to set up. Furthermore, the metabolites for which effects on glucose 
metabolism were seen in the muscle could be tested for their potential roles in 
mitochondrial function too. The effects of quercetin were dose-dependent, with effects 
on complex I activity and ROS levels seen with 2.5 µM; any lower and the effects would 
likely not have been detected. To investigate effects even closer to the typical 
physiological range, a model could be established to try growing the HepG2 cells for a 
longer period (and/or through multiple passages) and treating with quercetin long-term 
i.e. daily treatments with 1 µM or even 0.1 µM, to see if changes are detectable in these 
assays, with comparisons to the 24 h treatments with 10 µM. Further investigations into 
the effects of quercetin on metabolic flux could be investigated using ion 
chromatography; analyses of lactate, pyruvate, succinate, citrate and so on would be 
interesting in the current HepG2 system and one would hypothesise seeing quercetin 
driving flux away from the glycolytic-dependent ATP synthesis towards the TCA cycle 
and mitochondrial respiration. Extracellular metabolites were measured by high-
performance liquid chromatography recently (Niklas, Nonnenmacher et al. 2012) and 
this could be taken further by measuring intracellular metabolites in cell lysate extracts 
as well as the extracellular in the media, and comparing normal and high glucose. 
Furthermore, the effects on mitochondria will affect lipid metabolism as well as glucose, 
so analysis of the lipidome in HepG2 grown in normal and high glucose and treated with 
quercetin would be an interesting additional study; quercetin was already shown to exert 
lipid-lowering effects in the livers of diabetic mice via increased mitochondrial function 
(Kim, Kwon et al. 2015). 
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It would be challenging to investigate the effects of quercetin on hepatic mitochondria in 
vivo for obvious reasons; mitochondria could be isolated from rodent livers following 
quercetin intervention for example, but this certainly wouldn’t be possible in humans. 
An in vitro setup could involve obtaining primary hepatocytes from normal and diabetic 
patients and treating these with quercetin to see how the effects compare, but this heavily 
relies on tissue availability and a large cohort to see beyond inter-individual variability. 
An easier ex vivo approach may be to take muscle biopsies following a long-term 
quercetin intervention and analyse the samples on the high-resolution respirometer 
and/or isolate mitochondria from the tissue. 
The obvious studies to be carried out next for the effects of (poly)phenol metabolites on 
glucose uptake and metabolism are human interventions. With an in vitro mechanism of 
action established for IVAS, this would be a promising compound to start with. An 
intervention with the berry purée used in the studies by Pimpão et al. (Pimpao, Dew et 
al. 2014, Pimpao, Ventura et al. 2015), from which the phenolic sulfate profile in this 
study was selected, may lower glycaemia in participants, though it would be unclear if 
this was an effect on muscle uptake or more so on the inhibition of carbohydrate digestion 
and absorption seen with berries in previous interventions (Nyambe-Silavwe and 
Williamson 2016). Intervention with a cyanidin 3-O-glucoside tablet, such as that used 
in pharmacokinetic studies (Czank, Cassidy et al. 2013, de Ferrars, Czank et al. 2014), 
instead of berries may result in more specific metabolites at least, or encapsulating IVAS 
so a controlled dose reaches the bloodstream. 
Finally, to expand on the beneficial roles of (poly)phenol metabolites, and to make the 
in vitro models closer to the in vivo situation, the HepG2 and/or LHCN-M2 cells could 
be transfected with OAT-expressing plasmids to upregulate the transporters associated 
with the facilitated uptake of the sulfated conjugates (Wong, Akiyama et al. 2012). In the 
muscle study here the sulfated conjugates were not taken up and their effects may differ 
if they were. It would also be interesting to compare the effects of quercetin aglycone 
and quercetin 3′-O-sulfate on the mitochondrial function and cellular metabolism in 
HepG2 cells. Likewise, LHCN-M2 transfected with GLUT4 to increase expression 
beyond the low endogenous level would further confirm the GLUT4 translocation-
stimulated mechanism of IVAS and other metabolites.  
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Appendix 
 
Supplementary Figure 1: PGC-1α expression in HepG2 cells normalised to TBP 
housekeeping gene. Cells were seeded in NG or HG media and after 60 h (referred to as 
T = -12 h) serum (FBS) was removed from half. The medium was changed again at T = 
0 h for the final 24 h of the experiment, still ± serum accordingly. Cells were lysed at 
various time-points, RNA extracted and PGC-1α measured alongside TBP control using 
droplet digital PCR (see Chapter 2). Data are expressed as mean ratios of PGC-1α/TBP 
± SEM (n/N = 18/6). *p < 0.05 vs NG/HG +FBS controls (A). Cells were grown without 
FBS from 60 h after seeding but with 20 µM quercetin (Q) (or DMSO controls) added 
for varying times in the final 24 h. PGC-1α/TBP ratios were measured and expressed as 
means ± SEM (n/N = 18/6). *p < 0.05 vs NG or HG controls (B-C). 
